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ABSTRACT 
INTEGRATION OF FERMENTATION AND ORGANIC SYNTHESIS: STUDIES 
OF ROQUEFORTINE C AND BIOSYNTHETIC DERIVATIVES 
Claire Marie Gober 
Madeleine M. Joullié 
Roquefortine C is one of the most ubiquitous indoline alkaloids of fungal origin. It 
has been isolated from over 30 different species of Penicillium fungi and has 
garnered attention in recent years for its role as a biosynthetic precursor to the 
triazaspirocyclic natural products glandicoline B, meleagrin, and oxaline. The 
triazaspirocyclic motif, which encompasses three nitrogen atoms attached to one 
quaternary carbon forming a spirocyclic scaffold, is a unique chemical moiety that 
has been shown to impart a wide array of biological activity, from anti-bacterial 
activity and antiproliferative activity against cancer cell lines to anti-biofouling 
against marine organisms.  Despite the promise of these compounds in the 
pharmaceutical and materials industries, few syntheses of triazaspirocycles exist 
in the literature. The biosynthesis of roquefortine C-derived triazaspirocycles, 
however, provides inspiration for the synthesis of these compounds, namely 
through a nitrone-promoted transannular rearrangement. This type of internal 
rearrangement has never been carried out synthetically and would provide an 
efficient stereoselective synthesis of triazaspirocycles. This work encompasses 
efforts towards elucidating the biosynthetic pathway of roquefortine C-derived 
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triazaspirocycles as well as synthetic efforts towards the construction of 
triazaspirocycles. Chapter 1 will discuss a large-scale fermentation procedure for 
the production of roquefortine C from Penicillium crustosum. Chapters 2 and 3 
explore (through enzymatic and synthetic means, respectively) the formation of the 
key indoline nitrone moiety required for the proposed transannular rearrangement. 
Finally, chapter 4 will discuss synthetic efforts towards the synthesis of 
triazaspirocycles. This work has considerably enhanced our understanding of the 
roquefortine C biosynthetic pathway and the unique chemistry of this natural 
product, and our efforts towards the synthesis of triazaspirocycles will facilitate the 
use of these compounds in numerous applications. 
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CHAPTER ONE 
LARGE SCALE FERMENTATION OF ROQUEFORTINE C 
 
 
Material in this chapter reproduced in part with permission from: 
Newmister, S. A.; Gober, C. M.; Romminger, S.; Yu, F.; Tripathi, A.; Parra, L. L. L.; 
Williams, R. M.; Berlinck, R. G. S.; Joullié, M. M.; Sherman, D. H. J. Am. Chem. Soc. 
2016, 138(35), 11176-11184. Copyright 2016 American Chemical Society. 
Gober, C.; Joullié, M. M. Athens Journal of Science 2015, 3(4), 257-264 
Gober, C.; Carroll, P. J.; Joullié, M. M. Mini Rev. Org. Chem. 2016, 13, 126-142. 
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I. Introduction 
Prenylated indoline alkaloids make up one of the largest classes of 
biologically active compounds of microbial origin. Fungal alkaloids in particular 
comprise a large portion of this class of compounds. The biological activity 
displayed by prenylated indoline alkaloids of fungal origin is wide ranging, from 
anti-bacterial activity1,2 and antiproliferative activity against human T-cell leukemia3 
to anti-fouling against marine organisms.4 
One of the most ubiquitous prenylated indoline alkaloids is roquefortine C 
(1, Figure 1.1). Roquefortine C is found in low levels in industrially produced blue 
cheese,5 grain,6-9 and animal feedstocks,10 and has been isolated from 30 different 
Penicillium species11-26 (see Appendix 1A). It has been a subject for research for 
several years due to its unique structure, its biological activity, and its role as a 
biosynthetic precursor to related metabolites glandicoline B (2), meleagrin (3), and 
oxaline (4). The first total synthesis of roquefortine C was carried out in the Joullié 
laboratory in 2008; however, this synthesis was lengthy, expensive, and low 
yielding, thus limiting further studies of roquefortine C and its downstream 
metabolites. Therefore, it was of interest to develop a fermentation-based 
approach towards roquefortine C production. 
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Figure 1.1: Roquefortine C and related metabolites 
II. Background 
A. Isolation and Structure Determination 
Roquefortine C was first isolated from cultures of Penicillium roqueforti 
Thom along with the related compounds roquefortines A (5) and B (6) by Matazo 
Abe and coworkers in 1975.14 Though characterization data was reported for 
roquefortine C, Abe et al. were unable to propose a structure for this novel 
compound. The following year, Scott and coworkers isolated roquefortine C from 
a sample of P. roqueforti (strain CS1) and determined its structure via a series of 
chemical and spectroscopic studies. Similar to many indoline alkaloids, 
roquefortine C was found to be composed of a tryptophan-proline diketopiperazine 
skeleton. Platinum-catalyzed hydrogenation of roquefortine C yielded 24,25-
dihydroroquefortine C (7), and nuclear magnetic resonance (NMR) analysis of this 
compound as compared to roquefortine C suggested that the prenyl group was 
positioned in the reverse orientation to the indoline moiety (Scheme 1.1). 
Reduction with zinc in acetic acid at 70 °C afforded two 3,17-dihydroroquefortine C 
isomers (8) and corresponded with the disappearance of a singlet at 6.40 ppm in 
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the 1H NMR spectra. Acidic hydrolysis of these two isomers yielded histidine, 
leading Scott and coworkers to conclude that roquefortine C possessed a unique 
dehydrohistidine side chain extending from the diketopiperazine.12  
 
Scheme 1.1: Structural determination of roquefortine C (1) by chemical reduction and 
hydrolysis  
 The stereochemistry of the dehydrohistidine moiety was confirmed in 1979 
by Scott and coworkers.27 Photoisomerization of roquefortine C corresponded to a 
shift of H17 in the 1H NMR spectrum from 6.35 ppm in roquefortine C to 6.67 ppm 
in the photoisomer isoroquefortine C (9, Scheme 1.2). In previous comparisons 
between (E) and (Z)-3-benzylidene-1-methyl-2,5-piperazinedione, deshielding of 
this nature had been observed in the E species due to the adjacent carbonyl.28 The 
dehydrohistidine moiety in roquefortine C was thus determined to be in the E 
configuration.  
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Scheme 1.2: Photoisomerization of roquefortine C and configuration of the 
dehydrohistidine moiety  
B. Biological Properties of Roquefortine C 
The cytotoxicity of roquefortine C has been a subject of debate for many 
years. The toxicity of this compound appears to be highly organism-specific; 
roquefortine C has been reported to induce neurotoxic and inflammatory 
responses in mice12,29,30 and paralytic activity in cockerels,31 but it has shown little 
to no cytotoxicity in a number of human cell lines.9,32,33  Roquefortine C may also 
be significant in indoor air contamination, as it has been isolated from numerous 
mold-contaminated indoor environments and as inflammatory responses have 
been reported for mouse lungs intratracheally instilled with roquefortine C.29,34-36  
Roquefortine C is known to inactivate hepatic cytochrome P450s37 and 
inhibit growth of gram-positive bacteria containing heme proteins.38,39  The 
E-dehydrohistidine moiety of roquefortine C has been shown to be a key factor in 
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this inhibition. Computational studies of roquefortine C suggest internal hydrogen 
bonding between H19 and the C4 carbonyl oxygen (Figure 1.2).40 As a 
consequence of this intramolecular hydrogen bonding, the imidazole moiety does 
not experience tautomerization. The nitrogen on the periphery of roquefortine C, 
N21, forms a strong Fe-N interaction through its lone pair, inhibiting hepatic 
cytochrome P450s and peroxidases. 
Interestingly, isoroquefortine C demonstrates no such inhibition of heme 
proteins. Isoroquefortine C also possesses intramolecular hydrogen bonding; 
however, in this case, N19 becomes the hydrogen bond acceptor. As 
isoroquefortine C also does not experience tautomerization, the N21 lacks the sp2 
lone pair needed to form a strong bond to iron and fails to inhibit hepatic 
cytochrome P450s.37 
 
Figure 1.2: Inhibition of hepatic cytochrome P450s as a result of intramolecular hydrogen 
bonding  
C. Biosynthesis of Roquefortine C and Related Metabolites 
The genome of Penicillium chrysogenum was sequenced in 2008, setting 
the stage for the exploration of roquefortine C biosynthesis.41 In 2011, a single 
cluster of coregulated genes encoding the biosynthesis of roquefortine C and 
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meleagrin was discovered by Martín and coworkers (Scheme 1.3). Open reading 
frames (ORFs) within the roquefortine-meleagrin gene cluster in the 
P. chrysogenum genome have been subjected to a series of RNA silencing 
experiments, which enabled a putative biochemical assignment for each step of 
the biosynthetic pathway.42 Pc21g15480 was found to encode a nonribosomal 
peptide synthetase (NRPS) RoqA, which is proposed to promote the biosynthesis 
of histidyltryptophanyldiketopiperazine (HTD, 10) from histidine and tryptophan. 
RoqA was shown to contain two modules each containing activation, thiolation, 
and condensation domains. Subsequent gene deletion studies by Vreeken and 
coworkers uncovered a branched pathway leading to the biosynthesis of 
roquefortine C.43 A gene encoding prenyltransferase RoqD (Pc21g15430) was 
found to promote the biosynthesis of roquefortine D (8) from HTD and 
roquefortine C from dehydrohistidyltryptophanyldiketopiperazine (DHTD, 11). 
Pc21g15470 encodes cytochrome P450 oxidoreductase RoqR, which was found 
to promote the dehydrogenation of HTD to DHTD and of roquefortine D to 
roquefortine C. 
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Scheme 1.3: Biosynthesis of roquefortine C (1)  
The biosynthetic pathway connecting roquefortine C to its downstream 
metabolites has been a subject of investigation for several years.  A radiolabeling 
study by Vleggaar (Scheme 1.4) was the first evidence to suggest a biosynthetic 
pathway containing Penicillium indole alkaloids roquefortine C, glandicolines A 
(15) and B (2), meleagrin (3), and oxaline (4).44 He proposed that the pathway 
began with the hydroxylation of roquefortine C, followed by a rearrangement to 
give glandicoline A, N-oxidation to give glandicoline B, and methylation to give 
meleagrin and oxaline. 
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Scheme 1.4: Roquefortine biosynthetic pathway proposed by Vleggaar et al., with 
potential intermediates in brackets  
It was unclear from this study, however, whether oxaline was made 
biosynthetically via a direct oxidation and rearrangement of roquefortine C, as is 
suggested in Scheme 1.4, or if it were instead made via a separate pathway. A 
later study by Reshetilova provided evidence of direct oxidation and 
rearrangement as incorporation of exogenous 14C labeled roquefortine C into the 
proposed downstream metabolites was shown to occur in cell suspensions and 
growing cultures of Penicillium glandicola.45,46  
Whole genome sequencing, analysis, and substrate modeling with 
P. chrysogenum Wis54-1255 have enabled the determination of the gene cluster 
that encodes the biosynthesis of roquefortine C derived metabolites.41 In the first 
reports of this gene cluster, Martín and coworkers found the transformation of 
roquefortine C (1) into glandicoline A (15) to be promoted by a MAK1-like 
monooxygenase RoqM (encoded by Pc21g15460), as evidenced by loss of 
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production of 2, 15, and 4 upon gene silencing.  Subsequent gene deletion analysis 
of the P. chrysogenum strain DS54555 roquefortine C gene cluster43 confirmed the 
results obtained by gene silencing,42 leading to a mechanism identical to the one 
previously proposed by Steyn and Vleggaar.44  
More recently, rigorous structural elucidation of the metabolites of this 
pathway prompted a revision of the biosynthetic mechanism for this particular 
rearrangement.47 The key revision to this newly proposed metabolic pathway is 
the generation of the nitrone-bearing intermediate roquefortine L (17) by RoqM 
from 1 (Scheme 1.5). Since roquefortine L (17) has a molecular weight identical to 
that of glandicoline A (15), it was proposed that 17 had been mistakenly 
characterized as 15 in the initial gene silencing and gene deletion studies. 
Cytochrome P450 monooxygenase RoqO (encoded by Pc21g15450) was 
proposed to catalyze the rearrangement of 15 to give the triazaspirocyclic core of 
glandicoline B (2) as deletion of this gene resulted in loss of production of 3 and 2. 
Novel metabolites roquefortine F (18) and neoxaline (19), presumably formed from 
hydroxylamine 16, were also reported in this work as well as roquefortines M (20) 
and N (21), which were formed following non-enzymatic hydrolysis of 
roquefortine L. 
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Scheme 1.5: Biosynthesis of roquefortine C-derived metabolites  
D. Total Synthesis of Roquefortine C 
The first and only total synthesis of roquefortine C was published by our 
laboratory in 2008 (Scheme 1.6).40 This total synthesis included a novel elimination 
strategy to construct the thermodynamically disfavored E-dehydrohistidine moiety. 
However, this synthesis did little to improve the availability or cost of the 
compound: only 17 milligrams were produced as a result of the total synthesis, and 
the cost of raw materials to produce 1 gram of 1 by total synthesis is estimated to 
be over $1800. 
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Scheme 1.6: Total synthesis of roquefortine C (1)  
E. Prior Art: Small Scale Fermentation of Roquefortine C 
While fermentation has never been previously implemented for large-scale 
roquefortine C production, several experiments have revealed key factors that 
influence the production of roquefortine C by fermentation on small scale. 
Roquefortine C production by P. roqueforti was found by Abe et al. to improve 
significantly upon increasing temperature (up to 30 °C) and was observed to peak 
around day 20 following incubation in MGS (mannitol, glucose, succinic acid) 
media.24 A parallel study by P.M. Scott and coworkers examined roquefortine C 
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production by four strains of P. roqueforti using five unique growth conditions.48 
Roquefortine C production was found to parallel mycelial growth, with the majority 
of roquefortine C being isolated from the mycelia as opposed to the liquid growth 
media. Extractions of roquefortine C from the mycelia were carried out with 
acetone, which was determined to be the ideal extraction solvent. Growth media 
containing yeast extract and higher concentrations of sucrose gave superior yields 
of roquefortine C, with maximum yields from mycelia estimated at 295 mg per liter 
of growth media at 40 days from P. roqueforti strain HPB 111275. 
Roquefortine C has also been isolated in high yields from other species of 
Penicillia. In 1980, Diener et al. isolated roquefortine C in 101 mg per liter from 
mycelia of Pencillium commune grown in a yeast extract-sucrose growth medium 
and determined that stationary cultures were imperative for roquefortine C 
production.31 Alkaline environments tended to correlate with higher roquefortine 
production, as the pH of growth media yielding the largest quantities of roquefortine 
C rose to 8 or 9 following 10 days of mycelial growth. Initial mycelial growth rate 
was shown to be more rapid with smaller volumes of growth media in conical 
flasks. Roquefortine C was also isolated from Penicillium crustosum by Mantle and 
coworkers in 1983.49 Grown for 12 days in Czapek-Dox liquid growth media 
supplemented with 0.5% yeast extract, roquefortine C production was found to 
approach 13 mg per 50 mL growth media, which equates to 260 mg per liter. 
Mantle also observed the necessity of mycelial growth for roquefortine C 
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production and found that poor mycelial growth negatively impacted roquefortine C 
production.  
III. Results and Discussion 
A. Large Scale Fermentation of Roquefortine C 
While P. roqueforti, in particular the HPB 111275 strain, would have been 
the ideal strain for our fermentation based on the previously discussed work by P. 
M. Scott, its limited availability in the United States led us to select P. crustosum 
ATCC 90174 (strain NHL 6491 [I-31]) for development of the fermentation process 
(Scheme 1.7). Czapek-Dox broth supplemented with 5% yeast extract (Table 1.1) 
was selected as the growth media for the fermentation of roquefortine C as 
roquefortine C production was previously shown to be accelerated with high 
concentrations of sucrose and yeast extract. 
 
Scheme 1.7: Roquefortine C fermentation process 
Geometry optimization of roquefortine C was carried out at the HF/6-311+G(2d,p) level of 
theory 
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Table 1.1: Roquefortine C fermentation growth media composition 
Reagent Quantity† 
Sucrose 30.000 g 
Sodium nitrate 3.000 g 
Dipotassium phosphate 1.000 g 
Magnesium sulfate 0.500 g 
Potassium chloride 0.500 g 
Ferrous sulfate 0.010 g 
Yeast extract 5.000 g 
†Per liter ultrapure (Type 1) water 
Preliminary fermentation trials were carried out in Erlenmeyer flasks (1, 2, 
4, and 6 L) containing relatively small volumes (200-1000 mL) of growth media. 
Pyrex borosilicate trays (3.5 L) eventually proved to be a superior vessel for the 
fermentation process. These trays eliminated the extraneous headspace present 
in the Erlenmeyer flask system, which provided greater ease of storage and 
harvest of the mycelial cultures as well as cleaning of the growth vessels.  
Exposure to light (both sunlight and standard laboratory lighting) was found 
to negatively impact mycelial growth, and subsequently roquefortine C production. 
In particular, exposure to light in the initial stages of mycelial growth was found to 
impede mycelial growth, even if cultures were subsequently shielded from light 
(Figure 1.3). As a result, liquid cultures of P. crustosum were grown in darkness 
for the entirety of the fermentation process. 
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Figure 1.3: Effects of light on P. crustosum mycelial growth 
Roquefortine C in this fermentation procedure was isolated exclusively from 
the mycelia, as the liquid growth media has been shown to yield minimal amounts 
of roquefortine C. Lyophilization of the mycelia to remove water proved to be 
extremely important to obtaining good yields of roquefortine C. The polarity of 
roquefortine C allows for straightforward extraction and purification. Roquefortine 
C exhibits high solubility in polar aprotic solvents such as chloroform, acetone, and 
dichloromethane, which permits its extraction from the mycelial material. Two 
extractions were performed in this fermentation procedure: one 3 hour extraction 
in a 1:1 mixture of chloroform and acetone and one 18 hour extraction in acetone. 
The polarity of roquefortine C with respect to the other metabolites extracted from 
the P. crustosum mycelia allowed for its purification by column chromatography 
using an 85:10:5 mixture of CH2Cl2/CH3OH/acetone, providing roquefortine C in 
excellent purity in quantities of 150 mg per liter of growth media.  
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B. Comparison to Other Methods of Roquefortine C Production 
The production of roquefortine C by fermentation has proven to be much 
more efficient than production by traditional organic synthesis. The total synthesis 
of roquefortine C only yielded 17 mg after 12 steps, which included 7 extractions 
and 10 chromatography purifications. Two major challenges in this synthesis 
include the installation of the reverse prenyl moiety, which required the use of 
stoichiometric organostannane, and the installation of the E-dehydrohistidine 
moiety, which could only be synthesized in a 1:1 mixture with the Z isomer. 
Fermentation of roquefortine C requires only one extraction and one 
chromatography purification and allows for a significant reduction in cost of raw 
materials. To produce a gram of roquefortine C by total synthesis is estimated to 
cost over 100 times the amount to produce one gram of roquefortine C by 
fermentation. Additionally, the amount of active experimental time of the 
researcher is significantly reduced. 
While our production of roquefortine C ultimately gave less of the title 
compound per liter than the two highest yielding procedures by Abe and Scott, this 
fermentation procedure is scalable and can afford good yields, comparable to the 
majority of small scale fermentations of roquefortine C. Following the development 
of this fermentation procedure, a patent was filed by researchers at the First 
Institute of Oceanography in China describing a fermentation procedure for the 
production of roquefortine C.50 This patent detailed the fermentation of Penicillium 
sp.  Y32 in a variety of growth media. The fungal liquid cultures were allowed to 
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grow for 25-35 days, after which the mycelia was extracted with acetone and ethyl 
acetate and purified by column chromatography. This procedure gave roquefortine 
C yields between 6.8 and 33 µg per mL liquid growth media, paling in comparison 
to the procedure described in this chapter. 
IV. Conclusions 
The fermentation procedure described herein allows for the production of 
gram quantities of roquefortine C in excellent purity. With yields of 150 mg per liter, 
this method provides significant benefits over the traditional organic synthesis of 
roquefortine C and will allow for further exploration of roquefortine C and its 
downstream metabolites. 
V. Experimental Details 
General Information 
Roquefortine C was purified by flash column chromatography (FCC) on 230-400 
mesh silica gel. 1H and 13C NMR spectra were recorded on a spectrometer 
operating at 500 MHz for 1H and 125 MHz for 13C unless otherwise stated. 
Chemical shifts are reported in ppm relative to tetramethylsilane (TMS) as the 
internal standard for 1H and chloroform as the internal standard for 13C. NMR data 
is reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, t = triplet, q = quartet, br = broad, m = multiplet), coupling 
constants (Hz), and integration. 1H-1H Homonuclear correlation spectroscopy 
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(COSY), 1H-13C heteronuclear single quantum correlation experiment (HSQC), 
and 1H-13C heteronuclear multiple bond correlation (HMBC) NMR spectra were 
recorded on a spectrometer operating at 500 MHz.  High-resolution mass spectra 
(HRMS) were recorded on an electrospray ionization time-of-flight (ESI-TOF) 
spectrometer (Agilent). Waters software calibrates and reports by use of neutral 
atomic mass. The mass of the electron is not included. 
Isolation of roquefortine C (1) from P. crustosum 
Freeze-dried samples of P. crustosum were rehydrated for 1 hour in double 
distilled (dd) water and inoculated onto malt extract agar plates (Blakeslee’s 
formula). Fungal samples were allowed to grow on plates for 3-5 days in darkness 
at room temperature until colonies of blue-green fungus were observed. Twelve 
borosilicate glass trays (9 by 13 inch) were each filled with 825 mL autoclave-
sterilized Czapek-Dox yeast extract (CDY) liquid media, prepared using 35 g/L 
Czapek-Dox broth and 5 g/L yeast extract. The CDY broth was inoculated with 
fungal culture using a sterile loop. P. crustosum samples were grown in liquid 
culture for 12-14 days until a sufficient mycelial mat covered the surface of the 
liquid media. Mycelial material was harvested by filtering off liquid media, 
macerating the mycelial mat using a mortar and pestle, and lyophilizing. 
Lyophilized samples were extracted in 1:1 CHCl3/acetone for 3 hours and then 
again in acetone for 18 hours. Organic extracts were then concentrated by rotary 
evaporation to give a crude mycelial extract. Roquefortine C was purified by flash 
chromatography (retention factor (Rf) 0.26, 85:10:5 CH2Cl2/CH3OH/acetone), to 
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yield 1 g of purified material. 1H NMR (500 MHz, CDCl3) δ 12.92 (s, br, 1H), 10.27 
(s, 1H), 7.68 (s, 1H), 7.23 (s, 1H), 7.17 (d, J = 6.0 Hz, 1H), 7.09 (t, J = 6.0 Hz, 1H), 
6.76 (t, J = 6.0 Hz, 1H), 6.59 (d, J = 6.5 Hz, 1H), 6.35 (s, 1H), 5.97 (dd, J = 9, 
14.5 Hz, 1H), 5.63 (s, 1H), 5.14 (s, 1H), 5.11 (d, J = 7.0 Hz, 1H), 5.08 (s, 1H), 4.03 
(dd, J = 5.0, 9.5 Hz, 1H), 2.58 (dd, J = 4.5, 15.0 Hz, 1H), 2.45 (t, J = 10.0 Hz, 1H), 
1.13 (s, 1H), 1.02 (s, 1H). 13C NMR (125 MHz, CDCl3) δ 167.3, 159.6, 150.2, 143.6, 
137.1, 135.7, 129.3, 128.8, 125.7, 125.4, 121.9, 119.4, 115.0, 111.6, 109.4, 78.6, 
61.8, 59.0, 41.2, 37.0, 23.1, 22.7. 15N NMR (600 MHz, CDCl3) δ: 257.9, 167.8, 
147.4, 138.1, 83.4. IR (KBr): 3199, 1681, 1607, 1435, 1412, 1215, 1102, 752 cm-1 
(lit. (Ohmomo et al., 1975)14 IR (KBr) 3180, 1690, 1660, 1604 cm-1). -700.5 
(c 0.77, CHCl3) (lit. (Ohmomo et al., 1975)14  -764 (c 0.50, pyr.)). HRMS (ESI-
TOF) m/z [M + H]+ calcd for C22H24N5O2 390.1930, found 390.1930 (lit. (Joullié et 
al., 2008)40 calcd for C22H24N5O2 390.1930, found 390.1920. 
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Appendix 1A: Species of Penicillium that Produce Roquefortine C 
Penicillium species Investigator Reference 
number 
P. albocoremium Frisvad,1989 
Overy, 2003 
20, 25 
P. allii Frisvad, 1989 20 
P. atramentosum Frisvad, 1989 20 
P. carneum Boysen, 1996 26 
P. chrysogenum El-Banna, 1987 
Frisvad, 1989 
18, 20 
P. concentricum, Frisvad,1989 20 
P. confertum, Frisvad,1989 20 
P. coprobium Frisvad, 1989 20 
P. coprophilum Frisvad,1989 20 
P. crustosum Kyriakidis, 1981 
Kozlovsky, 1981 (as P. farinosum) 
16, 17 
P. expansum Ohmomo, 1980 
Frisvad, 1983 
15, 19 
P. flavigenum Banke, 1997 13 
P. glandicola Frisvad, 1983 (as P. granulatum) 
Frisvad, 1989 
19, 20 
P. griseofulvum Ohmomo, 1980 (as P. urticae)  
Frisvad, 1983 
15, 19 
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P. hirsutum Ohmomo, 1980 (as P. corymbiferum) 
Frisvad, 1989 (as P. corymbiferum) 
15, 20 
P. hordei Frisvad, 1989 20 
P. marinum Frisvad, 2004 23 
P. melanoconidium Frisvad, 1989 20 
P. paneum Boysen, 1996 26 
P. persicinum Frisvad, 2004 23 
P. radicicola Overy, 2003 25 
P. roqueforti Ohmomo, 1975 
Scott, 1976 
Yamaguchi, 1991 
11, 12, 14 
P. sclerotigenum Frisvad, 1990 21, 22 
P. tulipae Overy, 2003 25 
P. venetum Frisvad, 1989 20 
P. vulpinum Frisvad, 1983 (as P. claviforme) 19 
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Appendix 1B: Spectra Relevant to Chapter 1 
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Supplementary Figure 1.1: 1H NMR (500 MHz, CDCl3) Spectrum of 1 
C
H
C
l3
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Supplementary Figure 1.2: 13C NMR (125 MHz, CDCl3) Spectrum of 1 
C
H
C
l3
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Supplementary Figure 1.3: 1H-1H COSY NMR (500 MHz, CDCl3) Spectrum of 1  
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Supplementary Figure 1.4: 1H-13C HSQC NMR (500 MHz, CDCl3) Spectrum of 1  
 34 
 
 
Supplementary Figure 1.5: 1H-13C HMBC NMR (500 MHz, CDCl3) Spectrum of 1  
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Supplementary Figure 1.6: IR (KBr pellet) Spectrum of 1 
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CHAPTER TWO 
N-OXIDATION OF ROQUEFORTINE C BY OXAD 
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I. Introduction 
In recent years, downstream metabolites of roquefortine C have acquired 
renewed interest due to their unique triazaspirocyclic core and their biological 
activity. Until recently, the triazaspirocyclic core of glandicoline B, meleagrin, and 
oxaline was thought to be biosynthesized via an indole imine intermediate 
glandicoline A. Recent work by the Vreeken lab, however, indicates that these 
metabolites are formed via a nitrone intermediate, roquefortine L. The uniqueness 
of this nitrone natural product as well as the general lack of robust synthetic 
methods towards synthesizing indoline nitrones led us, in collaboration with the 
Sherman laboratory at the University of Michigan, to develop flavin 
monooxygenase OxaD as a biocatalyst for indoline nitrone synthesis. We herein 
report the isolation, characterization, and enzymatic activity of OxaD, which can 
be produced in significant yields by heterologous expression. OxaD is a 
flavoprotein that has been harnessed for the biocatalytic conversion of 
roquefortine C and roquefortine C semisynthetic derivatives to afford the resulting 
indoline nitrones in very good yield and in a single step. To the best of our 
knowledge, this work represents the first biocatalytic synthesis of indoline nitrones.  
II. Background 
A. Nitrones 
The nitrone functional group, which is an N-oxide of an imine, is a unique 
and versatile chemical moiety. The extreme electrophilicity of the nitrone carbon 
allows for its participation in nucleophilic addition reactions as well as 1,3-dipolar 
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cycloaddition reactions. Synthesis of nitrones generally occurs through either 
condensation of a ketone with a hydroxylamine or oxidation of an N,N-disubstituted 
hydroxylamine. 
Chemical conversion of indolines into their respective nitrones has been 
reported in only a few instances. This transformation requires either mild oxidative 
conditions to give very moderate yields,1,2 or a multi-step procedure affording good 
yield.3 Oxidation of N-aryl secondary amines generally gives poor yields, as 
electron transfer from the amine to the oxidant typically results in C-N bond 
cleavage and subsequent oxidation of the fragments. The powerful electrophilicity 
of the nitrone α-carbon makes it susceptible to intra- and intermolecular 
nucleophilic attack, often resulting in numerous side products. 
Fungal production of roquefortine L (17) is particularly relevant, since very 
few indoline nitrones are known as natural products.4-8 With the exception of the 
recently isolated versicamide E (30), alstoyunine D (31), and perakine N1,N4-
dioxide (32), the remaining fungal indole nitrones share a common avrainvillamide 
(33) core (Figure 2.1). Nitrone incorporation into these compounds can promote 
several biologically relevant events. For example, the nitrone functional group on 
avrainvillamide is required for dimerization to stephacidin B (35).9 The nitrone 
function of avrainvillamide also plays a vital role in its anti-proliferative activity. 
Avrainvillamide has been shown to bind to oncogenic protein nucleophosmin, 
which is frequently overexpressed in solid tumors, with expression levels often 
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correlating to tumor metastasis. The proposed mechanism of anti-proliferation 
involves nucleophilic attack of the nitrone functionality by cysteine residues in 
cellular proteins.8,10-12 Such properties generate great interest in the chemical 
synthesis of these molecules, as evidenced by the syntheses of avrainvillamide 
(33) and stephacidin B (35) published in recent years. 1,13,14 
 
Figure 2.1: Known indoline nitrone natural products 
Discovery of a biocatalyst that could efficiently perform such a reaction in a 
single high-yielding step would be of major interest for the synthesis of nitrone 
functionalized indolines, particularly of complex and biologically active indoline 
alkaloids.  
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B. Nitrone Biosynthesis 
The biosynthetic oxidation of amines to hydroxylamines is well documented; 
however, the biosynthesis of nitrones has been observed in relatively few 
instances. The biosynthetic oxidation of amines is typically carried out by either 
flavin-dependent monooxygenases or cytochrome P450s. These enzymes both 
implement cofactors for the activation of molecular oxygen. Cytochrome P450s 
carry out oxidations through use of iron bound to an organic cofactor such as a 
heme (Scheme 2.1). The iron is attached to the P450 via a cysteine residue. The 
substrate first binds proximal to the heme, displacing water. Electron transfer from 
reduced nicotinamide adenine dinucleotide (NADH) or nicotinamide adenine 
dinucleotide phosphate (NADPH) converts the iron(III) to the iron(II) species. 
Molecular oxygen binds to iron(II) giving a peroxy radical, which is converted to the 
corresponding peroxo anion via a second electron transfer. Rapid protonation of 
the peroxo anion generates the highly reactive iron(IV) oxo species, which allows 
for oxidation of the substrate and regeneration of the initial iron-water complex. 
Flavin-dependent monooxygenases incorporate molecular oxygen using an 
organic flavin cofactor (Scheme 2.2). Molecular oxygen is incorporated into the 
reduced flavin species, giving a peroxo anion. Protonation generates a reactive 
hydroperoxyflavin, which delivers oxygen in an electrophilic fashion on its 
substrate. The reduced flavin is regenerated via dehydration and subsequent 
electron transfer. 
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Scheme 2.1: Cytochrome P450 oxidation mechanism 
 
Scheme 2.2: Flavin monooxyganase mechanism 
Previous accounts of enzymatic nitrone formation have focused on 
metabolism of xenobiotic secondary amines and hydroxylamines by hepatic 
microsomal enzymes;15-20 however, in the majority of these instances, nitrone 
formation was accompanied by a number of additional oxidative side reactions. 
Additionally, thorough characterization of the nitrone products in these instances 
is generally lacking, with nitrone formation often assumed following observation of 
nitrone addition or degradation products. 
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III. Results and Discussion 
A. Oxaline Biosynthetic Gene Cluster 
While the biosynthesis of the roquefortine C-derived alkaloids 1-4 has been 
the subject of investigations employing genetic approaches,21-23 enzymatic 
characterization relating to assembly and processing steps is completely lacking 
for these indoline alkaloid pathways. 
In order to investigate the biogenesis of oxaline in mechanistic detail, the 
genome of P. oxalicum F30 was sequenced by the Sherman group and gene 
cluster analysis was performed using antiSMASH (antibiotics & Secondary 
Metabolite Analysis Shell), followed by a deep annotation of the oxaline 
biosynthetic pathway (Scheme 2.3A). The composition of the oxaline (oxa) gene 
cluster is highly similar to that of roquefortine/meleagrin (roq) cluster from 
P. chrysogenum,21 with an average 78.4% similarity between homologous ORFs 
in the respective systems. One exception is a second methyltransferase (OxaC), 
which is absent in P. chrysogenum and suggests that this enzyme is responsible 
for the enol O-methylation that distinguishes 3 from 4. By homology, we reason 
that the initial biosynthetic steps toward 4 match those previously reported for 3 
(Scheme 2.3B). Briefly, the first biosynthetic intermediate HTD (10), is generated 
by an NRPS-mediated condensation of the corresponding L-amino acids. HTD 
undergoes reverse prenylation at C3 catalyzed by OxaF and dehydrogenation 
catalyzed by OxaB to give 1. The flavin oxidase, OxaD, and the P450 
monooxygenase, OxaH, are homologous to P. chrysogenum RoqM and RoqO, 
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respectively. RoqM and RoqO have been proposed to generate the core 
intermediate 2 from 1 by proceeding through intermediate 17, as identified by 
Vreeken et al.22 The conversion of 17 to 2 is proposed to arise from a P450-
dependent hydroxylation catalyzed by OxaH, although this transformation has not 
been observed in vitro. Two O-methylations by OxaG and OxaC generate the final 
product 4. 
A B C D E F G H Iorf J orf
 
 
Scheme 2.3: Oxaline biosynthetic gene cluster  
(A) Schematic representation of the ORFs in the oxaline (oxa) gene cluster. (B) Proposed 
biosynthetic pathway in P. oxalicum F30. The homologous enzymes from the 
roquefortine C/meleagrin (roq) gene cluster in P. chrysogenum are also shown. A second 
methyltransferase, OxaC, lacks a homolog in P. chrysogenum.  
B. OxaD, a Flavin-Dependent Nitrone Synthase 
OxaD was cloned by the Sherman group from a P. oxalicum F30 cDNA 
library and heterologously expressed in Escherichia coli. The purified enzyme 
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exhibited an intense yellow color. High-performance liquid chromatography-mass 
spectrometry (HPLC-MS) analysis of the supernatant of boiled OxaD shows near 
quantitative incorporation of flavin adenine dinucleotide (FAD). In order to obtain 
sufficient quantities of roquefortine C, a fermentation-based isolation using P. 
crustosum was implemented, as described in Chapter 1.24 Gram quantities of pure 
1 were obtained for enzymatic testing and chemical derivatization.  Both NADH 
and NADPH were shown by the Sherman group to be effective in the oxidation of 
1 by OxaD. Incubation of OxaD with 1 and reduced nicotinamide cofactor resulted 
in the formation of several products. After 4 hours incubation of 1 with OxaD, 
HPLC-MS analysis (50:50 CH3OH:H2O) showed peaks with molecular weights 
corresponding to the nitrone 17, the hydrated product 36, and a presumed CH3OH 
adduct (Figure 2.2). Low levels of the hydroxylamine 16 were also detected. 
Preparative scale enzymatic reactions were conducted in the Joullié laboratory 
using 1 (20 mg) in order to characterize the major reaction product. As reverse-
phase C18 chromatography led exclusively to the hydrolysis product 36, 
subsequent reactions were designed to minimize the exposure of 17 to aqueous 
conditions, acidic or basic pH, and light. Biocatalytic reactions were performed for 
1 hour prior to extraction with EtOAc and normal phase chromatography 
purification on deactivated silica gel in the absence of unhindered alcohols. These 
conditions led to 17 in a single step in good yield.  
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Figure 2.2: Reactions with OxaD and 1 led to the detection of a hydroxylamine 
intermediate 16 and the hydrolysis product 36 
Identification of nitrones has long been a challenge with regard to their 
differentiation from other products of N-oxidation, such as imines, amine oxides, 
or oxaziridines. The presence of the nitrone functionality in 17 was confirmed by 
analysis of 1H NMR, 13C NMR, and infrared (IR) spectra.  Analysis of the 1H NMR 
spectrum of 17 confirms the double oxidation event at the indoline nitrogen, 
demonstrated conclusively by the disappearance of the H6 signal at δ 6.35 ppm. 
Moreover, chemical shifts of H9, H10, H11 and H12 were observed further 
downfield. Analysis of the 13C NMR spectrum of 17 was further indicative of the 
nitrone formation, as the chemical shift of the C-6 peak shifted from δ 78 ppm to 
δ 150 ppm. Additionally, previous infrared analysis of N-phenyl nitrones shows a 
very strong band between 1000-1100 cm-1 corresponding to the N-O stretch.25 This 
band disappears upon isomerization of N-phenyl nitrones to the corresponding 
oxaziridines. Following the oxidation of roquefortine C by OxaD, an intense band 
was observed at 1014 cm-1 in the IR spectrum of 17, providing additional support 
for the presence of a nitrone functionality rather than an oxaziridine.   
As the natural abundance of 15N is quite low (0.36%), 20 mg of roquefortine 
L proved to be an insufficient amount to carry out 15N NMR experiments. Thus, 
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P. crustosum was cultured in 15N-enriched medium to give 15N-labeled 1 (86% 15N 
incorporation). This material was subjected to the same reaction conditions as 1 
to provide 15N-labeled 17, which was characterized by analysis of the 1H-15N 
HMBC spectrum. Nitrogen atoms in N-aryl nitrones display a characteristic peak 
between δ 270-300 ppm, while the corresponding amine nitrogens are observed 
between δ 0-100 ppm. In the 1H-15N HMBC spectrum of 15N-enriched 17 the signal 
at δ 83 ppm disappeared, and a new peak was observed at δ 281 ppm, which 
correlated to H9 and H10. 
C. Investigating the Mechanism of Oxidation 
The observation of hydroxylamine 16 led us to investigate the mechanism 
of roquefortine C (1) oxidation by OxaD. The full catalytic cycle encompasses a 
four-electron reduction, in which two equivalents of NADH are consumed en route 
to the nitrone product. We considered two possible mechanisms for this reaction, 
the first proceeding via a hydroxylamine intermediate and the second proceeding 
via the indole imine (37, Scheme 2.4). 
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Scheme 2.4: Possible mechanisms of roquefortine L (17) biosynthesis by OxaD 
Single turnover experiments were performed in which only one equivalent 
of NADH was provided to equimolar concentrations of OxaD and roquefortine C. 
Analysis of the reaction products showed an approximate 1:2 ratio of singly-
oxidized hydroxylamine 16 species relatively to the doubly-oxidized nitrone 
product (Table 2.1), conclusively demonstrating that the reaction proceeds through 
a hydroxylamine intermediate. The abundance of 16 with respect to 17 under 
single turnover conditions also suggested that oxidation by OxaD is catalyzed in 
an iterative rather than a processive manner. To further support this proposal, 
single-turnover reactions were run with a 10-fold stoichiometric excess of 
roquefortine C with respect to NADH and OxaD in an effort to preclude re-binding 
of dissociated hydroxylamine. Under these conditions, 16 was the dominant 
reaction product, further supporting an iterative mechanism for OxaD. This iterative 
N-oxidation mechanism has been previously reported with human flavin containing 
monooxygenase 3 (FMO3) using various substrates.20,26 The steady state kinetic 
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constants of OxaD with roquefortine C were determined by the Sherman group 
using an high-performance liquid chromatography (HPLC) based assay. These 
data show a turnover number (kcat) of 0.017 s-1 with a Michaelis constant (KM) of 
71 nM resulting in a catalytic efficiency (kcat/KM) of 2.3 x 105 M-1s-1. 
Table 2.1: Single turnover studies of OxaD 
Entry 
Roquefortine C 
(1) equiv. 
Conversion 
(%) 
Product ratio 
Hydroxylamine (16) Roquefortine L (17) 
1 1 75 1 2 
2 10 10 1 0 
 
D. Roquefortine L Undergoes 1,3-Dipolar Cycloaddition 
Since nitrones undergo 1,3 dipolar cycloadditions with dipolarophiles such 
as alkenes, alkynes, and nitriles, 17 was screened with known dipolarophiles for 
1,3-dipolar cycloaddition reactions. Appropriate dipolarophile candidates for 1,3-
dipolar cycloaddition with 17 were predicted by computational HOMO-LUMO 
analysis performed by the Joullié group (Table 2.2).  
Methyl acrylate showed the best reactivity toward 17. Optimized reaction 
conditions developed by the Sherman group generated cycloadduct 38 in a single 
step with 84% conversion, 24% yield (Scheme 2.5). The observed regiochemistry 
of this reaction is consistent with predictions based on frontier molecular orbital 
interactions described by Sustmann and Trill.27 The stereochemistry of this species 
was determined by NOESY (Nuclear Overhauser effect spectroscopy). While this 
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cycloaddition is highly indicative of the presence of a nitrone functionality in 17, 
oxaziridines are also known to thermally rearrange to nitrones before undergoing 
1,3-dipolar cycloadditions.28,29 
Table 2.2: Potential dipolarophile candidates for 1,3-dipolar cycloaddition with 
roquefortine L (17) 
Dipolarophile LUMO structure 
HOMO-LUMO gap† 
(eV) 
 
Trichloroacetonitrile 
 
11.54 
 
Dimethyl fumarate 
 
10.56 
 
Dimethyl maleate  
11.33 
 
Methyl acrylate 
 
11.78 
†HOMO-LUMO energy gaps calculated using HOMO of roquefortine L (17) and LUMO of 
dipolarophile. Calculations was carried out at the HF/6-311+G(2d,p) level of theory. 
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Scheme 2.5: Roquefortine L (17) undergoes 1,3-dipolar cycloaddition with methyl acrylate 
to generate 38 
E. Oxidation of Roquefortine C Derivatives by OxaD 
In order to explore the substrate scope of OxaD, the roquefortine C 
derivatives 9, 39–42 were assayed under the same conditions as described above 
for the native substrate 1 (Figure 2.3A). Compounds 9, 39–41 were generated by 
semisynthesis from 1 (Scheme 2.6) while roquefortine E (42) was purchased from 
Enzo (Ann Arbor, MI). Isoroquefortine C (9) was obtained by photochemical 
reaction of 1 using broad spectrum UV light.30 Isomerization of roquefortine C was 
also observed upon exposure to direct sunlight over the course of several days. 
Electrophilic aromatic substitution of 1 using N-bromosuccinimide (NBS) and N-
iodosuccinimide (NIS) yielded 11-bromoroquefortine C (39)31 and 11-
iodoroquefortine C (40), respectively.  
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Figure 2.3: (A) Roquefortine C and derivatives. (B) Nitrones derived from OxaD N-
oxidation 
Modifications to the roquefortine C scaffold highlighted in red. 
 
Scheme 2.6: Semisynthesis of roquefortine C derivatives 9, 39, and 40 
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A number of fluorination and trifluoromethylation methods were attempted, 
including trifluoromethylation using the Baran sodium and zinc 
trifluoromethanesulfinates and electrophilic fluorination using SelectFluor, 1-
(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane dihexafluorophosphate 
(F-TEDA-PF6), and 1-fluoro-2,4,6-trimethylpyridin-1-ium tetrafluoroborate (Figure 
2.4). Unfortunately, reactions using these conditions gave only starting material. 
Synthesis of the arylstannane derivative from 11-iodo roquefortine C (40), in 
preparation for silver-catalyzed electrophilic fluorination as described by Ritter,32 
also proceeded poorly.  
 
Figure 2.4: Electrophilic fluorinating reagents 
Attempted electrophilic fluorination with N-fluorobis(phenyl)sulfonamide 
(NFSI) did not afford a fluoro derivative but instead introduced a sulfonyl group on 
the C20 position of the imidazole ring (Scheme 2.7). Although the reaction was 
unexpected, there is precedent for a similar reaction on a purine derivative 
proposed to occur via a single electron transfer (SET) mechanism.33 
 53 
 
 
Scheme 2.7: Unexpected NFSI phenylsulfonyl transfer 
A number of synthesized roquefortine C derivatives were tested for 
antimicrobial activity in collaboration with the Moulder Center for Drug Discovery 
Research at Temple University and the University of Rochester.  Compounds 40 
along with the imidazole N21 carboxybenzyl (Cbz) protected derivative of 1 
showed modest activity (64 μg/mL) against Staphylococcus aureus UAMS 1 (a 
penicillin sensitive strain) despite their low aqueous solubility. 
Processing 9, 39–42 to their corresponding nitrone products (43-47, Figure 
2.3B) demonstrated that OxaD can accommodate variation at several positions in 
the roquefortine C skeleton. Total turnover numbers (TTN) were measured by the 
Sherman group to quantify the effect of these variations on the OxaD biocatalyst 
(Figure 2.5). Modifications to the histidine moiety, including both alkene 
isomerization (43) and reverse prenylation (47), were well tolerated. Only the 
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phenylsulfonyl derivative (46) showed a substantial decrease in TTN. To test 
whether the diminished turnover of 46 was observed due to the poor solubility of 
this substrate, TTNs were measured using both 10% and 20% dimethyl sulfoxide 
(DMSO) cosolvent. While elevated cosolvent increased the solubilization of 46, 
only a modest increase in TTN was observed, likely indicating that the benefit was 
offset by attenuated enzymatic activity. Modifications to the indole ring via 
halogenation (compounds 44 and 45) were also processed efficiently by OxaD.  
 
Compound      17  46         44     45           47      43 
Figure 2.5: Total turnover number of roquefortine C and derivatives by OxaD 
TTN was calculated as moles product/moles enzyme. 
F. OxaD Catalyzes Indole 2,3-Oxidation of Notoamide S 
Based on the broad reactivity that OxaD displayed with roquefortine C 
derivatives, the Sherman group subjected additional indole alkaloids to the enzyme 
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to examine whether this substrate flexibility extended beyond the roquefortine C 
scaffold. These include brevianamide F (48), 6-OH-deoxybrevianamide E (49), 
notoamide S (50), notoamide E (51), (+)-stephacidin A (52), notoamide T (53) and 
pre-paraherquamide (54) (Scheme 2.8A). Of particular interest was to assay 52, a 
presumed biosynthetic precursor to the nitrone-bearing avrainvillamide (32);34 
however no reaction was observed for substrates 48, 49, and 51-53. Enzyme-
dependent generation of a new product with m/z = +16 Da was uniquely observed 
by liquid chromatography-mass spectrometry (LC-MS) with 50. The total 
conversion (20%) was lower than that of the roquefortine C alkaloids. Biocatalytic 
reaction of 50 with OxaD gave rise to a 2-indolinone 55 rather than the expected 
indole N-hydroxylamine (Scheme 2.8B). The product 55 is presumed to arise via 
2,3-epoxidation followed by a pinacol-like rearrangement in an analogous fashion 
to the NotB catalyzed formation of notoamides C (56) and D (57) (Scheme 2.9).35 
Compound 55 was observed as a single reaction product between 50 and OxaD, 
as opposed to the reaction between notoamide E (51) and NotB which generated 
notoamides C (56) and D (57). OxaD appears to play a role in directing reaction 
selectivity, although low enzyme activity with notoamide S (50) could limit the 
detection of minor reaction products.  This outcome shows that OxaD presents 
remarkable functional plasticity in addition to its broad substrate scope. Further 
structural investigation would be required to determine the mechanistic basis of 
this branch in reaction specificity.  
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Scheme 2.8: OxaD reactivity with notoamides 
(A) Synthetic notoamides tested with OxaD. Only 50 was converted by the enzyme. 
(B) Pinacol-like rearrangement of the OxaD catalyzed 2,3-indole epoxidation on 50 gives 
rise to the novel product 55. 
 57 
 
 
Scheme 2.9: NotB-catalyzed formation of notoamides C (56) and D (57) from notoamide 
E (51) 
G. Speculation on Glandicoline A Formation in P. glandicola 
Our extensive work with OxaD coupled with the striking similarities of the 
roquefortine C gene clusters in P. oxalicum and P. chrysogenum give further 
support to the role of roquefortine L as the exclusive biosynthetic precursor to 
glandicoline B. Hydroxylation at C16 of 1 leading to 12 appears insufficient to 
induce rearrangement, since this metabolite has been previously isolated and 
identified;36,37 therefore, both hydroxylation at C16 and nitrone generation to give 
58 are likely required for the core rearrangement to occur. Roquefortine L (17) 
involvement is supported by the fact that glandicoline A (15) has not been 
observed in P. chrysogenum, and that disruption of roqM (81% homology with 
oxaD) abolished the production of glandicoline B (2).22 The first report of 15 in 
P. glandicola is sufficiently supported by spectroscopic data;38 however, 
subsequent reports of 15 were based on mass spectrometry analysis, 
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chromatographic retention time (Rf) and/or UV signature, but not by NMR 
analysis.21,23,39 As substantial structural characterization of metabolites is 
imperative in differentiating glandicoline A from 17, we have unequivocally 
assigned the nitrone group in 17 by NMR, IR, and chemical transformation. 
At present, the mechanism of formation of 15 in P. glandicola is unclear. It 
could require a yet unknown route to the 1,2-imine in 14 proposed by Steyn and 
Vleggaar33 or arise by modification of 2 (Scheme 2.10). Investigation of the 
biosynthetic gene clusters in strains that produce 15 will be necessary to identify 
candidate enzymes that could give rise to 15, either through a different oxidation 
cascade involving 1 or enzymatic processing of 2. Understanding the role of the 
oxidative enzymes involved in the rearrangement of 1 to 2 will be critical for in vitro 
reconstitution and for future mutasynthetic efforts based on derivatives of 1. There 
is ample precedence for plasticity in these pathways, as mutasynthesis with roqA 
gene disruption mutant strains has been used to generate novel roquefortine D 
derivatives.40 Characterization of OxaD reported in this study also reveals the 
ability of the roquefortine C nitrone synthase to accept an array of modified 
substrates that enables the generation of novel indoline nitrones that would be 
synthetically appealing for the preparation of further elaborated alkaloid scaffolds. 
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Scheme 2.10: Proposed biogenesis of glandicoline A (15) and B (2) 
IV. Conclusions 
The enzymatic characterization of OxaD, along with the results of gene 
disruptions,23 indicates that formation of roquefortine L (17) is a key biosynthetic 
intermediate toward formation of the glandicoline core. The results herein illustrate 
that the combination of biological and chemical approaches for the generation of 
new and diverse natural products can lead to a number of applications in chemistry 
and chemical biology. Understanding the genetic and metabolic information of 
biological systems can provide access to complex chiral molecular scaffolds, which 
can be further synthetically elaborated into novel molecules. These natural 
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product-based modified frameworks are of considerable interest in chemistry, 
biochemistry, and chemical biology as bioactive chemical entities or as unique 
biochemical tools. Heterologous production and enzymatic characterization of 
OxaD constitutes a proof of concept that unique biocatalysts can generate versatile 
and powerful chemical and biochemical tools for structural diversification. 
V. Experimental 
P. oxalicum genomic DNA sequencing 
P. oxalicum was cultivated in liquid medium (20% artificial seawater with 12.0 g/L 
glucose, 6.0 g/L starch, 12.0 g/L soytone, 3.0 g/L peptone, 0.18 g/L meat extract, 
3.0 g/L yeast extract) in still mode at 28 °C for 14 days. The mycelia were harvested 
by filtration and genomic DNA was extracted using the Wizard Genomic DNA 
isolation kit (Promega). Genomic DNA was analyzed by using a HiSeq 2000 
sequence analyzer using 100 cycle paired end reads (Illumina). De novo assembly 
of genomes was performed using Velvet version 0.7.63. The summary of dataset 
and parameters of genome sequencing and assembly is shown in Tables S1-2. 
Probes from the published sequence for meleagrin biosynthetic gene cluster were 
used to identify the contig containing the oxaline biosynthetic gene cluster.  
Supplementary Table 2.1: P. oxalicum F30 genome sequencing and assembly 
Genome Number of reads k-mer Coverage cutoff N50 Number of contigs 
P. oxalicum 62,981,204 71 28 24,473 9,807 
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Supplementary Table 2.2: Annotation of OXA gene cluster 
Proteins Size (AA)* Function Relative 
(identity/similarity) (%) 
Accession 
number 
ORF01 800 hypothetical protein, 
phosphoenolpyruvate 
synthase 
Hypothetical protein 
ATEG 02219 
[Aspergillus terreus 
NIH2624] (72/83) 
XP_001211397.1 
OxaA 2390 NRPS Pc21g15480 [Penicillium 
chrysogenum Wisconsin 
54-1255] (53/69) 
XP_002568558.1 
 
 
OxaB 477 cytochrome P450 
oxidoreductase 
Pc21g15470 [Penicillium 
chrysogenum Wisconsin 
54-1255] (73/84) 
XP_002568557.1 
OxaC 405 O-methyltransferase O-methyltransferase 
[Aspergillus flavus 
NRRL3357](49/65) 
XP_002384741.1 
OxaD 456 MAK1 Pc21g15460 [Penicillium 
chrysogenum Wisconsin 
54-1255] (66/79) 
XP_002568556.1 
OxaE 482 MFS toxin efflux 
pump 
Pc21g15420 [Penicillium 
chrysogenum Wisconsin 
54-1255] (69/81) 
XP_002568552.1 
OxaF 419 dimethylallyl 
tryptophan synthase, 
putative 
Pc21g15430 [Penicillium 
chrysogenum Wisconsin 
54-1255] (70/80) 
XP_002568553.1 
OxaG 288 UbiE/COQ5 family 
methyltransferase, 
putative 
Pc21g15440 [Penicillium 
chrysogenum Wisconsin 
54-1255] (73/84) 
XP_002568554.1 
 
 
OxaH 499 cytochrome P450 
monooxygenase 
Pc21g15450 [Penicillium 
chrysogenum Wisconsin 
54-1255](64/77) 
XP_002568555.1 
OxaI 322 hp** Pc12g13620 [Penicillium 
chrysogenum Wisconsin 
54-1255](62/75) 
XP_002558169.1 
OxaJ 419 hp** hypothetical protein 
AKAW_10943 
[Aspergillus kawachii 
IFO 4308](57/72) 
GAA92830.1 
OxaK 322 sucrase/ferredoxin-
like family protein 
Fmi1 
Pc12g04290 [Penicillium 
chrysogenum Wisconsin 
54-1255](73/83) 
XP_002557299.1 
*AA: amino acid; **hypothetical protein 
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Molecular cloning of oxaD gene 
P. oxalicum F30 was cultivated in liquid medium as above. RNA was isolated from 
filter paper-dried mycelia using the TRIzol® Reagent (Ambion RNA, Life 
Technologies) and protocol. The reverse transcription PCR (RT-PCR) was 
performed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) using Oligo dT primer (Life Technologies). The cDNA generated from 
one microgram of total RNA was used as the template for PCR amplification of the 
oxaD gene. The forward primer based on the oxaD gene is 5’- 
aattcgGCTAGCATGACTGTTCCGAACAGCGCC-3’ (the NheI restriction site is 
underlined) and reverse, 5’- 
cgaattCTCGAGCTATGTTGAGACAGTCTTTTTGTAGTCATG-3’ (the XhoI site is 
underlined). The amplified oxaD gene was doubly digested by NheI and XhoI, and 
then ligated into an NheI/XhoI digested pET28b vector, which was modified to 
include eight His residues followed by a tobacco etch virus (TEV) protease 
recognition sequence, to generate the pET28b-oxaD construct for protein 
expression.  
Overexpression and purification of OxaD 
The Escherichia coli BL21 (DE3) pRARE transformant carrying pET28b-oxaD was 
grown at 37 °C overnight in lysogeny broth (LB) containing 50 μg/mL of kanamycin. 
Baffled Fernbach flasks (6 x 1.5 L of LB in 2.8 L) containing 50 μg/mL of kanamycin 
were inoculated with 20 mL overnight culture. Cells were grown at 37 °C until A600 
reached ~ 0.6. Isopropyl β-D-thiogalactoside (IPTG, 1 mM) was added to induce 
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protein overexpression. Cells were cultured at 18 °C overnight, harvested by 
centrifugation, and frozen directly into liquid nitrogen prior to storage at -80 °C. All 
subsequent purification steps were performed on ice or at 4 °C. Frozen cells (15 g) 
were resuspended in 100 mL of lysis buffer (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.6, 50 mM NaCl, 10% glycerol, 
0.2 mM tris(2-carboxyethyl)phosphine (TCEP)). Lysis was achieved by the 
addition of lysozyme (0.5 mg/mL), benzonase (Merck kGaA, 1 kU), and MgSO4 
(5 mM) followed by sonication on ice. The lysate was clarified by centrifugation at 
60,000 g for 30 minutes at 4 °C. NaCl and imidazole were added to the supernatant 
to final concentrations of 300 mM and 20 mM, respectively, prior to loading a 
column containing 7 mL of Ni-NTA resin (Qiagen) equilibrated with NiNTA wash 
buffer (20 mM HEPES pH 7.6, 300 mM NaCl, 20 mM imidazole, 10% glycerol, 
0.2 mM TCEP). The column was washed with 150 mL of wash buffer. The bound 
N-terminal His8-tagged OxaD was eluted by elution buffer (300 mM imidazole pH 
8.0, 10% glycerol, 0.2 mM TCEP). The eluant was concentrated on a Millipore 
Amicon Ultra centrifugal concentrator (30 kDa MWCO). The concentrated protein 
was exchanged into storage buffer (10 mM HEPES pH 7.6, 50 mM NaCl, 10% 
glycerol, 0.2 mM TCEP) using a PD-10 desalting column (GE Healthcare). The 
purified OxaD protein was flash frozen in liquid nitrogen, and stored at -80 °C. 
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Isolation of 15N-enriched roquefortine C (1) from P. crustosum 
Freeze-dried samples of P. crustosum were inoculated onto malt extract agar 
plates as described in Chapter 1. 15N-Enriched Czapek-Dox liquid media was 
prepared as follows: 10 g sucrose; 1 g 15N-enriched (98%+) NaNO3; 0.33 g 
K2HPO4; 0.167 g MgSO4; 0.167 g KCl; 0.003 g FeSO4; and 333 mL dd H2O. Media 
was inoculated with fungal culture as described above and was grown in liquid 
culture for 21 days. Mycelial material was harvested and extracted as described 
above and 15N-enriched roquefortine C was purified from the other metabolites by 
flash chromatography (Rf 0.33, 85:10:5 CH2Cl2/CH3OH/acetone). HRMS (ESI-
TOF) m/z [M + H]+ calcd for C22H2415N5O2 395.1782, found 395.1787. 
Supplementary Table 2.3: 15N Incorporation into roquefortine C (1) determined 
by mass spectrometry 
Experimental 
IDCalc prediction 
(86% 15N incorporation) 
m/z Intensity 
Relative 
Abundance 
m/z 
Relative 
Abundance 
391.2823 6080 5.20 391.1948 0.29 
392.1895 16600 14.19 392.1972 3.64 
393.1912 40400 34.53 393.1995 22.79 
394.1828 90500 77.35 394.2019 72.82 
395.1801 117000 100.00 395.2042 100.00 
396.1850 29200 24.96 396.2066 22.57 
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Semi-synthesis of roquefortine C analogues: General Information 
Starting materials, reagents and solvents were purchased from commercial 
suppliers and used without further purification unless otherwise noted. Anhydrous 
tetrahydrofuran (THF) and CH2Cl2 were obtained from a solvent dispensing system 
stored under positive pressure of argon. The sample of roquefortine E (42) was 
purchased from Enzo (Ann Arbor, MI). All reactions were conducted in oven-dried 
glassware. The progress of reactions was monitored by silica gel thin layer 
chromatography (TLC) plates (250 µm with fluorescent indicator), visualized under 
UV, and stained using a phosphomolybdic acid (PMA) stain. Products were 
purified by flash column chromatography (FCC) on 230-400 mesh silica gel. 1H 
and 13C NMR spectra were recorded on a spectrometer operating at 500 MHz for 
1H and 125 MHz for 13C unless otherwise stated. Chemical shifts are reported in 
ppm relative to tetramethylsilane (TMS) as the internal standard for 1H and 
chloroform as the internal standard for 13C. 15N NMR spectra were recorded on a 
spectrometer operating at 600 MHz. Chemical shifts are reported in ppm relative 
to nitromethane as the external standard. 1H-1H Homonuclear correlation 
spectroscopy (COSY), 1H-1H NOESY, 1H-13C heteronuclear single quantum 
correlation experiment (HSQC), 1H-13C heteronuclear multiple quantum coherence 
(HMQC), and 1H-13C heteronuclear multiple bond correlation (HMBC) NMR 
spectra were recorded on a spectrometer operating at 500 MHz. 1H-1H Gradient 
correlation spectroscopy (gCOSY), 1H-13C  gradient heteronuclear single quantum 
coherence adiabatic (gHSQCAD), and 1H-13C gradient heteronuclear multiple 
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bond correlation adiabatic (gHMBCAD) NMR spectra were recorded on a 
spectrometer operating at 700 MHz. NMR data is reported as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = 
quartet, br = broad, m = multiplet), coupling constants (Hz), and integration. High-
resolution mass spectra (HRMS) were recorded on an electrospray ionization time-
of-flight (ESI-TOF) spectrometer (Agilent). Waters software calibrates and reports 
by use of neutral atomic mass. The mass of the electron is not included. 
 
11-Bromoroquefortine C (39) 
In a round-bottomed flask under argon, roquefortine C (100 mg, 0.26 mmol) was 
dissolved in dry CH2Cl2 (6 mL). A solution of NBS (46 mg, 0.26 mmol) in dry CH2Cl2 
(6 mL) was prepared and added dropwise via syringe to the round-bottomed flask 
containing roquefortine C. The reaction mixture was allowed to stir overnight 
(15 hours), after which it was washed three times with saturated aqueous 
NaHCO3. The organic solution was then dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by flash chromatography (98:2 to 90:10 
CH2Cl2-CH3OH) to give 11-bromoroquefortine C (72 mg, 59%) as a yellow powder. 
1H NMR (500 MHz, CDCl3) δ 9.83 (s, 1H), 7.70 (s, 1H), 7.28 (d, J = 1.5 Hz, 1H), 
7.26 (s, 1H), 7.20 (dd, J = 8.5, 1.5 Hz, 1H), 6.49 (d, J = 8.0 Hz, 1H), 6.35 (s, 1H), 
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5.99 (s, 1H), 5.96 (d, J = 6.5 Hz, 1H), 5.93 (s, 1H), 4.09 (dd, J = 6.0, 11.5 Hz, 1H), 
2.56 (dd, J = 5.0, 12.5 Hz, 1H), 2.47 (t, J = 12.0 Hz, 1H), 1.15 (s, 1H), 1.05 (s, 1H). 
13C NMR (125 MHz, CDCl3) δ 166.9, 159.6, 149.2, 143.0, 137.0, 135.1, 132.0, 
131.3, 128.3, 125.7, 121.9, 115.4, 111.6, 110.8, 110.6, 78.7, 61.9, 58.9, 41.1, 37.0, 
23.0, 22.6. HRMS (ESI-TOF) m/z [M + H]+ calcd for C22H2379BrN5O2 468.1035, 
found 468.1035 (lit. (da Silva et al., 2014)31 HRMS (ESI) m/z [M + H]+ calcd for 
C22H2381BrN5O2 470.1186, found 470.1182).  
 
11-Iodoroquefortine C (40) 
In a round-bottomed flask under argon, roquefortine C (40 mg, 0.1 mmol) was 
dissolved in CHCl3 (1 mL). NIS (27 mg, 0.12 mmol) and AcOH (0.3 mL) were added 
to the round-bottomed flask, and the reaction mixture was allowed to stir overnight 
(15 hours), after which it was washed three times with saturated aqueous NaHCO3. 
The organic solution was then dried over Na2SO4 and concentrated in vacuo. The 
crude product was purified by flash chromatography (100:0 to 90:10 CH2Cl2-
CH3OH) to give 11-iodoroquefortine C (14 mg, 27%) as a yellow powder. 1H NMR 
(500 MHz, CDCl3) δ 11.61 (s, 1H), 9.71 (s, 1H), 7.65 (s, 1H), 7.38 (d, J = 1.5 Hz, 
1H), 7.32 (dd, J = 8.0 Hz, 1.5 Hz, 1 H), 7.14 (s, 1H), 6.67 (s, 1H), 6.35 (d, J = 
7.0 Hz), 5.91 (dd, J = 17.0 Hz, 6.0 Hz, 1H), 5.60 (s, 1H) 5.08 (m, 2H), 4.99 (s, 1H), 
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4.09 (dd, J = 6.0, 11.5 Hz, 1H), 2.50 (dd, J = 5.5, 12.0 Hz, 1H), 2.43 (t, J = 12.0 Hz, 
1H), 1.09 (s, 3H), 1.00 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 165.4, 158.6, 150.2, 
143.2, 137.8, 137.5, 135.4, 134.0, 132.0, 126.6, 117.5, 115.1, 111.1, 105.4, 79.5, 
78.1, 61.8, 59.2, 41.1, 37.4, 23.0, 22.6 ppm. HRMS (ESI-TOF) m/z [M + H]+ calcd 
for C22H23IN5O2 516.0897, found 516.0912.   
 
20-Phenylsulfonylroquefortine C (41) 
In a round-bottomed flask under argon, roquefortine C (40 mg, 0.10 mmol) was 
dissolved in dry THF (1 mL) and chilled in a dry ice/acetone bath. A 1.0 M solution 
of lithium bis(trimethylsilyl)amide (LiHMDS) in THF (0.11 mL, 0.11 mmol) was 
added dropwise via syringe and the reaction mixture was allowed to stir for 10 
minutes. NFSI (32 mg, 0.10 mmol) was then added and the reaction mixture was 
gradually warmed to room temperature. After stirring for 3 hours, the reaction 
mixture was concentrated in vacuo. The residue was diluted with H2O, extracted 
three times with CH2Cl2, dried over Na2SO4, and concentrated in vacuo. The crude 
residue was purified by flash chromatography (98:2 to 90:10 CH2Cl2-CH3OH) to 
give 20-phenylsulfonylroquefortine C (29 mg, 55%) as a yellow solid. 1H NMR 
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(500 MHz, CDCl3) δ 9.31 (s, 1H), 8.57 (s, 1H), 7.96 (d, J = 10.0 Hz, 3H), 7.65 (t, 
J = 7.5 Hz, 1H), 7.53 (t, J = 8.0 Hz, 2H), 7.12 (d, J = 7.5 Hz, 1H) 7.06 (t, J = 7.5 Hz, 
1H), 6.72 (t, J = 7.5 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 6.34 (s, 1H), 5.93 (dd, J = 
17.0, 11.0 Hz, 1H), 5.60 (s, 1H), 5.07 (m, 3H), 4.00 (dd, J = 6.0, 11.5 Hz, 1H), 2.52 
(dd, J = 12.5 Hz, 6.0 Hz, 1H), 2.38 (t, J = 12.0 Hz, 1H), 1.09 (s, 1H), 0.98 ppm (s, 
1H). 13C NMR (125 MHz, CDCl3) δ 167.6, 158.0, 150.4, 143.6, 137.9, 137.5, 136.1, 
135.1, 130.0, 129.1, 128.8, 127.7, 126.8, 125.4, 120.3, 119.0, 114.9, 114.7, 109.2, 
78.1, 61.6, 59.1, 41.1, 37.0, 23.0, 22.6 ppm. HRMS (ESI-TOF) m/z [M + H]+ calcd 
for C28H28N5O4S 530.1862, found 530.1866. 
 
Isoroquefortine C (9) 
In a round-bottomed flask, roquefortine C (90 mg, 0.23 mmol) was dissolved in 
EtOH (90%, 100 mL) and degassed with argon for 15 minutes. The solution was 
then irradiated with a broad-spectrum UV light bulb (Exo-Terra UVB 200 Intense 
Compact Fluorescent Lamp, 26 W) under argon for 2 days. The reaction mixture 
was concentrated in vacuo, and the residue was purified by flash chromatography 
(95:5 CH2Cl2:CH3OH) to furnish isoroquefortine C (59 mg, 66%) as a pale yellow 
solid. 1H NMR (500 MHz, CDCl3) δ 11.67 (s, 1H), 7.63 (s, 1H), 7.24 (s, 1H), 7.11 
(m, 2H), 7.05 (t, J = 7.5 Hz, 1H), 6.71 (t, J = 7.5 Hz, 1H), 6.63 (s, 1H), 6.56 (d, J = 
7.5 Hz, 1H), 5.94 (dd, J = 11.0, 17.5 Hz, 1H), 5.62 (s, 1H), 5.07 (m, 2H), 5.03 (s, 
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1H), 4.03 (dd, J = 6.0, 11.5 Hz, 1H), 2.53 (dd, J = 6.0, 12.5 Hz, 1H), 2.42 (t, J = 
12.0 Hz, 1H), 1.10 (s, 1H), 0.99 (s, 1H). 13C NMR (125 MHz, CDCl3) δ 165.9, 158.5, 
150.5, 143.6, 136.9, 135.8, 129.1, 128.9, 126.2, 125.3, 119.0, 118.2, 114.7, 109.2, 
105.8, 78.1, 61.7, 59.2, 41.1, 37.4, 23.1, 22.6. IR (KBr): 3149, 2969, 1685, 1609, 
1438, 1216, 1082, 748.31 cm-1 (lit. (Joullié et al., 2002)41 IR (KBr) 1680, 1630 cm-1). 
𝛼𝐷
22 -281.5146 (c 0.96, CHCl3) (lit. (Joullié et al., 2002)41 𝛼𝐷
20 -390 (c 0.05, CHCl3)). 
HRMS (ESI-TOF): m/z [M + H]+ calcd for C22H23N5O2 390.1930, found 390.1932 
(lit. (Joullié et al., 2002)41 HRMS (ESI-TOF) m/z [M + H]+ calcd for C22H24N5O2 
390.1930, found 390.1956). 
Enzymatic generation of roquefortine L and derivatives: General Information 
The biocatalytic reaction was set up as follows: 10 µM OxaD (0.05 mg), 0.5 mM 
roquefortine C (20 mg), 5 mM NADH (382 mg), 10% DMSO, 50 mM Na/K/PO4 pH 
7.3, 10% glycerol, 1 mM EDTA. A 100 mL reaction was run in 10 mL aliquots in 9 
dram glass vials for 2 hours at room temperature with mild agitation (100 rpm, 
orbital shaker). Solid NaCl was added to saturation and the reaction was extracted 
3 times with an equal volume of EtOAc. Centrifugation at 1000 x g for 2 minutes in 
a swinging bucket centrifuge was necessary to break the emulsion which formed 
upon addition of solvent. The combined organic fractions were washed twice with 
an equal volume of saturated aqueous NaCl, dried over Na2SO4, concentrated by 
rotary evaporation, and placed under high vacuum to remove DMSO. The product 
was applied to a silica column equilibrated with 2% Et3N in CH2Cl2, washed with 
CH2Cl2, followed by step-gradient elution with increasing i-PrOH (0-20%) in CH2Cl2 
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to give the nitrone product as a pale yellow solid. The solid was dissolved in a 
minimal volume of HPLC grade EtOAc and triturated with HPLC grade hexanes in 
an ice bath. The resulting fine solid was precipitated via centrifuge, and pellets 
were washed three times with HPLC grade hexanes, vortexing vigorously before 
centrifuging. Residual EtOAc was removed by dissolving the pellets in a small 
volume of CCl4, concentrating via rotary evaporator to give a fluffy solid, and drying 
under reduced pressure overnight. 
 
Roquefortine L (17)  
(86% conversion, 8 mg (40%) isolated yield). 1H NMR (600 MHz, DMSO-d6/CDCl3) 
δ 10.69 (s, 1H), 7.75 (s, 1H), 7.60 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.48 (m, 2H), 
7.40 (t, J = 7.4 Hz; 1H), 6.53 (s, 1H), 5.76 (dd, J = 11.0, 17.3 Hz, 1H), 5.08 (dd, J = 
3.7, 11.4 Hz, 1H), 5.03 (d, J = 11.4 Hz, 1H), 4.99 (s, 1H), 2.86 (dd, J = 3.8, 14.1 Hz, 
1H), 2.21 (dd, J = 11.5, 13.6 Hz, 1H), 1.03 (s, 3H), 0.83 (s, 3H). 13C NMR (150 MHz, 
CDCl3) δ 164.7, 156.4, 148.6, 146.8, 141.7, 138.0, 128.7, 128.3, 124.1, 121.6, 
115.5, 114.5, 63.4, 27.9, 42 .8, 22.3, 22.2. IR (KBr): 2961.82, 1682.40, 1384.58, 
1258.38, 1091.79, 1014.45, 794.80 cm-1. HRMS (ESI-TOF) m/z [M + H]+ calcd for 
C22H22N5O3 404.1723, found 404.1727 (lit. (Vreeken et al., 2013)22 HRMS (FTICR-
MS) m/z [M + H]+ calcd for C22H22N5O3 404.1723, found 404.1706). 
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Roquefortine L (17), 15N enriched  
(93% conversion, 5 mg (21%) isolated yield). 15N NMR (600 MHz, DMSO-
d6/CDCl3) δ 282.3, 134.7, 126.9. HRMS (ESI-TOF) m/z [M + H]+ calcd for 
C22H2215N5O3 409.1574, found 409.1574. 
 
11-Bromoroquefortine L (44)  
(70% conversion, 5 mg (60%) isolated yield). 1H NMR (500 MHz, CDCl3) δ 12.40 
(s, 1H), 8.64 (br. s, 1H), 7.70, (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.06 (m, 2H), 7.34 
(s, 1H), 6.44 (s, 1H), 5.81 (dd, J = 10.5, 17.5 Hz, 1H), 5.16 (d, J = 11.0 Hz, 1H), 
5.12 (s, 1H), 5.03 (m, 1H), 3.05 (dd, J = 3.5, 14.0 Hz, 1H), 2.29 (t, J = 12.5 Hz, 
1H), 1.15 (s, 1H), 0.99 (s, 1H). 13C NMR (125 MHz, CDCl3) δ 165.1, 157.6, 148.1, 
143.6, 141.6, 140.2, 138.1, 135.7, 132.9, 129.5, 127.9, 125.4, 123.3, 119.4, 117.5, 
115.0, 63.9, 59.0, 43.9, 23.1, 23.0. HRMS (ESI-TOF) m/z [M + H]+ calcd for 
C22H2179BrN5O3 482.0828, found 482.0833. 
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Isoroquefortine L (43)  
(81% conversion, 10 mg (52%) isolated yield). 1H NMR (500 MHz, CDCl3) δ 11.92 
(br. s, 1H), 11.71 (br. s, 1H), 7.77 (m, 2H), 7.51 (m, 2H), 7.42 (m, 2H), 6.92 (s, 1H), 
5.82 (dd, J = 11.0, 16.5 Hz, 1H), 5.12 (m, 2H), 5.03 (m, 1H), 3.06 (dd, J = 3.5, 
14.0 Hz, 1H), 2.25 (t, J = 11.5 Hz, 1H), 1.12 (s, 1H), 0.88 (s, 1H). 13C NMR 
(125 MHz, CDCl3) δ 163.8, 156.9, 150.1, 149.2, 141.8, 138.1, 136.7, 136.5, 129.5, 
129.0, 128.8, 124.6, 124.5, 120.7, 117.1, 115.8, 109.4, 64.3, 29.3, 44.0, 25.2, 22.9. 
HRMS (ESI-TOF) m/z [M + H]+ calcd for C22H22N5O3 404.1723, found 404.1720. 
 
20-Phenylsulfonylroquefortine L (46)  
(90% conversion, 11 mg (42%) isolated yield). 1H NMR (500 MHz, CDCl3) δ 9.14 
(s, 1H), 8.64 (s, 1H), 8.02 (m, 2H), 7.74 (d, J = 7.5 Hz, 1H), 7.65 (t, J = 7.0 Hz, 1H), 
7.56 (m, 2H), 7.51 (t, J = 12.5 Hz, 1H), 7.42 (m, 2H), 6.55 (s, 1H), 5.81 (dd, J = 
10.5, 17.5 Hz, 1H), 5.10 (d, J = 4.5 Hz, 1H), 5.08 (s, 1H), 4.96 (d, J = 11.0 Hz, 1H), 
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3.03 (dd, J = 3.5, 14.5 Hz, 1H), 2.23 (t, J = 11.0 Hz, 1H), 1.13 (s, 1H), 0.88 (s, 1H). 
13C NMR (125 MHz, CDCl3) δ 165.9, 155.5, 149.2, 148.2, 142.2, 138.6, 137.9, 
137.1, 136.4, 135.1, 130.1, 129.6, 128.9, 127.9, 125.2, 124.5, 120.9, 117.3, 117.0, 
116.1, 64.1, 58.9, 43.8, 25.6, 23.2, 22.8. HRMS (ESI-TOF) m/z [M + H]+ calcd for 
C28H26N5O5S 544.1655, found 544.1655. 
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Supplementary Figure 2.1: OxaD reaction products 
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Enzymatic conversion of notoamide S (50) 
Notoamide S (50) was synthesized as previously described.42 Notoamide S (50) 
(6 mg) was subjected to the same biocatalytic reaction conditions that were used 
for the roquefortine C derivatives and extracted in the same manner. The extracted 
material was purified by HPLC on a Waters XBridge Prep Phenyl 5 µm (10 x 
250 mm) column using isocratic separation (33% acetonitrile in water) at flow rate 
of 4 mL/min. 1H NMR (700 MHz, DMSO-d6) δ 10.67 (s, 1H), 8.51 (s, 1H), 6.73 (d, 
J = 8.1 Hz, 1H), 6.65 (s, 1H), 6.38 (d, J = 8.0 Hz, 1H), 6.01 (dd, J = 17.5, 10.8 Hz, 
1H), 5.11 (t, J = 6.4 Hz, 1H), 5.06 (d, J = 10.9 Hz, 1H), 4.96 (d, J = 17.4 Hz, 1H), 
4.05 (t, J = 7.9 Hz, 1H), 3.3 (m, 2H), 3.2 (m, 2H), 3.18 (m, 2H), 2.86 (d, J = 14.5 Hz, 
1H), 2.00 (m, 2H), 1.79 (m, 2H), 1.68 (s, 3H), 1.60 (s, 3H), 1.87 (s, 3H), 0.94 (s, 
3H). 13C NMR (175 MHz, DMSO-d6) δ 182.3, 165.6, 165.4, 155.6, 143.2, 142.3, 
130.7, 123.1, 122.5, 119.2, 112.9, 110.5, 107.5, 57.8, 56.5, 51.6, 44.7, 30.2, 27.1, 
25.2, 23.1, 21.7, 17.5 (obtained from HSQC/HMBC). HRMS (ESI-TOF) m/z [M + 
H]+ calcd for C26H34N3O4 452.2544, found 452.2545. 
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Single turnover studies with OxaD 
Single turnover reactions were set up with 120 µM OxaD, 100 µM NADH, 110 µM 
or 1 mM roquefortine C, 10% DMSO, 50 mM Na/K/PO4 pH 7.3, 10% glycerol, 1 mM 
EDTA and run for 4 minutes at room temperature. The reactions were quenched 
by extraction using EtOAc/saturated aqueous NaCl and analyzed by LC-MS, in 
which the intermediates were resolved using a linear gradient of 5-100% CH3CN 
in H2O over 20 minutes (0.3 mL/min flow rate) on an Agilent Extend C18 column 
(4.6x150 mm, 5 µm).  
Standards for the roquefortine C hydroxylamine (16) were generated by reduction 
of roquefortine L (17) using 5 equivalents NaBH4 in CH3OH. The reduction was run 
for 15 minutes at room temperature and quenched using an equal volume 
deionized water to give 16 as a single stereoisomer. 1H NMR (500 MHz, CD3OD) 
δ 7.74 (s, 1H), 7.30 (s, 1H), 7.25 (d, J = 8 Hz, 1H), 7.21 (t, J = 8 Hz, 1H), 6.96 (t, 
J = 7.5 Hz, 1H), 6.90 (d, J = 7.5 Hz, 1H), 6.36 (s, 1H), 5.99 (dd, J = 6.5, 11 Hz, 
1H), 5.89 (s, 1H), 5.09 (m, 2H), 3.98 (t, J = 8.5 Hz, 1H), 2.41 (m, 2H), 1.08 (s, 1H), 
0.95 (s, 1H). 13C NMR (125 MHz, CD3OD) δ 168.0, 159.8, 154.2, 145.0, 137.7, 
131.8, 130.3, 126.0, 125.0, 124.4, 119.7, 115.9, 115.3, 111.1, 110.2, 87.9, 62.3, 
59.7, 42.5, 40.1, 24.3, 23.5. HRMS (ESI-TOF) m/z [M + H]+ calcd for C22H24N5O3 
406.1879, found 406.1890. 
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Supplementary Figure 2.2: OxaD single turnover reactions 
 
 
Steady state kinetics of OxaD with roquefortine C 
Initial experiments which sought to determine kinetic constants in a continuous 
spectrophotometric assay by following the oxidation of NADH at 340 nm were 
hampered by the low KM for roquefortine C. Similarly, direct HPLC analysis could 
not achieve the sensitivity required to detect initial velocities at nanomolar 
concentrations of roquefortine C. The steady state kinetic constants of OxaD with 
roquefortine C were ultimately determined using an HPLC-based assay following 
a lyophilization step to concentrate the enzymatic reactions prior to analysis. 
Reactions were initiated by the addition of 100 μL of varied concentrations of 
roquefortine C in 100% DMSO to 4.1 mL of 1.6 nM OxaD, 200 μM NADH, 50 mM 
16 
16 
17 
1 
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Na/K/PO4 pH 7.4, 1 mM EDTA at room temperature (23 °C). 1.0 mL aliquots were 
quenched by plunging into liquid N2 at various time points (5-60 min) to achieve 
less than 20% substrate consumption over the reaction time course. Four time 
points were taken in each time course. All reactions were performed in duplicate. 
The frozen aliquots were lyophilized to dryness over 24 hours and resuspended in 
80 μL CH3OH. The resuspended samples were analyzed by HPLC in which the 
reaction mixture was resolved using a linear gradient of 15-65% CH3CN in 
dd H2O + 0.1% formic acid over 6 minutes (2.5 mL/min flow rate) on a ZORBAX 
SB-Phenyl column (4.6x150 mm, 5 μm) at 35 °C column oven temperature. Initial 
velocities were determined by the loss of roquefortine C signal and quantified using 
a standard curve for the substrate. The product signals were often below the UV 
detection limit at low substrate concentrations, and additionally the nitrone product 
was prone to hydrolysis and CH3OH addition, giving rise to multiple product peaks. 
Initial velocities were plotted against substrate concentration (Supplementary 
Figure 2.3) and fit by non-linear regression to the Michaelis-Menten equation 
(Supplementary Figure 2.4) using GraphPad Prism Version 6.01 software to 
determine the kinetic constants kcat and KM (Supplementary Table 2.4). 
Supplementary Table 2.4: Steady state kinetics of OxaD with roquefortine C 
Enzyme Substrate kcat (s-1) KM (nM) kcat/KM (M-1 s-1) 
OxaD Roquefortine C 0.017 ± 0.001 71 ± 15 2.3 x 105 
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Supplementary Figure 2.3: OxaD Initial Velocity 
 
Supplementary Figure 2.4: OxaD Michaelis-Menten Plot 
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1,3-Dipolar cycloaddition of roquefortine L (17) with methyl acrylate 
Roquefortine L (17) was generated as above with the omission of the silica gel 
flash chromatography step as the 1H NMR for the crude product of the biocatalytic 
reaction showed >90% purity with trace amounts of 1 and the nitrone hydrolysis 
product. After enzymatic conversion and extraction, ~20 mg of 17 was dried 
overnight under high vacuum in a 25 mL round-bottomed flask. To the dried 
material 10 mL of dry THF and 1 mL methyl acrylate were added, the flask was 
quickly purged with vacuum/dry nitrogen using a Schlenck line and left under 
positive pressure of nitrogen. The reaction was run in the dark at 45 °C for 60 hours 
without stirring. The material was evaporated to dryness and purified on silica 
using CH2Cl2:CH3OH (0-12% CH3OH step-gradient) as the mobile phase. This 
material was subjected to further purification on C18 reverse phase HPLC 
chromatography to give the cycloadduct 38 (84% conversion, 24% yield) as a pale 
brown solid. 1H NMR (600 MHz, CHCl3) δ 8.50 (s, 1H), 7.87 (s, 1H), 7.39 (d, J = 
7.7 Hz, 2H), 7.30 (m, 3H), 7.18 (td, J = 1.3, 7.9 Hz, 1H), 6.41 (s, 1H), 6.16 (dd, J = 
11.0, 17.3 Hz, 1H), 5.66 (t, J = 7.9, 1H), 5.15 (s, 1H), 5.11 (d, J = 8.6 Hz, 1H), 4.13 
(t, J = 8.5 Hz, 1H), 3.73 (s, 3H), 3.36 (dd, J = 8.9, 13.8 Hz, 1H), 3.23 (dd, J = 7.0, 
13.7 Hz, 1H), 2.90 (dd, J = 9.5, 13.6 Hz, 1H), 2.47 (dd, J = 8.1, 13.3 Hz, 1H), 1.31 
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(s, 3H), 1.26 (s, 3H). 13C NMR (150 MHz, CHCl3) δ 170.3, 167.4, 160.4, 148.0, 
144.5, 136.9, 135.3, 134.4, 129.2, 126.5, 125.3, 125.1, 121.8, 120.0, 113.8, 112.3, 
101.3, 80.0, 62.8, 57.0, 52.4, 41.9, 36.3, 35.9, 21.0. HRMS (ESI-TOF) m/z [M + 
H]+ calcd for C26H28O5N5 490.2085, found 490.2097. 
Total turnover number calculation 
Total turnover numbers (TTN = mol product/mol enzyme) were calculated in 
triplicate for all derivatives using 250 µM substrate in 50 mM Na/K/PO4 pH 7.3, 
10% glycerol, 1 mM EDTA. The OxaD concentration was 40 nM for substrates 1, 
9, 39; 80 nM for substrates 41, 42; and 320 nM for substrate 40, and the reactions 
were performed in 10% and 20% DMSO cosolvent. The reactions were run 
overnight at room temperature and analyzed by HPLC, in which products were 
resolved using a linear gradient of 5-100% CH3CN in H2O over 11 minutes 
(1.5 mL/min flow rate) on an Agilent Extend C18 column (4.6x150 mm, 5 µm). 
Moles of product formed in the assay were inferred by substrate consumption, 
which was quantified from standard curves of the respective substrate generated 
using the same separation method. 
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Appendix 2A: Spectra Relevant to Chapter 2 
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Supplementary Figure 2.5: 1H-15N HMQC NMR (600 MHz, CDCl3) Spectrum of 1 
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Supplementary Figure 2.6: 1H-15N HMBC NMR (600 MHz, CDCl3) Spectrum of 1 
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Supplementary Figure 2.7: 15N NMR (500 MHz, CDCl3) Spectrum of 1 
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Supplementary Figure 2.8: 1H NMR (600 MHz, DMSO-d6/CDCl3) Spectrum of 17 
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Supplementary Figure 2.9: 13C NMR (150 MHz, DMSO-d6/CDCl3) Spectrum of 17
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Supplementary Figure 2.10: IR Spectrum of 17 
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Supplementary Figure 2.11: 1H-15N HMBC NMR (600 MHz, DMSO-d6/CDCl3) Spectrum 
of 15N-17 
**Signals corresponding to imidazole nitrogens not observed due to rapid tautomerization. 
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Supplementary Figure 2.12: 15N NMR (600 MHz, DMSO-d6/CDCl3) Spectrum of 15N-17 
**Signals corresponding to imidazole nitrogens not observed due to rapid tautomerization. 
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Supplementary Figure 2.13: 1H NMR (500 MHz, CD3OD) Spectrum of 16  
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Supplementary Figure 2.14: 13C NMR (125 MHz, CD3OD) Spectrum of 16  
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Supplementary Figure 2.15: 1H NMR (600 MHz, CDCl3) Spectrum of 38  
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Supplementary Figure 2.16: 13C NMR (150 MHz, CDCl3) Spectrum of 38  
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Supplementary Figure 2.17: 1H-1H COSY NMR (600 MHz, CDCl3) Spectrum of 38  
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Supplementary Figure 2.18: 1H-13C HSQC NMR (600 MHz, CDCl3) Spectrum of 38  
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Supplementary Figure 2.19: 1H-13C HMBC NMR (600 MHz, CDCl3) Spectrum of 38  
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Supplementary Figure 2.20: 1H-1H NOESY NMR (600 MHz, CDCl3) Spectrum of 38 
 105 
 
 
Supplementary Figure 2.21: 1H NMR (500 MHz, CDCl3) Spectrum of 9  
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Supplementary Figure 2.22: 13C NMR (125 MHz, CDCl3) Spectrum of 9 
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Supplementary Figure 2.23: 1H-1H COSY NMR (500 MHz, CDCl3) Spectrum of 9 
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Supplementary Figure 2.24: 1H-13C HSQC NMR (500 MHz, CDCl3) Spectrum of 9  
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Supplementary Figure 2.25: 1H-13C HMBC NMR (500 MHz, CDCl3) Spectrum of 9  
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Supplementary Figure 2.26: 1H NMR (500 MHz, CDCl3) Spectrum of 39  
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Supplementary Figure 2.27: 13C NMR (125 MHz, CDCl3) Spectrum of 39  
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Supplementary Figure 2.28: 1H-1H COSY NMR (500 MHz, CDCl3) Spectrum of 39  
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Supplementary Figure 2.29: 1H-13C HSQC NMR (500 MHz, CDCl3) Spectrum of 39  
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Supplementary Figure 2.30: 1H-13C HMBC NMR (500 MHz, CDCl3) Spectrum of 39  
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Supplementary Figure 2.31: 1H NMR (500 MHz, CDCl3) Spectrum of 40 
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Supplementary Figure 2.32: 13C NMR (125 MHz, CDCl3) Spectrum of 40  
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Supplementary Figure 2.33: 1H-1H COSY NMR (500 MHz, CDCl3) Spectrum of 40  
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Supplementary Figure 2.34: 1H NMR (500 MHz, CDCl3) Spectrum of 41  
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Supplementary Figure 2.35: 13C NMR (125 MHz, CDCl3) Spectrum of 41 
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Supplementary Figure 2.36: 1H-1H COSY NMR (500 MHz, CDCl3) Spectrum of 41  
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Supplementary Figure 2.37: 1H-13C HSQC NMR (500 MHz, CDCl3) Spectrum of 41 
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Supplementary Figure 2.38: 1H-13C HMBC NMR (500 MHz, CDCl3) Spectrum of 41 
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Supplementary Figure 2.39: 1H NMR (500 MHz, CDCl3) Spectrum of 43 
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Supplementary Figure 2.40: 13C NMR (125 MHz, CDCl3) Spectrum of 43 
g
re
a
s
e
 
C
H
C
l3
 
 125 
 
 
Supplementary Figure 2.41: 1H-13C HSQC NMR (500 MHz, CDCl3) Spectrum of 43 
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Supplementary Figure 2.42: 1H NMR (500 MHz, CDCl3) Spectrum of 44  
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Supplementary Figure 2.43: 13C NMR (125 MHz, CDCl3) Spectrum of 44 
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Supplementary Figure 2.44: 1H NMR (500 MHz, CDCl3) Spectrum of 46  
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Supplementary Figure 2.45: 13C NMR (125 MHz, CDCl3) Spectrum of 46 
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Supplementary Figure 2.46: 1H-1H COSY NMR (500 MHz, CDCl3) Spectrum of 46 
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. Supplementary Figure 2.47: 1H-13C HSQC NMR (500 MHz, CDCl3) Spectrum of 46 
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Supplementary Figure 2.48: 1H-13C HMBC NMR (500 MHz, CDCl3) Spectrum of 46 
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Supplementary Figure 2.49: 1H NMR (700 MHz, DMSO-d6) Spectrum of 55 
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Supplementary Figure 2.50: 1H-1H gCOSY NMR (700 MHz, DMSO-d6) Spectrum of 55  
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Supplementary Figure 2.51: 1H-13C gHMBCAD NMR (700 MHz, DMSO-d6) Spectrum 
of 55  
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Supplementary Figure 2.52: 1H-13C gHSQCAD NMR (700 MHz, DMSO-d6) Spectrum of 
55  
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CHAPTER THREE 
ROQUEFORTINE C N-OXIDATION BY SYNTHETIC MEANS 
 
 
 
 
 
 
Material in this chapter reproduced in part with permission from: 
Gober, C.; Joullié, M. M. Isr. J. Chem. 2016, 57(3-4), 303-308.  
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I. Introduction  
While the biomimetic synthesis of roquefortine L has been carried out using 
flavin monooxygenase OxaD,1 the synthesis of roquefortine L by traditional 
synthetic methods has not yet been explored. Little has been done in the way of 
comparison studies to investigate the capacities of different oxidants towards N-
oxidation,2 particularly on systems as complex as roquefortine C. The fundamental 
differences between various oxidants are often not investigated, and investigation 
of the chemical kinetics of each of these oxidants may elicit new information 
regarding their reactivity towards complex systems. Therefore, it was of interest to 
examine the oxidation of the secondary amine functionality in roquefortine C to a 
nitrone functionality by a variety of oxidizing reagents in an attempt to understand 
the etiology of the process. 
II. Background 
A. Nitrones  
The nitrone is simultaneously one of the most valuable yet underutilized 
functional groups in organic chemistry. These N-oxides are excellent building 
blocks for the synthesis of complex molecules, acting as electrophiles as well as 
1,3-dipoles in cycloaddition reactions (Scheme 3.1).3 Nitrones have also been 
implemented as ligands in transition metal complexes.4 These compounds show 
promise in several applications; nitrones have been shown to inhibit oncogenic 
proteins as well as serving as spin traps for free radicals, which have been 
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implicated in neurodegenerative disease.5,6 Aryl nitrones in particular have found 
use in photolithography techniques as photo-bleachable compounds used to 
enhance contrast.7 
 
Scheme 3.1: Nitrones as chemical building blocks 
The oxidation of amines, typically carried out with organic reagents such as 
dimethyldioxirane (DMDO), peroxyacids, and sulfonyloxaziridines as well as metal 
peroxo complexes, is one of the most common methods to synthesize nitrones. In 
this method of synthesis, a nitrone is formed following two sequential oxidations of 
the amine and subsequent elimination of water (Scheme 3.2). 
 
Scheme 3.2: Mechanism of amine oxidation to nitrones 
Despite the numerous approaches that have been developed for this 
transformation, the synthesis of nitrones is often fraught with complications. The 
 140 
 
oxidation of unsymmetrical amines is plagued with regioselectivity issues,8 and 
owing to its electrophilic α-carbon, nitrones are subject to attack by nucleophiles, 
particularly in the presence of acidic media. N-Aryl amines such as roquefortine C 
are particularly difficult to oxidize as single electron transfer to form a relatively 
stable aminium radical cation results in C-N bond cleavage.9 N-Aryl nitrones are 
also particularly unstable, as formation of the nitrone eliminates lone pair 
delocalization onto the aromatic ring.10 
B. Chemical Kinetics and Reaction Progress Kinetic Analysis 
The study of chemical kinetics examines how one compound is converted 
to another. Chemical kinetics is particularly important in the field of organic 
chemistry as it can be implemented to elucidate mechanisms to new reactions or 
to compare rates of reaction between different reactants. Chemical reactions occur 
as a result of collisions between molecules, and as such, the rate of any reaction 
is proportional to the concentration of the reactant (Eq. 3.1). Reaction rate is also 
proportional to a rate constant k, which is a representation of a reaction’s 
dependence on temperature and activation energy. 
𝑟𝑎𝑡𝑒 ∝ 𝑘[𝑅]     (Eq. 3.1) 
This relationship between rate, reactant concentration, and the rate 
constant is also time dependent. As more of reactant R (Eq. 3.2) is consumed over 
the course of a reaction, the rate of the reaction changes. This change can be 
reflected by writing the rate as a derivative as a function of time (Eq. 3.3). 
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𝑅 
𝑘
→ 𝑃      (Eq. 3.2) 
𝑟𝑎𝑡𝑒 =  −𝑘
𝑑[𝑅]
𝑑𝑡
= 𝑘
𝑑[𝑃]
𝑑𝑡
     (Eq. 3.3) 
Rate laws describe the rate of a chemical reaction as a function of rate 
constant and the concentration of reactants. The rate law for a given reaction 
A + B → P (Eq. 3.4) is described in Eq. 3.5.  The degree to which the rate of 
reaction is controlled by the concentration of the reactants is reflected in the partial 
reaction orders x and y. The sum of all partial reaction orders for a given reaction 
represents the overall reaction order. 
𝐴 + 𝐵
𝑘
→ 𝑃                  (Eq. 3.4) 
𝑑[𝑃]
𝑑𝑡
= 𝑘[𝐴]𝑥[𝐵]𝑦    (Eq. 3.5) 
Integration of differential rate equations provides integrated rate equations 
that describe the reactant concentration as a function of time. A simple first order 
reaction (Eq. 3.6) can be described by the rate law in Eq. 3.7. Integration of this 
equation gives the integrated rate law (Eq. 3.8), showing an exponential 
dependence of A with respect to the rate constant. 
𝐴
𝑘
→ 𝑃      (Eq. 3.6) 
𝑑[𝑃]
𝑑𝑡
= −
𝑑[𝐴]
𝑑𝑡
= 𝑘[𝐴]     (Eq. 3.7) 
[𝐴] = [𝐴]0𝑒
−𝑘𝑡        (Eq. 3.8) 
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Integration of a second order bimolecular differential rate law (Eq. 3.10) 
leads to the integrated rate law as shown in Eq. 3.11. 
𝐴 + 𝐵
𝑘
→ 𝑃     (Eq. 3.9) 
𝑑[𝑃]
𝑑𝑡
= 𝑘[𝐴][𝐵]    (Eq. 3.10) 
1
[𝐵]0−[𝐴]0
ln (
[𝐴]0[𝐵]
[𝐵]0[𝐴]
) = 𝑘𝑡    (Eq. 3.11) 
Reactions that are second order in nature can often be simplified using 
experimental conditions to mimic first order behavior. This is accomplished by 
holding one of the reactants in great excess (usually more than 10 equivalents). In 
this way, the concentration of reactant B remains essentially constant over the 
course of the reaction, allowing for the reaction to be analyzed as if it were first 
order (Eq. 3.12). This process is known as pseudo-first order kinetics. 
𝑑[𝑃]
𝑑𝑡
= 𝑘[𝐴][𝐵]0 = 𝑘
′[𝐴]   (Eq. 3.12) 
Many reactions have more than one step, which leads to rate laws involving 
the sum of two terms (Eq. 3.14).  
𝐴
𝑘1
→ 𝐶
𝑘2
→ 𝑃    (Eq. 3.13) 
𝑑[𝐶]
𝑑𝑡
= 𝑘1[𝐴] − 𝑘2[𝐶]    (Eq. 3.14) 
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The rate laws for multi-step reactions can become extraordinarily complex; 
however, if over the course of a multi-step reaction a transient intermediate is 
formed, the steady state approximation can be used to simplify the resulting rate 
equations. The steady state approximation assumes that the transient 
intermediate C reacts quickly and is thus always low in concentration. Using this 
approximation, the concentration of this fleeting intermediate is assumed to be 
constant during the course of the reaction (Eq. 3.16). Rearrangement of Eq. 3.16 
and substitution of Eq. 3.17 into Eq. 3.15 gives Eq. 3.18, which predicts first order 
behavior with respect to A. 
𝑑[𝑃]
𝑑𝑡
= 𝑘2[𝐶]     (Eq. 3.15) 
𝑑[𝐼]
𝑑𝑡
= 𝑘1[𝐴] − 𝑘2[𝐶] = 0    (Eq. 3.16) 
[𝐶] =
𝑘1[𝐴]
𝑘2
     (Eq. 3.17) 
𝑑[𝑃]
𝑑𝑡
= 𝑘1[𝐴]     (Eq. 3.18) 
Using reaction progress kinetics techniques to monitor the concentration of 
each reactant as a function of time allows one to solve for each reactant’s partial 
reaction order and the rate constant. These values can provide insight into the 
mechanism of a reaction or the reactivity of a particular species.  Reaction 
progress kinetics can be analyzed using a number of experimental techniques, 
including UV-Vis spectroscopy, IR spectroscopy, high performance liquid 
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chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), and 
NMR spectroscopy.  
III. Results and Discussion 
A. Roquefortine C N-Oxidation Products 
A recently published method using a hydrogen peroxide-trichloroacetonitrile 
system for the oxidation of secondary amines to nitrones11 prompted us to 
investigate the kinetics of roquefortine C oxidation (Scheme 3.3). This oxidant was 
particularly interesting given that it yielded higher percentages of the 
hydroxylamine intermediate (16) than other more reactive oxidants such as m-
chloroperbenzoic acid (mCPBA).  
 
Scheme 3.3: Roquefortine C N-oxidation products 
In addition, roquefortine L was shown to be further oxidized to a compound 
of novel structure (61). LC-MS analysis indicated the addition of 16 Da following 
the oxidation of roquefortine L, pointing to overall addition of one atom of oxygen. 
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Additionally, 1H NMR of the unknown oxidation product in methanol-d4 revealed a 
doublet at 6.60 ppm (J = 1.3 Hz), a doublet of doublets at 6.63 ppm (J = 1.4, 
9.7 Hz), and a doublet at 7.60 ppm (J = 9.7 Hz). This splitting pattern is indicative 
of oxidative substitution at C11, para to the nitrone functionality. 1H-13C HMBC 
analysis also showed a strong correlation between the C9 hydrogen at 7.60 ppm 
and the 186.7 ppm peak in the 13C NMR spectrum. As 3JCH is generally larger than 
2JCH and 4JCH for aromatic systems, this correlation also points to oxidative 
substitution at C11.12  
The formation of phenol 61 was an unexpected result that warranted further 
discussion. The hydroxylation of an N-aryl nitrone has been observed in only one 
other instance in the literature.13 Electrophilic aromatic hydroxylation with mCPBA 
has been observed, however only in activated arenes.14 Formation of 61 is 
particularly interesting in this instance as hydroxylation occurs para to the nitrone 
and not at the meta position as one might expect for electrophilic aromatic 
substitution of a deactivated arene. This result leads us to believe that the 
hydroxylation is occurring via a non-electrophilic mechanism. Given the 
substitution pattern, one might imagine this reaction proceeding via a nucleophilic 
mechanism. Vicarious nucleophilic substitution of nitroarenes to form o- and p-
nitrophenols has been reported with tert-butyl and cumene hydroperoxides;15 
however, these reactions were carried out in strongly basic conditions to form the 
necessary nucleophilic alkyl hydroperoxide anions.  
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One could also imagine this reaction to proceed through a free radical 
process. Homolysis of the peroxy bond of peracids and peroxyimidic acids has 
been suggested based upon density functional theory (DFT) calculations;16 
however, attempts to inhibit free radicals using butylated hydroxytoluene (BHT) did 
not affect formation of 61. This experiment leads us to believe that either this 
reaction is not occurring by a free radical mechanism or 17 is more effective at 
trapping free radicals than BHT, which is possible given that nitrones are known 
spin traps. Given these conflicting results, it is difficult at this time to ascertain the 
mechanism of formation of compound 61. 
B. Derivation of N-Oxidation Rate Laws 
Due to the unique kinetics of this oxidant, it was of interest to examine the 
kinetics of this reaction sequence as compared to other electrophilic oxidants 
(Scheme 3.4). The kinetics of this reaction sequence can be described by 
Equations 3.19-3.24. The generation of the reactive peroxyimidic acid species 62 
is expressed by the equilibrium constant K (Eq. 3.19). Using a large excess of 
hydrogen peroxide and trichloroacetonitrile, and thus peroxyimidic acid, the rate of 
consumption of roquefortine C (1) can be expressed as pseudo first order, 
assuming the rate of oxidation by hydrogen peroxide alone is negligible (Equation 
3.20). Similarly, the rate of consumption of the hydroxylamine 16 can be expressed 
as a pseudo first order reaction (Equation 3.21).  Assuming the dehydration of 60 
is extremely rapid, we can simplify the rate expression for 60 using the steady state 
approximation (Equation 3.22). The equations expressing the concentration of the 
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nitrone roquefortine L (17) versus time and the concentration of the phenol (61) 
versus time were derived using the integrating factor method (Equations 3.23 and 
3.24). 
 
Scheme 3.4: Roquefortine C oxidation pathway 
 [62]= 𝐾[𝐻2𝑂2][𝐶𝑙3𝐶𝐶𝑁]     (Eq. 3.19) 
[𝟏] = [𝟏]0𝑒
−𝑍𝑡        (Eq. 3.20) 
𝑤ℎ𝑒𝑟𝑒 𝑍 = (𝑘1𝐾[𝐶𝑙3𝐶𝐶𝑁]0 + 𝑘𝑤)[𝐻2𝑂2]0 
 148 
 
[𝟏𝟔] =  
𝑍 [𝟏]0
𝑌−𝑍
(𝑒−𝑍𝑡 − 𝑒−𝑌𝑡)    (Eq. 3.21) 
𝑤ℎ𝑒𝑟𝑒 𝑌 = (𝑘2𝐾[𝐶𝑙3𝐶𝐶𝑁]0 + 𝑘𝑤2)[𝐻2𝑂2]0 
[𝟔𝟎] =  
𝑌[𝟏𝟔]
𝑘3
      (Eq. 3.22) 
[𝟏𝟕] =  
𝑌𝑍 [𝟏]0𝑒
−(𝑘4
′ +𝑈)𝑡
𝑌−𝑍
 (
𝑒
(𝑘4
′ +𝑈−𝑍)𝑡
−1
𝑘4
′ +𝑈−𝑍
+
𝑒
(𝑘4
′ +𝑈−𝑌)𝑡
−1
𝑘4
′ +𝑈−𝑌
)  (Eq. 3.23) 
𝑤ℎ𝑒𝑟𝑒 𝑘4
′ =  𝑘4[𝐻2𝑂],   𝑈 = 𝑘5𝐾[𝐶𝑙3𝐶𝐶𝑁]0[𝐻2𝑂2]0 
[𝟔𝟏] =
𝑈𝑌𝑍 [𝟏]0𝑒
−(𝑘6
′ )𝑡
𝑌−𝑍
(
1
𝑘4
′ +𝑈−𝑍
(
𝑒
(𝑘6
′ −𝑍)𝑡
−1
𝑘6
′ −𝑍
−
𝑒
(𝑘6
′ −𝑘4
′ −𝑈)𝑡
−1
𝑘6
′ −𝑘4
′ −𝑈
) −
1
𝑘4
′ +𝑈−𝑌
(
𝑒
(𝑘6
′ −𝑌)𝑡
−1
𝑘6
′ −𝑌
−
𝑒
(𝑘6
′ −𝑘4
′ −𝑈)𝑡
−1
𝑘6
′ −𝑘4
′ −𝑈
))  (Eq. 3.24) 
𝑤ℎ𝑒𝑟𝑒 𝑘6
′ =  𝑘6[𝐻2𝑂] 
C. Attempts to Monitor Reaction Kinetics 
The equilibrium constant K for the formation of 62 was determined through 
reaction with methyl p-tolyl sulfide (MTS) and analysis of the sulfide/sulfoxide ratio 
by 1H NMR (Scheme 3.5). Simultaneous addition of manganese dioxide to rapidly 
decompose the hydrogen peroxide prevented any shift in equilibrium following the 
addition of methyl p-tolyl sulfide.17 The equilibrium constant K was determined to 
be K = 23.0 ± 3.99 M (n=3). 
A number of methods were attempted to observe the reaction progress 
kinetics of this reaction. The various oxidized species did not possess unique 
enough UV absorbances to carry out this analysis by UV-Vis spectroscopy. Gas 
chromatography-mass spectrometry (GC-MS) analysis resulted in significant 
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fragmentation of the oxidized species, precluding accurate analysis. As acidic 
conditions are known to drastically increase the rate of hydrolysis of nitrone, HPLC 
and LC-MS analysis was carried out in neutral conditions. This resulted in severe 
line broadening and overlap of the peaks of interest. Each of the species in this 
reaction sequence could be resolved by 1H NMR (Figure 3.1); however, in situ 
monitoring of this reaction by 1H NMR proved fruitless due to the significant 
changes in shimming over the course of the reaction as well as interference by 
hydrogen peroxide. 
 
 
 
Scheme 3.5: Determination of K for the formation of peroxyimidic acid 62 
(A) Oxidation of methyl p-tolyl sulfide (MTS) by peroxyimidic acid 62; (B) 1H NMR spectrum 
of MTS/MTSO mixture 
 
MTSO 
MTSO 
MTS 
MTS 
 
 
A 
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Figure 3.1: 1H NMR spectra of roquefortine C (1) and N-oxidation products 
1H NMR spectra taken in methanol-d4 
D. N-Oxidation Product Analysis 
With previous attempts to monitor the reaction progress kinetics of this 
reaction sequence proving unsuccessful, we turned our attention towards the 
analysis of the product mixture of roquefortine C N-oxidation using two equivalents 
of oxidant. The trichloroacetonitrile-hydrogen peroxide oxidation system was 
analyzed along with mCPBA, DMDO, Na2WO4/H2O2, potassium 
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peroxymonosulfate (OXONE ®), and Davis oxaziridine. All of the oxidants 
investigated gave mixtures of starting material and various oxidized compounds 
(Table 3.1). Compound 61 was the most abundant product in the majority of the 
reactions, indicating that the nitrone roquefortine L is most reactive towards 
oxidation as compared to 1 or the hydroxylamine (16). DMDO (Entry 2) and 
OXONE ® (Entry 4) exhibited the best conversion from 1, indicating that these 
oxidants were sufficiently reactive with roquefortine C. The other oxidants featured 
higher levels of unreacted starting material, indicating that the oxidized products 
were much more reactive towards further oxidation by the oxidant than the starting 
amine. Reactions carried out at 0 °C (Entries 7-10) exhibited greater conversion of 
starting material, indicating that the rapid conversion to 17 and 61 was inhibited by 
colder temperatures. Davis oxaziridine (Entry 6) and sodium tungstate-hydrogen 
peroxide (Entry 3) proved to be ineffective at promoting the N-oxidation of 1. 
In an attempt to elucidate the fundamental reasons behind the difference in 
reactivity of the oxidants, molecular energy calculations were carried out to 
estimate the partial charge of the electrophilic oxygen atom in each oxidant (Table 
3.2). The results of these calculations generally correlate with experimental 
observations as mCPBA and DMDO, the two oxidants with the least negative 
partial charges on their electrophilic oxygens, displayed the fastest reaction times. 
The electrophilicity of the oxidants is not the only factor when determining reaction 
efficiency, however. Davis oxaziridine, which has comparable electrophilicity to 
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DMDO, displayed poor reactivity with roquefortine C, likely due to the increased 
steric bulk of this oxidant.  
Table 3.1: Roquefortine C N-oxidation distribution of products 
Entry Oxidizing agent Time (h) Temp (°C) Products (%) 
1 5 2 6 
1 mCPBA 0.25 25 35 10 34 20 
2 DMDO 0.25 25 12 18 29 40 
3 Na2WO4/H2O2 4 25 88 2 3 7 
4 OXONE ® 4 25 17 18 29 34 
5 62 (Cl3CCN/H2O2) 4 25 24 19 15 40 
6 Davis oxaziridine 4 (96) 25 85 (75) 5 (6) 7 (3) 3 (15) 
7 mCPBA 0.25 0 30 7 37 25 
8 DMDO 0.25 0 18 33 13 35 
9 OXONE ® 4 0 9 15 33 42 
10 62 (Cl3CCN/H2O2) 4 0 15 16 13 55 
 
While N-oxidations involving organic oxidants are generally thought to 
involve a concerted mechanism, the mechanism of oxidation by mononuclear 
tungsten peroxo complexes is still debated. As there is also debate surrounding 
the active structure of mononuclear tungsten peroxo complexes,18-20 this oxidant 
was not included in the partial charge calculations.  
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Table 3.2: Electrophilicity of electrophilic oxidizing reagents 
Entry Oxidant Oxygen partial charge (e)a 
1 
 mCPBA 
-0.352038 
2 
 DMDO 
-0.372807 
3 
 Davis oxaziridine 
-0.386358 
4 
 62 
-0.414521 
5 
  OXONE ® 
-0.47801 
a Calculations carried out at HF/6-311+G(2d,p) level of theory 
IV. Conclusions 
The oxidation of roquefortine C to roquefortine L was demonstrated using a 
number of different electrophilic oxidizing reagents. While nitrone formation on a 
complex substrate such as roquefortine C proves feasible, it is evident that 
oxidizing agents cannot compete with enzymatic approaches with respect to 
selectivity and efficiency. In general, mCPBA and OXONE ® gave the greatest 
yields of 17 at both room temperature and at 0 °C. Production of 17 using DMDO 
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was comparable to mCPBA at room temperature but was retarded when the 
reaction was performed at 0 °C. N-Oxidation of roquefortine C was found to be 
highly influenced by sterics, as the bulky Davis oxaziridine was shown to be 
ineffective at the transformation. Additionally, each of the oxidants was shown to 
produce the phenol nitrone 61, an unexpected reaction with minimal literature 
precedent. As nitrone incorporation in naturally occurring products could produce 
new biological activity, it is of interest to elucidate the reactivity of various oxidants 
on complex molecules. With the increase of molecular complexity of today’s 
pharmaceutical compounds, late stage modification of complex molecules is now 
more important than ever and thoughtful implementation of these reagents can 
only be accomplished through study of their reactivity with complex systems. 
V. Experimental Section 
General Information 
Starting materials, reagents and solvents were purchased from commercial 
suppliers and used without further purification unless otherwise noted. DMDO was 
prepared as a solution in acetone as described by Murray and Singh.21 DMDO 
content of the solution was determined by reaction with thioanisole and 
subsequent 1H NMR analysis. All reactions were conducted in oven-dried 
glassware. Products were purified by flash column chromatography (FCC) on 230-
400 mesh silica gel. 1H and 13C NMR spectra were recorded on a spectrometer 
operating at 500 MHz for 1H and 125 MHz for 13C unless otherwise stated. 
Chemical shifts are reported in ppm relative to tetramethylsilane (TMS) as the 
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internal standard for 1H and chloroform as the internal standard for 13C. NMR data 
is reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, t = triplet, q = quartet, br = broad, m = multiplet), coupling 
constants (Hz), and integration. High-resolution mass spectra (HRMS) were 
recorded on an ESI-TOF spectrometer (Agilent). Waters software calibrates and 
reports by use of neutral atomic mass. The mass of the electron is not included. 
Liquid-chromatography-mass spectrometry (LC-MS) experiments were carried out 
using a Waters 2767 sample manager comprised of a Waters 2525 binary gradient 
HPLC with diode array detector and a Waters Micromass ZQ mass spectrometer 
with S-4 electro-spray ionization. The LC-MS chromatography was carried out on 
an Atlantis–C18 column (4.6 ×50 mm; 5 µm) with a linear gradient of 10-90% 
acetonitrile in water (15 minutes, 2 mL/min). 
 
Roquefortine C hydroxylamine (16) 
Roquefortine C (100 mg, 0.26 mmol) was dissolved in dry dichloromethane (5 mL) 
in a round-bottomed flask. mCPBA (77%, 172.6 mg, 0.78 mmol) was added, and 
the reaction was allowed to stir for 20 minutes. NaBH4 (160 mg, 4.24 mmol) was 
then added, and the reaction was allowed to stir until bubbling initiated by addition 
of NaBH4 had subsided. The reaction was quenched with methanol (1 mL), and 
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the reaction mixture was concentrated by rotary evaporation. The residue was 
purified first by column chromatography (0-7% CH3OH/CH2Cl2, deactivated with 
Et3N) then by prep plate (5% CH3OH/CH2Cl2) to afford the hydroxylamine (12 mg, 
11%) as a single stereoisomer. 1H NMR (500 MHz, CD3OD) δ 7.74 (s, 1H), 7.30 
(s, 1H), 7.25 (d, J = 8 Hz, 1H), 7.21 (t, J = 8 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 6.90 
(d, J = 7.5 Hz, 1H), 6.36 (s, 1H), 5.99 (dd, J = 6.5, 11 Hz, 1H), 5.89 (s, 1H), 5.09 
(m, 2H), 3.98 (t, J = 8.5 Hz, 1H), 2.41 (m, 2H), 1.08 (s, 1H), 0.95 (s, 1H). 13C NMR 
(125 MHz, CD3OD) δ 168.0, 159.8, 154.2, 145.0, 137.7, 131.8, 130.3, 126.0, 
125.0, 124.4, 119.7, 115.9, 115.3, 111.1, 110.2, 87.9, 62.3, 59.7, 42.5, 40.1, 24.3, 
23.5. HRMS (ESI-TOF) m/z [M + H]+ calcd for C22H24N5O3 406.1879, found 
406.1890. 
 
Roquefortine L (17) 
Roquefortine C (200 mg, 0.51 mmol) was dissolved in dry dichloromethane 
(10 mL) in a round-bottomed flask and chilled in an ice bath under argon. The 
reaction mixture was stirred over 3Å molecular sieves. In a separate vial, mCPBA 
(77%, 571 mg, 2.55 mmol) was dissolved in dichloromethane (10 mL) and washed 
twice with phosphate buffer, pH 7.5. The mCPBA solution was dried over Na2SO4 
and was added dropwise over 10 minutes to the roquefortine C solution. The 
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reaction mixture was stirred for 30 minutes, after which the reaction was quenched 
with two drops of dimethyl sulfide. The reaction mixture was concentrated by rotary 
evaporation and was purified by column chromatography (0-40% i-PrOH/CH2Cl2) 
on silica gel deactivated with Et3N to give roquefortine L (20 mg, 10%).  1H NMR 
(600 MHz, DMSO-d6/CHCl3) δ 10.69 (s, 1H), 7.75 (s, 1H), 7.60 (s, 1H), 7.58 (d, J = 
8.0 Hz, 1H), 7.48 (m, 2H), 7.40 (t, J = 7.4 Hz; 1H), 6.53 (s, 1H), 5.76 (dd, J = 11.0, 
17.3 Hz, 1H), 5.08 (dd, J = 3.7, 11.4 Hz, 1H), 5.03 (d, J = 11.4 Hz, 1H), 4.99 (s, 
1H), 2.86 (dd, J = 3.8, 14.1 Hz, 1H), 2.21 (dd, J = 11.5, 13.6 Hz, 1H), 1.03 (s, 3H), 
0.83 (s, 3H). 13C NMR (150 MHz, CDCl3) δ 164.7, 156.4, 148.6, 146.8, 141.7, 
138.0, 128.7, 128.3, 124.1, 121.6, 115.5, 114.5, 63.4, 27.9, 42 .8, 22.3, 22.2. IR 
(KBr): 2961.82, 1682.40, 1384.58, 1258.38, 1091.79, 1014.45, 794.80 cm-1; 
HRMS (ESI-TOF) m/z [M + H]+ calcd for C22H22N5O3 404.1723, found 404.1727 
(lit. (Vreeken et al., 2013)22 HRMS (FTICR-MS) m/z [M + H]+ calcd for C22H22N5O3 
404.1723, found 404.1706). 
 
11-Hydroxyroqueforitne L (61) 
Roquefortine C (200 mg, 0.51 mmol) was dissolved in dry dichloromethane (10 
mL) in a round-bottomed flask and chilled in an ice bath under argon. The reaction 
mixture was stirred over 3Å molecular sieves. In a separate vial, mCPBA (77%, 
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571 mg, 2.55 mmol) was dissolved in dichloromethane (10 mL) and washed twice 
with phosphate buffer, pH 7.5. The mCPBA solution was dried over Na2SO4 and 
was added dropwise over 10 minutes to the roquefortine C solution. The reaction 
mixture was stirred for 30 minutes, after which the reaction was quenched with two 
drops of dimethyl sulfide. The reaction mixture was concentrated by rotary 
evaporation and purified by column chromatography (0-40% i-PrOH/CH2Cl2) on 
silica gel deactivated with Et3N to give 11-hydroxyroquefortine L (30 mg, 15%). 1H 
NMR (500 MHz, CD3OD) δ 7.69 (s, 1H), 7.52 (d, J = 9.5 Hz, 1 H), 6.58 (d, J  = 9.5 
Hz, 1H), 6.53, (s, 1H), 6.46 (s, 1H), 6.36 (s, 1H), 5.87 (dd, J = 10.5, 17.5 Hz, 1H), 
5.33 (d, J = 5.5 Hz, 1H), 5.18 (m, 1H), 4.33 (dd, J = 6.5, 11.5 Hz, 1 H), 2.58 (dd, 
J = 6.0, 13.0 Hz), 2.50 (t, J = 11.5 Hz, 1H), 1.16 (s, 3H), 1.11 (s, 1H). 13C NMR 
(125 MHz, DMSO-d6) δ185.7, 163.6, 156.8, 151.1, 142.4, 141.2, 132.7, 122.6, 
122.3, 121.8, 115.5, 88.5, 57.8, 55.8, 48.6, 40.7, 22.9, 22.1. HRMS (ESI-TOF) m/z 
[M + H]+ calcd for C22H22N5O4 420.1672, found 420.1668. 
Oxidation with DMDO 
Roquefortine C (15 mg, 0.038 mmol) was dissolved in acetone (0.4 mL) in a vial. 
DMDO (1.3 mL, 0.059 M in acetone, 0.077 mmol) was added dropwise and stirred 
until DMDO was consumed (15 minutes, monitored by potassium iodide starch 
paper). A 200 μL aliquot was removed from the reaction mixture and diluted to 1 
mL with dry CH2Cl2 for LC-MS analysis. 
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Oxidation with mCPBA 
Roquefortine C (15 mg, 0.038 mmol) was dissolved in chloroform (0.4 mL) in a 
vial. mCPBA (77%, 10 mg, 0.077 mmol) was dissolved in chloroform (0.8 mL) and 
was added dropwise to roquefortine C. The reaction was stirred until mCPBA was 
consumed (15 minutes, monitored by potassium iodide starch paper). A 100 μL 
aliquot was removed from the reaction mixture and diluted to 1 mL with dry CH2Cl2 
for LC-MS analysis. 
Oxidation with sodium tungstate/hydrogen peroxide 
Roquefortine C (40 mg, 0.10 mmol) was suspended in methanol (2.0 mL) in a vial. 
Na2WO4·2H2O (3 mg, 0.010 mmol) and H2O2 (30% in H2O, 23 μL, 0.20 mmol) were 
added sequentially and stirred for 4 hours. A 75 μL aliquot was removed from the 
reaction mixture and diluted to 1 mL with dry CH2Cl2 for LC-MS analysis. 
Oxidation with trichloroacetonitrile/hydrogen peroxide 
H2O2 (30% in H2O, 8.7 μL, 0.077 mmol) and Cl3CCN (7.7 μL, 0.077 mmol) were 
dissolved in methanol (0.38 mL) in a vial. Roquefortine C was added and stirred 
for 4 hours. A 50 μL aliquot was removed from the reaction mixture and diluted to 
1 mL with dry CH2Cl2 for LC-MS analysis. 
Oxidation with Davis oxaziridine 
Roquefortine C (30 mg, 0.077 mmol) was dissolved in dichloromethane (0.77 mL) 
in a vial. Davis oxaziridine (40 mg, 0.15 mmol) was dissolved in dichloromethane 
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(1.5 mL) in a separate vial and was added dropwise to roquefortine C. The reaction 
mixture stirred for 4 hours. A 50 μL aliquot was removed from the reaction mixture 
and diluted to 1 mL with dry CH2Cl2 for LC-MS analysis. 
Oxidation with OXONE ® 
Roquefortine C (15 mg, 0.038 mmol) was dissolved in 1:4 THF:CH3CN (0.5 mL) in 
a vial. EDTA-2Na (0.01 M in H2O, 0.38 mL, 0.0038 mmol), NaHCO3 (16 mg, 0.19 
mmol), and OXONE ® (47 mg, 0.077 mmol) were added sequentially to the 
roquefortine C solution and stirred for 4 hours. A 50 μL aliquot was removed from 
the reaction mixture and diluted to 1 mL with dry CH2Cl2 for LC-MS analysis. 
LC-MS calibration 
Roquefortine C (50 mg, 0.13 mmol) was dissolved in dry dichloromethane (3 mL) 
in a round-bottomed flask and chilled in an ice bath. In a separate vial, mCPBA 
(77%, 85 mg, 0.64 mmol) was dissolved in dichloromethane (6 mL) and washed 
twice with phosphate buffer, pH 7.5. The mCPBA solution was dried over Na2SO4 
and was added dropwise over 10 minutes to the roquefortine C solution. The 
reaction mixture was stirred for 30 minutes, after which the reaction was quenched 
with two drops of dimethyl sulfide. The reaction mixture was concentrated by rotary 
evaporation and the residue was washed three times with diethyl ether. A sample 
of the residue was analyzed by 1H NMR to quantify the amount of each reaction 
intermediate present in the sample. LC-MS response factors (Supplementary 
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Table 3.1) were determined using calibration standards of five different 
concentrations. 
Supplementary Table 3.1: LC-MS response ratios for roquefortine C and oxidation 
products 
Compound Response factor 
Roquefortine C (1) 103945 ± 30 M-1 
Roquefortine C hydroxylamine (16) 169810 ± 24 M-1 
Roquefortine L (17) 41410 ± 27 M-1 
11-Hydroxyroquefortine L (61) 37988 ± 13 M-1 
Errors represent the standard error of the estimate (σest). 
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Appendix 3A: Spectra Relevant to Chapter 3 
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Supplementary Figure 3.1: 1H NMR (500 MHz, CD3OD) Spectrum of 61 
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Supplementary Figure 3.2: 13C NMR (125 MHz, CD3OD) Spectrum of 61 
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Supplementary Figure 3.3: 1H-13C HSQC (500 MHz, CD3OD) Spectrum of 61 
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Supplementary Figure 3.4: 1H-13C HMBC (500 MHz, CD3OD) Spectrum of 61 
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I. Introduction 
Triazaspirocycles are unique chemical motifs found in several biologically 
active natural products. These compounds feature three nitrogen atoms attached 
to one quaternary carbon forming a spirocyclic scaffold. The rigid chemical 
backbone of these structures contributes towards their application in both the 
materials and pharmaceuticals industries. Despite their industrial promise, few 
syntheses of these compounds exist in the literature. The biosynthesis of 
roquefortine C, however, provides inspiration for the synthesis of these 
compounds, namely through a nitrone-promoted transannular rearrangement. This 
type of internal rearrangement has never been carried out synthetically and would 
provide an efficient stereoselective synthesis of triazaspirocycles. Herein are 
reported synthetic efforts towards triazaspirocycles. 
II. Background 
A. Triazaspirocycle Natural Products 
A number of natural products contain the triazaspiro motif, most commonly 
in the form of a tethered triazaspirocycle (Figure 4.1).1  
 
Figure 4.1: Triazaspirocycle scaffolds 
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The majority of naturally derived triazaspirocycles are of Penicillium origin (Figure 
4.2), and of those, most have been shown to originate from biosynthetic 
transformations of roquefortine C (1).2-7  
 
Figure 4.2: Triazaspirocyclic natural products 
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As mentioned in Chapters 1 and 2, the biosynthesis of roquefortine C derived 
triazaspirocycles in P. chrysogenum and P. oxalicum is initiated by indoline N-
oxidation to give roquefortine L (17). A cytochrome P450 monooxygenase 
(RoqO/OxaH) is then proposed to promote α-hydroxylation. The newly-generated 
hemiaminal is proposed to open to the 9-membered α-diketone, which, upon 
transannular attack of the nitrone α-carbon by N2, gives the triazaspirocyclic core 
of glandicoline B (2) (Scheme 4.1).3 
 
Scheme 4.1: Biogenesis of roquefortine C derived triazaspirocycles in P. chrysogenum 
and P. oxalicum 
B. Triazaspirocycles: Properties and Applications 
Natural products containing the triazaspirocyclic motif display a wide range 
of biological activity. Oxaline (4), whose structure has been established by X-ray 
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crystallography,8 and neoxaline have been observed to exhibit antiproliferative 
activity and to arrest the cell cycle at the M phase in Jurkat cells via inhibition of 
tubulin polymerization (see Appendix 4A for description of cell lines).9  
Meleagrin (3) and several of its semisynthetic derivatives have shown 
activity against several strains of multiple-drug resistant bacteria, whose rapid 
emergence has ignited a threat to global health in recent years. Meleagrin was 
observed to inhibit the bacterial enoyl-acyl carrier protein reductase FabI, a novel 
antibacterial target and key enzyme in the synthesis of bacterial type 2 fatty acid, 
which is essential for bacterial cell growth.10  Meleagrin was also shown to possess 
moderate antitumor activity when applied to cell lines A-549 and HL-60 and caused 
cell cycle arrest in the G2/M phase, presumably by inhibiting tubulin polymerization 
(see Appendix 4A for description of cell lines).11 Recent reports indicate that 
meleagrin is also a promising lead for the treatment of breast cancer.12 
Additionally, meleagrin has been reported to be a fibrinolysis inhibitor.13  
Both meleagrin and glandicoline B (2) have shown anti-fouling activity 
against the barnacle larva Balanus amphitrite, inhibiting their attachment to wetted 
surfaces.14,15,16 Glandicoline B (2) was also found to be active at 100 μg/mL against 
S. aureus, Microccus luteus, and E. coli.17  
Several imidazole-substituted biosynthetic derivatives of meleagrin have 
been isolated from deep sea Penicillium fungi (Figure 4.2) and were shown to 
exhibit a range of cytotoxic effects against HL-60, MOLT-4, A-549, and BEL-7402 
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cell lines (see Appendix 4A for description of cell lines).11 Meleagrin B (68) 
displayed moderate cytotoxicity, with half maximal inhibitory concentration (IC50) 
values in the 1.8 to 6.7 µM range for each cell line. Meleagrin C (69) displayed less 
potent activity, particularly against the HL-60 cell line, where IC50 values were 
greater than 50 μM. Meleagrins D (70) and E (71) showed significantly weaker 
activity than meleagrins A-C against the A-549 cell line and displayed virtually no 
activity against the HL-60 cell line (IC50 > 100 µM). 
In addition to their biological activity, triazaspirocycles have found use in 
several other applications. In 2013, Horino, Tokita, and Oshima patented a bi-
imidazole-based photochromic material that demonstrates negative 
photochromism (Scheme 4.2).18 Photochromic materials undergo reversible color 
change as a result of isomerization. They can be broadly categorized as inducing 
negative photochromism, a change from colored to uncolored accompanying 
isomerization, or positive photochromism, a change from uncolored to colored 
accompanying isomerization. Compounds with photochromic properties have 
applications in color changing lens and molecular switches, among others. Horino, 
Tokita, and Oshima found that, in compounds where R4 and R5 were sterically 
bulky groups, irradiation with visible light caused isomerization from the pale yellow 
[4.6] triazaspirocycle 72 to the colorless dispirocyclic system 73. Further 
isomerization to a red colored [4.5] spirocyclic system (74) was observed when 73 
was shielded from light, after which further isomerization restored the original pale 
yellow color.  
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Scheme 4.2: Photochromic triazaspirocycles 
Triazaspirocycles have also demonstrated applications in surface 
functionalization (Scheme 4.3).19 Following the synthesis of triazaspirocycles via 
the addition of isocyanates bearing silyl ethers to 1,5-diazabicyclo[4.3.0]non-5-ene 
(DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, Scheme 4.3A), 
functionalization of silicon dioxide surfaces was carried out via one of two methods; 
the first involving the reaction of the silyl ether functionalized triazaspirocycles with 
fumed silica and the second involving functionalization via the Stöber process 
(Scheme 4.3B).20 
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Scheme 4.3: Surface functionalization with triazaspirocycles 
C. Synthesis of Triazaspirocycles 
The most common synthetic method for the construction of 
triazaspirocycles is 1,3 dipolar cycloaddition (Scheme 4.4). In this particular 
reaction, a 1,3 dipole undergoes a [3+2] cycloaddition with a dipolarophile to form 
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a five-membered ring. 1,3 Dipoles share four electrons across a π system of three 
atoms and typically react with dipolarophiles such as olefins and isocyanates.21 
 
Scheme 4.4: Synthesis of triazaspirocycles via 1,3-dipolar cycloaddition  
Unlike bimolecular cycloadditions, intramolecular cyclizations often proceed 
stereo- and regioselectively and are thus advantageous in achieving asymmetric 
syntheses of triazaspirocyclic systems. In the total synthesis of 
dibromoagelaspongin by Feldman et al., oxidative cyclization to form the tethered 
triazaspirocycle was shown to occur in the presence of NBS, N-chlorosuccinimide 
(NCS), or ICl (Scheme 4.5).22-24 Following mechanistic investigation of this 
reaction, Feldman et al. demonstrated this transformation takes place via a 
Pummerer reaction, in which electrophilic halogenation of the -SR group leads to 
elimination to form sulfonium intermediate 84, which subsequently undergoes 
nucleophilic attack by the adjacent dibromopyrrole ring. Feldman et al. had initially 
synthesized the triazaspirocyclic core of dibromoagelaspongin via intramolecular 
ring opening of an epoxide, which led to the triazaspirocyclic hemiaminal 89 
following acidic workup (Scheme 4.6).25 
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Scheme 4.5: Pummerer reaction to access dibromoagelaspongin triazaspirocyclic core 
 
Scheme 4.6: Synthesis of dibromoagelaspongin core via intramolecular epoxide ring 
opening 
A transannular ring contraction promoted by acetic anhydride has been shown by 
Avendaño et al. to produce novel triazaspirocyclic β-lactams (Scheme 4.7).26 
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Scheme 4.7: Synthesis of fused β-lactams via acetic anhydride promoted transannular 
rearrangements 
The first asymmetric total synthesis of neoxaline (19) was accomplished in 
2013,27 and the first asymmetric total syntheses of meleagrin (3) and oxaline (4) 
and a second-generation asymmetric total synthesis of neoxaline were completed 
in 2015.28 The construction of the triazaspiro core in each of these syntheses was 
carried out in a stepwise fashion of oxidation and cyclization. Oxidation of 94 with 
H2O2·urea in the presence of NaWO4·2H2O provides a mixture of nitrone 95 and 
diaminal 96. Treatment of the crude mixture with triethylamine in benzene converts 
nitrone 95 to diaminal 96, and subsequent oxidation affords N-oxoamidine 97. 
Finally, cyclization using tetrabutylammonium hydroxide (TBAOH) affords indoline 
spiroaminal 98 (Scheme 4.8).27-29 
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Scheme 4.8: Triazaspirocycle formation in the total syntheses of oxaline and meleagrin 
III. Results and Discussion 
A. Geometry Optimization Studies of Roquefortine C Transannular 
Rearrangement 
While the synthesis of triazaspirocycles has been described in the literature, 
there are relatively few instances of stereoselective formation of triazaspirocycles. 
As roquefortine C-derived triazaspirocycles have already demonstrated a wide 
range of biological activity,9,10,14 we proposed to expand the scope of transannular 
ring contractions by exploring the synthesis of triazaspirocycles via transannular 
ring contraction of indoline nitrones. We believe it is possible to achieve the desired 
transformation in a single step following the generation of the indoline nitrone. 
As our inspiration for this methodology draws heavily on the roquefortine C 
biosynthetic pathway, it seemed most logical to investigate this methodology using 
roquefortine C as our initial substrate.  The proposed biosynthetic mechanism of 
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triazaspirocycle formation of glandicoline B (2) from roquefortine C (Scheme 4.1) 
is thought to involve four distinct steps: 1) N-oxidation of roquefortine C (1) to 
nitrone roquefortine L (17); 2) α-hydroxylation of roquefortine L at C16; 3) ring 
expansion of the newly formed hemiaminal; and 4) transannular attack of the 
nitrone α-carbon by N2. The ultimate success of this methodology lies in the 
energetic viability of ring expansion and subsequent contraction to form the 
triazaspirocycle. One might imagine that the energetic barrier of progressing from 
a fused 5,6-bicycle to a 9-membered ring could be too high to be achieved without 
assistance from an enzyme to lower the activation energy. Additionally, it is unclear 
whether the geometry of compound 59 lends itself to stereospecific ring 
contraction. Therefore, it was of interest to carry out computational studies of this 
rearrangement to determine its viability. 
Geometry optimization of compounds 58, 59, and 2 was carried out at the 
HF/6-311+G(2d,p) level of theory using WebMO (Figure 4.3). These computational 
studies suggest compound 59 exists in two conformations, one adopting a planar 
conformation (59a) and one adopting a folded configuration (59b). As compound 
58 is also rather planar in structure, compound 59a is presumed to be the first 
conformation adopted following cleavage of the hemiaminal C-N bond. 
Computational analysis suggests subsequent conformational isomerism of 59a to 
59b would result in a stabilization of nearly 20 kcal/mol. The curvature of 
compound 59b also places N2 within 2.7 Å of C6 with a trajectory consistent with 
the observed stereochemistry of glandicoline B (Figure 4.4). The transannular 
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reaction forming glandicoline B is also predicted to be thermodynamically 
favorable, resulting in a stabilization of 22.07 kcal/mol.   
 
Figure 4.3: Reaction coordinate diagram of roquefortine C transannular rearrangement to 
glandicoline B 
 
Figure 4.4: Geometry optimized structure of compound 59b  
Geometry optimization was carried out at HF/6-311+G(2d,p) level of theory. 
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Taken together, these computational studies indicate that transannular 
rearrangement from roquefortine C to glandicoline B is synthetically achievable 
and that the key intermediate 59 adopts a more thermodynamically favorable 
conformation to afford the stereochemistry observed in glandicoline B. 
B. Efforts toward Transannular Rearrangement Methodology using 
Roquefortine C 
Given the promising results of the geometry optimization studies, a 
synthetic route was established to explore the transannular rearrangement of 
roquefortine C to glandicoline B (Scheme 4.9). Retrosynthetically, following 
protection of the imidazole, diketopiperazine, and indoline nitrogens, a hydroxyl 
group would be installed at the C16 position. Oxidations of this nature are well 
documented for diketopiperazines, most notably in the syntheses of 
epidithiodiketopiperazine alkaloids by Movassaghi and Sodeoka (Figure 4.5).30-36 
These syntheses implemented free-radical oxidants to install α-hydroxy groups as 
precursors to the disulfide bridge. Electrophilic addition of oxygen to enolates is 
also well-documented for amides. Electrophilic oxygen species used in these 
transformations include DMDO, Davis oxaziridine, oxodiperoxymolybdenum-
(pyridine)(hexamethylphosphoric triamide) (MoOPH), and more.33,37  
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Scheme 4.9: Retrosynthetic analysis of glandicoline B formation 
 
Figure 4.5: Representative epidithiodiketopiperazine alkaloids synthesized by 
Movassaghi and Sodeoka 
Subsequent removal of the protecting groups and indoline N-oxidation would set 
the stage for transannular rearrangement to glandicoline B. Addition of a weak 
base is proposed to oxidize the hemiaminal to the 9-membered α-diketo species. 
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Support for this step is found in the synthesis of (+)-lyconadin A and (-)-lyconadin B 
by Smith et al., where hemiaminal 108 is treated with sodium bicarbonate to 
generate the open diketoamine 106 (Scheme 4.10).38 
 
Scheme 4.10: Formation of diketoamine 106 from hemiaminal 108 
While this route draws inspiration from the biosynthesis of glandicoline B, a 
conscious decision was made to carry out the α-hydroxylation prior to synthesis of 
the indoline nitrone, a significant departure from the biosynthetic pathway. Based 
on our previous experience with roquefortine L, we elected to install the nitrone 
functionality just prior to transannular rearrangement to avoid side reactions and 
hydrolytic degradation. 
Efforts to explore the transannular synthesis of glandicoline B from 
roquefortine C ultimately proved fruitless as no single protecting group nor 
combination of protecting groups could give the desired triply protected 
roquefortine C species. Protection with tert-butyloxycarbonyl (Boc) groups 
provided the doubly protected adduct, with N-protection (confirmed through 15N 
NMR) occurring first at the imidazole and second at the diketopiperazine nitrogen.  
This result is in agreement with precedent for acylation occurring at the less 
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nucleophilic diketopiperazine due to steric hindrance at the indoline nitrogen.39 α-
Hydroxylation did not proceed with this species, and attempts to trap the 
corresponding enolate as a silyl enol ether were unsuccessful as the Boc groups 
were cleaved in the presence of silyl chlorides and triflates. Protection using 
benzoyl, carbamate (fluorenylmethyloxycarbonyl (Fmoc) or Cbz), or sulfonamide 
(mesyl (Ms) or tosyl (Ts)) groups yielded only mono protection of the imidazole. 
These results were in contrast to literature precedent in which similar compounds 
were shown to undergo protection of the indoline nitrogen (Scheme 4.11).40 
 
Scheme 4.11: Representative protection of a pyrroloindoline diketopiperazine 
C. First Generation Model System  
With efforts to synthesize glandicoline B from roquefortine C proving 
ultimately unsuccessful, we turned our attention towards the design of a model 
system to investigate conditions for α-hydroxylation. This first generation model 
system (121) incorporated the diketopiperazine and imidazole functionalities of 
roquefortine C while eliminating the indoline portion that had proven difficult to 
protect in roquefortine C. 
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 The route to compound 121 implements methodology originally developed 
by Schmidt et al. for the synthesis of dehydroamino acid esters (Scheme 4.12).41 
Glyoxylic acid monohydrate was coupled to benzyl carbamate to give the α-
hydroxyglycine 113, which was converted to the methyl ether under acidic 
conditions.  Reaction with phosphorus trichloride gave the α-chloride, and a 
subsequent Michaelis–Arbuzov reaction with trimethyl phosphite gave 
dimethoxyphosphorylacetate 115 in 76% yield over two steps. Hydrogenolysis 
followed by coupling to N-Boc D-proline provided compound 118. Horner-
Wadsworth-Emmons reaction of compound 118 with aldehyde 118 followed by ring 
closing led to the exclusive isolation of the undesired Z isomer. We hypothesize 
that unfavorable lone pair interactions between the methyl ester and imidazole 
discourage formation of the trans oxaphosphetane trans-122 (Scheme 4.13). 
Additionally, oxaphosphetane cis-122, formed following anti addition of the 
aldehyde to the phosphonate ester, likely adopts an internal hydrogen bond, 
further aiding in the preferential formation of the Z isomer. 
Carrying out the Horner-Wadsworth-Emmons reaction following cyclization 
to the diketopiperazine also gave the undesired Z isomer as the internal 
interactions of the two oxaphosphetanes remained unchanged following 
cyclization. Attempts to alkylate the amide nitrogen in hopes of disrupting the 
internal hydrogen bonding network proved unsuccessful.  
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While this synthetic route ultimately did not lead to the desired E isomer, α-
hydroxylation conditions were nevertheless investigated using compound 121. 
Unfortunately, these efforts were not successful, as the presence of the Z 
dehydrohistidine moiety blocked functionalization of the amide nitrogen. 
α-Hydroxylation did not proceed in the presence of the unprotected amide. 
 
Scheme 4.12:  Synthetic route towards first generation model system 121 
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Scheme 4.13: Oxaphosphetane internal hydrogen bonding leads to exclusive formation 
of the Z isomer 
D. Second Generation Model System: Design and Computational Studies 
In light of the shortcomings of our first generation model system to develop 
an α-hydroxylation methodology, a second generation model system was 
designed, incorporating the pyrroloindoline diketopiperazine skeleton of 
roquefortine C (Scheme 4.14). Transannular formation of triazaspirocycle 123 
would proceed following α-hydroxylation, as planned in our initial synthetic route 
to glandicoline B. As mentioned previously, this hydroxylation could be carried out 
through use of a free-radical oxidant or though electrophilic addition of oxygen to 
an enolate. The construction of this model system would be carried out using 
simple amino acid building blocks, which could be derivatized to achieve the same 
folded conformation required for the stereospecific transannular rearrangement. 
The pyrroloindoline core would be synthesized via [3+2] cycloaddition of a 3-
substituted indole (125) with a 2-(2,2,2-trifluoroacetamido)acrylate (126). Coupling 
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of the pyrroloindoline skeleton to Boc-protected amino acid 127 would provide 
diketopiperazine 124. 
 
Scheme 4.14: Retrosynthesis of second generation model system 124 and 
triazaspirocycle 123 
Several factors played a role in the design of the second generation model 
system. As the ultimate success of this model system hinges on its ability to mimic 
the folded conformation of compound 59b, geometry optimization studies were 
carried out for a number of derivatives of diketoamine 128. All derivatives 
investigated were found to adopt both a planar conformation (128) as well as a 
folded conformation (129) (Table 4.1). The desired folded conformation was found 
to be thermodynamically favored when either R1 or R2 was a phenyl group; 
however, due to the fact that many of the reactions proposed to synthesize 
triazaspirocycle 123 are base-promoted, mono-substitution at C3 would likely 
result in epimerization and unwanted side reactions. We therefore elected to 
synthesize the R1 = R2 = CH3 model system 124a. While this species is predicted 
to favor the planar conformation, the activation energy required to achieve the 
desired folded conformation is attainable through heating of the reaction mixture.   
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Table 4.1: Calculated folding energy (ΔEfolding) of 128 
 
Entry R1 R2 ΔEfolding (kcal/mol) 
a CH3 CH3 12.02 
b H Ph -5.82 
c Ph H -1.19 
d H t-Bu 7.60 
e t-Bu H 16.74 
f H CH3 9.25 
g H H 10.83 
Geometry optimization was carried out at HF/6-311+G(2d,p) level of theory. 
Geometry optimization calculations were carried out for all intermediates 
involved in the transannular rearrangement from 130 to 123a (Figure 4.6). These 
calculations revealed that the planar 128a exhibits thermodynamic stability of 
nearly 12 kcal/mol as compared to compound 130. Conversion of 128a to 129a 
appears experimentally achievable, with subsequent triazaspirocycle formation 
imparting a 26.74 kcal/mol stabilization. The results of these calculations indicate 
that the synthetic route proposed to access triazaspirocycle 123a is reasonable 
and that this model system is a satisfactory mimic for roquefortine C. 
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Figure 4.6: Reaction coordinate diagram of transannular rearrangement to 123a 
E. Second Generation Model System: Synthetic Efforts 
The first step towards the construction of model system 123a was synthesis 
of the pyrroloindoline moiety. This step was accomplished using methodology 
developed by Reisman et al.42-44 This methodology consists of a tin(IV) chloride 
promoted formal [3+2] cycloaddition between a 3-substituted indole and a 2-
amidoacrylate (Scheme 4.15). Highly facially-selective protonation is achieved 
through use of an (R)-BINOL (1,1'-bi-2-naphthol) ligand. The matching and 
mismatching effects of the chiral catalyst complex with the chiral enolates allow for 
preferential formation of the exo diastereomer exo-140. 
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Scheme 4.15: Proposed mechanism of pyrroloindoline synthesis by formal [3+2] 
cycloaddition 
2-Amidoacrylate 126a had been shown by Reisman and coworkers to 
provide exo pyrroloindolines in greater diastereoselectivity as compared to the 
corresponding benzyl acrylate 126b, giving compound 140a in 84% yield with 5:1 
diastereomeric ratio (dr) (Scheme 4.16).42,43 In our hands, this reaction gave a 
similar diastereomeric ratio using 2-amidoacrylate 126a; however, the exo and ent-
endo diastereomers proved to be inseparable by flash chromatography. 
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Implementing benzyl trifluoroacetamidoacrylate 126b for the cycloaddition reaction 
allowed for the synthesis and separation of the exo and ent-endo diastereomers in 
comparable yield and dr to that reported by Reisman.44 (R)-3,3’-Cl2-BINOL 142 
had been identified by Reisman et al. from a screen of BINOL ligands to give 
optimal yields and diastereomeric ratios for this reaction. The synthesis of this 
ligand, however, required four steps (Scheme 4.17) and the high ligand loading 
concentration coupled with the difficulty of recycling the ligand following the 
reaction led us to implement commercially-available (R)-BINOL 143 for the 
majority of 140b syntheses, which provided the desired exo product in 54% yield.  
 
Scheme 4.16: Synthesis of pyrroloindolines 140a and 140b 
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Scheme 4.17: Synthesis of (R)-3,3’-Cl2-BINOL 142 
Transesterification of 140b to methyl ester 140a proceeded smoothly 
(Scheme 4.18). Following trifluoroacetyl (TFA) deprotection by triflic acid, peptide 
coupling of 147 to 127a was attempted; however, unfavorable steric interactions 
from the neighboring allyl group significantly hindered coupling. The indoline N-
allyl group was removed via a RhCl3-catalyzed deallylation reaction in n-propanol 
prior to the removal of the TFA moiety.45 Attempts to remove the allyl group 
following TFA deprotection resulted in low yields and numerous side reactions. 
Coupling of the less hindered 148 still proceeded with great difficulty, given the 
steric bulk of both the proline amine and the α-disubstituted carboxylic acid 
coupling partners. Increased concentration, prolonged reaction time, and excess 
base, coupling reagent, and 127a were needed to drive the reaction to modest 
yields. Smaller amine bases such as Et3N gave more rapid reaction times than 
i-Pr2EtN or 2,4,6-collidine. Formation of the indoline sulfonamide proceeded only 
under aqueous basic conditions; as such, protection of the indoline nitrogen was 
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carried out prior to formation of the diketopiperazine to prevent hydrolysis. TFA 
deprotection of the Boc group and subsequent cyclization gave 
diketopiperazine 151. 
 
Scheme 4.18: Synthesis of phenylsulfonyl protected model system 151 
With compound 151 in hand, we have initiated efforts towards the synthesis 
of triazaspirocycle 123a. As mentioned previously, the key reaction of this 
transformation involves the α-hydroxylation of the C16 position. Efforts to install 
this functionality via electrophilic hydroxylation of the corresponding enolate 
proved fruitless, so we turned our attention towards radical hydroxylation. As 
 197 
 
mentioned previously, permanganate-based oxidants such as n-Bu4NMnO4 and 
bis(pyridine) silver (I) permanganate (Py2AgMnO4) have been implemented for this 
transformation, notably in the synthesis of epidithiodiketopiperazines by 
Movassaghi and Sodeoka.30-36 Diketopiperazines are known to stabilize radicals 
at the α position, and this method of hydroxylation would take advantage of the 
captodative character of the C16 position (Table 4.2). The captodative character 
for several diketopiperazines, including roquefortine C and 151, was calculated 
using an isodesmic reaction. Direct calculation of bond dissociation energies 
(BDE) of radical hydrogen abstraction can result in significant computational 
errors; as such, diketopiperazine BDEs were calculated as the heats of isodesmic 
reactions (ΔH) using the known enthalpy of bond dissociation (DCH) for glycine 
(Scheme 4.19).46 
 
Scheme 4.19: Calculation of diketopiperazine αC-H BDE as heat of reaction ΔH 
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Table 4.2: Captodative character of select diketopiperazines 
Species 
αC-H BDE 
(kJ/mol) 
 
38747 
 
37448 
 
341 
 
319 
Calculations for roquefortine C and 151 performed at B3LYP/6-311+G(2d,p) level of 
theory, using neutral glycine in an isodesmic reaction46 
Appropriate protection of the indoline and diketopiperazine nitrogens 
proved to be a critical factor in this transformation. Protection of these positions 
was necessary as radical abstraction of the N-H hydrogen atom at either of these 
positions results in a resonance stabilized radical that effectively halts chain 
propagation. Secondly, the choice of protecting group for the indoline nitrogen in 
particular was shown to influence the reactivity of the oxidant. Implementing 
electron rich protecting groups such as para-methoxybenzyl (PMB) did not 
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significantly reduce the nucleophilicity of the indoline nitrogen and gave rise to 
indoline N-oxide formation. Protection of both the indoline and the diketopiperazine 
nitrogens with tert-butoxycarbonyl (Boc) groups failed to give any reaction under 
these conditions. α-Hydroxylation was finally achieved using phenylsulfonyl 
protected 154 and Py2AgMnO4 (Scheme 4.20). This reaction proceeded quite 
slowly and required excess oxidant and long reaction times to obtain modest 
yields. Additionally, it was observed that upon standing in solution, compound 155 
underwent isomerization, as evidenced by 1H NMR. This isomerization is likely a 
result of the opening and subsequent reformation of the hemiaminal bond. 
 
Scheme 4.20: α-Hydroxylation of model system 155 
IV. Conclusions and Future Directions 
While the biomimetic semisynthesis of glandicoline B from roquefortine C 
was ultimately unsuccessful, two model systems were synthesized to investigate 
the transannular synthesis of triazaspirocycles. The α-hydroxylation of compound 
153 was achieved using radical oxidant Py2AgMnO4. Future work to complete this 
synthetic route includes deprotection of the PMB and SO2Ph protecting groups, N-
oxidation of the indoline nitrogen to the nitrone, and rearrangement to give the 
desired triazaspirocycle (Scheme 4.21). The observed isomerization of compound 
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155 upon standing in solution demonstrates the potential for transannular 
rearrangement, as breaking of the hemiaminal bond appears to occur 
spontaneously at room temperature. 
 
Scheme 4.21: Future work towards the synthesis of triazaspirocycle 123a 
V. Experimental Details 
General information 
Starting materials, reagents and solvents were purchased from commercial 
suppliers and used without further purification unless otherwise noted. Anhydrous 
Et2O, THF, and CH2Cl2 were obtained from a solvent dispensing system stored 
under positive pressure of argon. All reactions were conducted in oven-dried 
glassware. The progress of reactions was monitored by silica gel thin layer 
chromatography (TLC) plates (250 µm with fluorescent indicator), visualized under 
UV, and stained using a phosphomolybdic acid (PMA) stain. Products were 
purified by flash column chromatography (FCC) on 230-400 mesh silica gel. 1H 
and 13C NMR spectra were recorded on a spectrometer operating at 500 MHz for 
1H and 125 MHz for 13C unless otherwise stated. Chemical shifts are reported in 
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ppm relative to tetramethylsilane (TMS) as the internal standard for 1H and 
chloroform as the internal standard for 13C. 1H-13C Heteronuclear single quantum 
correlation experiment (HSQC) NMR spectra were recorded on a spectrometer 
operating at 500 MHz. NMR data is reported as follows: chemical shift, multiplicity 
(s = singlet, d = doublet, dd = doublet of doublets, t = triplet, td = triplet of doublets, 
q = quartet, br = broad, m = multiplet), coupling constants (Hz), and integration. 
Accurate mass measurement data (HRMS) were acquired on ESI-TOF or electron 
ionization (EI) spectrometers (Waters). Waters software calibrates and reports by 
use of neutral atomic mass. The mass of the electron is not included. 
 
2-(((Benzyloxy)carbonyl)amino)-2-hydroxyacetic acid (113) 
Glyoxylic acid monohydrate (1.33 g, 14.40 mmol) and benzyl carbamate (2.00 g, 
13.00 mmol) were dissolved in dry Et2O (13 mL), and the solution was stirred at 
room temperature for 18 hours, forming a white precipitate.  An additional 30 mL 
of ether was added to the reaction mixture, and the precipitate was isolated via 
filtration to give 2-(((benzyloxy)carbonyl)amino)-2-hydroxyacetic acid as a fluffy 
white solid (2.36 g, 81% yield). 1H NMR (500 MHz, DMSO-d6) δ 12.79 (br s, 1H), 
8.12 (d, J = 8.7 Hz, 1H), 7.34 (m, 5H), 6.24 (br s, 1H), 5.21 (d, J = 8.8 Hz, 1H), 
5.05 (s, 2H). HRMS (EI) m/z [M + H]+ calcd for C10H12NO5 226.0715, found 
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226.0715 (lit. (Azuma et al., 2011)49 HRMS m/z [M + H]+ calcd for C10H12NO5 
226.0715, found 226.0716). 
 
Methyl 2-(((benzyloxy)carbonyl)amino)-2-methoxyacetate (114) 
2-(((Benzyloxy)carbonyl)amino)-2-hydroxyacetic acid (2.36 g, 10.40 mmol) was 
dissolved in CH3OH (24 mL) and chilled in an ice bath for 10 minutes. 
Concentrated H2SO4 (0.42 mL) was then added dropwise via syringe.  As ice 
melted, reaction mixture was allowed to gradually warm to room temperature as it 
was stirred for 48 hours. The reaction was then quenched by pouring over a 
mixture of ~50 g ice and ~60 mL saturated aqueous NaHCO3, causing a white 
precipitate to crash out of solution.  The reaction mixture was then extracted three 
times with EtOAc, dried over MgSO4 and concentrated to give a clear oil that 
crystallized after ~1 hour at room temperature to give methyl 2-
(((benzyloxy)carbonyl)amino)-2-methoxyacetate as a white crystalline solid 
(2.35 g, 89%). 1H NMR (500 MHz, CDCl3) δ 7.31 (m, 5H), 5.81 (br s, 1H), 5.32 (d, 
J = 9.5 Hz, 1H), 5.12 (s, 2H), 3.77 (s, 3H), 3.40 (s, 3H). HRMS (ESI-TOF) m/z 
[M + Na]+ calcd for C12H15NO5 276.0848, found 276.0835. (lit. (Azuma et al., 
2011)49 HRMS m/z [M + Na]+ calcd for C12H15NNaO5 276.0848, found 276.0846). 
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Methyl 2-(((benzyloxy)carbonyl)amino)-2-(dimethoxyphosphoryl)acetate 
(115) 
Methyl 2-(((benzyloxy)carbonyl)amino)-2-methoxyacetate (2.35 g, 9.30 mmol) was 
dissolved in dry toluene (10 mL) and was heated to 70 °C under argon.  PCl3 
(0.81 mL, 9.30 mmol) was added dropwise via syringe and the reaction mixture 
was allowed to stir for 18 hours at 70 °C.  P(OCH3)3 (1.10 mL, 9.30 mmol) was 
then added via syringe and stirring was continued for an additional 2 hours.  The 
reaction mixture was then concentrated to give a pale yellow oil, which was 
dissolved in EtOAc and washed three times with saturated aqueous NaHCO3. The 
EtOAc layer was dried over Na2SO4 and concentrated to ~10 mL.  Hexanes were 
added while stirring until a precipitate formed, which was subsequently isolated via 
filtration to give methyl 2-(((benzyloxy)carbonyl)amino)-2-(dimethoxyphosphoryl)-
acetate as a white crystalline solid (2.36 g, 76%). 1H NMR (CDCl3) δ 7.33 (m, 5H), 
5.56 (d, J = 9.0 Hz, 1H), 5.13 (s, 2H), 4.92 (dd, J = 9 Hz, 22 Hz, 1H), 3.80 (m, 9H). 
HRMS (ESI-TOF) m/z [M + H]+ calcd for C13H19NO7P 332.0899, found 332.0912. 
(lit. (Azuma et al., 2011)49 HRMS m/z [M + H]+ calcd for C13H19NO7P 332.0899, 
found 332.0905). 
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tert-Butyl (2S)-2-((1-(dimethoxyphosphoryl)-2-methoxy-2-oxoethyl)carba-
moyl)pyrrolidine-1-carboxylate (118) 
Methyl 2-(((benzyloxy)carbonyl)amino)-2-(dimethoxyphosphoryl)acetate (1.50 g, 
4.50 mmol) was dissolved in CH3OH (15 mL) under argon.  Palladium on carbon 
(10 wt. % loading, matrix activated carbon support, 0.056 g) was added and the 
reaction mixture was evacuated and fitted with a balloon of hydrogen gas.  The 
reaction mixture was allowed to stir for 2 hours at room temperature, after which it 
was filtered through a Celite plug and rinsed with EtOAc.  The EtOAc solution was 
concentrated to give methyl 2-amino-2-(dimethoxyphosphoryl)acetate as a clear 
oil, which was immediately dissolved in dry CH2Cl2 (45 mL) and cooled in an ice 
bath under argon. N-Boc-D-proline (1.11 g, 5.20 mmol) was then added, followed 
by sequential addition of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC, 1.07 g, 5.60 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 
0.64 g, 4.70 mmol), and N,N-diisopropylethylamine (1.18 mL, 6.8 mmol).  The 
reaction mixture was allowed to slowly warm to room temperature as it was stirred 
for 20 hours.  The reaction mixture was then sequentially washed with 10% 
aqueous HCl, 5% aqueous NaHCO3, and saturated aqueous NaCl.  The organic 
solution was dried over Na2SO4 and was concentrated by rotary evaporation to 
give a pale yellow oil.  The oil was purified via column chromatography (1:4 
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acetone:CH2Cl2) to give tert-butyl (2S)-2-((1-(dimethoxyphosphoryl)-2-methoxy-2-
oxoethyl)carbamoyl)-pyrrolidine-1-carboxylate as a clear oil (1.16 g, 65% over two 
steps). 1H NMR (CDCl3) δ 5.17 (dd, J = 9.1, 22.1 Hz, 1H), 4.31 (br s, 1H), 3.78 (m, 
9H), 3.43 (br s, 2H), 2.13 (br s, 2H), 1.85 (br s, 1H), 1.44 (s, 9H). 13C NMR 
(125 MHz, CDCl3) δ 172.1, 167.1, 155.9, 80.8, 61.0, 60.1, 54.3, 54.2, 53.4, 47.2, 
29.8, 28.4, 24.6, 23.7. HRMS (EI) m/z [M – Boc – OCH3]+ calcd for C9H15N2O5P 
262.0719, found 262.0724 (parent ion not observed). 
  
1-Tosyl-1H-imidazole-4-carbaldehyde (119) 
1H-Imidazole-4-carbaldehyde (1.32 g, 13.70 mmol) was dissolved in dry CH2Cl2 
(38 mL) in a round-bottomed flask under argon. Et3N (2.3 mL, 16.40 mmol) and 
TsCl (2.65 g, 13.80 mmol) were added sequentially, and the reaction was allowed 
to stir overnight at room temperature. After stirring for 18 hours, the reaction 
mixture was quenched with saturated aqueous NH4Cl. The aqueous layer was 
washed twice with CH2Cl2, and the combined organic layers were dried over 
Na2SO4 and concentrated in vacuo to give 1-tosyl-1H-imidazole-4-carbaldehyde 
(3.42 g, 99%) as an off white solid. 1H NMR (500 MHz, CDCl3) δ 9.85 (s, 1H), 8.02 
(d, J = 1.5 Hz, 1H), 7.89 (d, J = 1.0 Hz, 1H), 7.85 (d, J = 8.5 Hz, 2H), 7.38 (d, J = 
8.5 Hz, 2H), 2.44 (s, 3H). HRMS (ESI-TOF) m/z [M + Na]+ calcd for 
C11H10N2NaO3S 273.0310, found 273.0302 (lit (Arndt et al., 2016)50 HRMS (ESI) 
m/z [M + H]+ calcd for C11H11N2O3S 251.0485, found 251.0487). 
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tert-Butyl (S,Z)-2-((3-methoxy-3-oxo-1-(1-tosyl-1H-imidazol-4-yl)prop-1-en-2-
yl)carbamoyl)pyrrolidine-1-carboxylate (120) 
tert-Butyl (2S)-2-((1-(dimethoxyphosphoryl)-2-methoxy-2-oxoethyl)carbamoyl)-
pyrrolidine-1-carboxylate (0.67 g, 1.70 mmol) was dissolved in dry CH2Cl2 (68 mL) 
under argon and chilled in an ice bath. DBU (0.51 mL, 3.40 mmol) was added 
slowly via syringe, and the reaction mixture was allowed to stir for 10 minutes. 1-
Tosyl-1H-imidazole-4-carbaldehyde (0.68 g, 2.70 mmol) was then added, and the 
reaction mixture was allowed to stir overnight at room temperature. After stirring 
18 hours, the reaction was quenched with saturated aqueous NH4Cl and washed 
with 1 N KHSO4 (aq.), saturated aqueous NaHCO3, and saturated aqueous NaCl. 
The organic solution was dried over Na2SO4 and concentrated by rotary 
evaporation. The crude product was purified by column chromatography (1:4 
acetone:CH2Cl2) to give tert-butyl (S,Z)-2-((3-methoxy-3-oxo-1-(1-tosyl-1H-
imidazol-4-yl)prop-1-en-2-yl)carbamoyl)-pyrrolidine-1-carboxylate (0.66 g, 72%) 
as a white solid. 1H NMR (500 MHz, CDCl3) δ 10.72 (br s, 1H), 8.02 (s, 1H), 7.83 
(d, J = 7.9 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 7.28 (s, 1H), 6.29 (s, 1H), 4.24 (d, J = 
5.1 Hz, 1H), 3.81 (s, 3H), 3.81 (m, 1H), 3.65 (m, 1H), 2.45 (s, 3H), 2.21 (m, 1H), 
2.13 (m, 1H), 1.95 (m, 1H), 1.90 (m, 1H), 1.24 (s, 9H). 13C NMR (125 MHz, CDCl3) 
δ 171.8, 165.5, 154.4, 146.9, 139.8, 136.6, 134.6, 130.7, 130.1, 127.7, 116.7, 
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109.1, 80.4, 61.7, 52.6, 46.9, 31.1, 28.2, 23.9, 21.9. HRMS (ESI-TOF) m/z [M + 
H]+ calcd for C24H31N4O7S 519.1913, found 519.1926. 
 
(S,Z)-3-((1-Tosyl-1H-imidazol-4-yl)methylene)hexahydropyrrolo[1,2-a]-
pyrazine-1,4-dione (121) 
tert-Butyl (S,Z)-2-((3-methoxy-3-oxo-1-(1-tosyl-1H-imidazol-4-yl)prop-1-en-2-yl)-
carbamoyl)pyrrolidine-1-carboxylate (0.10 g, 0.19 mmol) was dissolved in CH2Cl2 
(0.4 mL) and trifluoroacetic acid (TFA, 0.18 mL, 2.47 mmol) and Et3SiH (0.08 mL, 
0.48 mmol) were added via syringe. The reaction mixture was allowed to stir at 
room temperature, and following full conversion of starting material after 1.5 hours 
(determined by TLC), the reaction mixture was concentrated by rotary evaporation. 
The crude residue was then dissolved in 10% NH4OH in CH3OH (2.7 mL). 4-
Dimethylaminopyridine (DMAP, 0.005 g, 0.038 mmol) was then added, and the 
reaction mixture was allowed to stir overnight at room temperature. After stirring 
for 17 hours, the reaction mixture was concentrated by rotary evaporation and 
purified by column chromatography (1:9 acetone:CH2Cl2) to give (S,Z)-3-((1-tosyl-
1H-imidazol-4-yl)methylene)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione as a white 
solid (0.56 g, 61%). 1H NMR (500 MHz, CDCl3) δ 10.96 (s, 1H), 7.98 (s, 1H), 7.81 
(d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.2965 (d, J = 1.2 Hz, 1H), 6.52 (s, 
1H), 4.17 (dd, J = 6.2, 10.6 Hz, 1H), 3.80 (m, 1H), 3.56 (m, 1H), 2.45 (m, 1H), 2.42 
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(s, 3H), 1.96 (m, 3H). 13C NMR (125 MHz, CDCl3) δ 165.5, 157.6, 147.1, 140.2, 
136.5, 134.5, 130.8, 129.5, 127.7, 116.9, 102.3, 59.5, 45.8, 29.5, 22.0, 21.8. 
HRMS (ESI-TOF) m/z [M + H]+ calcd for C18H19N4O4S 387.1127, found 387.1125. 
 
Benzyl 2-(2,2,2-trifluoroacetamido)acrylate (126b) 
L-Serine benzyl ester hydrochloride (1.32 g, 5.70 mmol) was dissolved in CH2Cl2 
(9.5 mL) and chilled in an ice bath. Trifluoroacetic anhydride (TFAA, 4 mL, 
28.60 mmol) and pyridine (2.8 mL, 34.30 mmol) were added sequentially via 
syringe, and the reaction mixture was stirred and allowed to warm to room 
temperature. After stirring overnight, the reaction mixture was chilled in an ice bath, 
diluted with CH2Cl2, and quenched with water. The organic layer was then washed 
with water and saturated aqueous NaCl, dried over Na2SO4, and concentrated by 
rotary evaporation. The crude residue was purified by column chromatography (2:3 
EtOAc:hexanes) to give benzyl 2-(2,2,2-trifluoroacetamido)acrylate (1.03 g, 66%) 
as a clear oil. 1H NMR (500 MHz, CDCl3) δ 8.53 (br s, 1H), 7.41 (m, 5H), 6.74 (s, 
1H), 6.20 (d, J  = 0.8 Hz, 1H), 5.33 (s, 2H). HRMS (EI) m/z [M]+ calcd for 
C12H10F3NO3 273.0613, found 273.0618. 
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1-Allyl-3-methyl-1H-indole (133) 
A slurry of NaH (60% in mineral oil, 4.60 g, 114.30 mmol) in DMF (67 mL) was 
prepared in a round-bottomed flask under argon. 3-Methylindole (5.00 g, 
38.10 mmol) was dissolved in DMF (32 mL) in a separate round-bottomed flask 
and was then added slowly via syringe to NaH slurry. The reaction mixture was 
allowed to stir 1 hour at room temperature, after which allyl bromide (4.3 mL, 
49.60 mmol) was added. After stirring overnight under argon, the reaction was 
poured over saturated aqueous NH4Cl and extracted with Et2O. The organic layer 
was washed with saturated aqueous NaCl, dried over MgSO4, and concentrated 
by rotary evaporation. The residue was purified by column chromatography (1:99 
EtOAc:hexanes) to give 1-allyl-3-methyl-1H-indole (5.77 g, 88%) as a pale yellow 
oil. 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 
7.22 (td, J = 1.0, 7.0 Hz, 1H), 7.14 (td, J = 1.0, 7.4 Hz, 1H), 6.89 (s, 1H), 6.01 (m, 
1H), 5.21 (dd, J = 1.5, 10.3 Hz, 1H), 5.12 (dd, J = 1.5, 17.0 Hz, 1H), 4.70 (td, J = 
1.6, 5.4 Hz, 2H), 2.37 (d, J = 1.0 Hz, 1H). HRMS (EI) m/z [M]+ calcd  for C12H13N 
171.1048, found 171.1043. 
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(R)-2,2'-Bis(methoxymethoxy)-1,1'-binaphthalene (144) 
NaH (60% in mineral oil, 0.308 g, 7.7 mmol) was suspended in dry THF (17 mL) in 
a round-bottomed flask under argon and was chilled in an ice bath. (R)-BINOL 
(1.00 g, 3.50 mmol) was dissolved in dry THF (6 mL) in a separate round-bottomed 
flask and was added slowly to NaH mixture via syringe. The reaction mixture was 
allowed to stir 1 hour at 0 °C and then allowed to warm to room temperature for 15 
minutes. MOM-Cl (0.6 mL, 7.70 mmol) was then added slowly via syringe, and the 
reaction mixture was stirred at room temperature for 4 hours. The reaction was 
quenched with saturated aqueous NH4Cl and was concentrated by rotary 
evaporation. The residue was suspended in CH2Cl2 and H2O and the aqueous 
layer was extracted three times with CH2Cl2. The combined organic extracts were 
then washed with saturated aqueous NaCl, dried over Na2SO4, and concentrated 
by rotary evaporation to give (R)-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene 
(1.27 g, 96%) as a white crystalline solid. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 
9.0 Hz, 2H), 7.84 (d, J = 8.2 Hz, 2H), 7.55 (d, J = 9.0 Hz, 2H), 7.32 (td, J = 1.2, 
6.7 Hz, 2H), 7.19 (td, J = 1.3, 6.7 Hz, 2H), 7.12 (d, J = 8.6 Hz, 2H), 5.05 (d, J = 
6.8 Hz, 2H), 4.95 (d, J = 6.8 Hz, 2H), 3.11 (s, 6H). HRMS (ESI-TOF) m/z [M]+ calcd 
for C24H22O4 374.1510, found 374.1518 (lit (Hediger, Reymond, et al., 2015)51 
HRMS m/z [M + Na]+ calcd for C24H22NaO4 397.1410, found 374.1518). 
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(R)-3,3'-Dichloro-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene (145) 
(R)-2,2'-Bis(methoxymethoxy)-1,1'-binaphthalene (1.27 g, 3.38 mmol) was added 
to an oven-dried round-bottomed flask under argon and dissolved in dry degassed 
Et2O (56 mL). n-BuLi (0.93M in hexanes, 12.7 mL, 11.84 mmol) was added 
dropwise via syringe and the reaction mixture was allowed to stir 3 hours at room 
temperature. The reaction mixture was then cooled in an ice bath, and dry 
degassed THF (37 mL) and C2Cl6 (2.40 g, 10.40 mmol) were then added. The 
reaction mixture was gradually warmed to room temperature and stirred overnight. 
The reaction mixture was then quenched with saturated aqueous NH4Cl and the 
layers were separated. The aqueous layer was extracted three times with CH2Cl2, 
and the combined organic layers were dried over Na2SO4 and concentrated by 
rotary evaporation. The residue was purified by column chromatography (1:10 
Et2O:hexanes) to give (R)-3,3'-dichloro-2,2'-bis(methoxymethoxy)-1,1'-
binaphthalene (1.00 g, 67%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 8.07 
(s, 2H), 7.79 (d, J = 8.3 Hz, 2H), 7.43 (td, J = 1.1, 6.8 Hz, 2H), 7.27 (td, J = 1.2, 
6.8 Hz, 2H), 7.19 (d, J = 8.5 Hz, 2H), 4.84 (dd, J = 5.9, 15.7 Hz, 4H), 2.58 (s, 6H). 
HRMS (ESI-TOF) m/z [M]+ calcd for C24H2035Cl2O4 442.0739, found 442.0735 (lit 
(Chong et al., 2011)52 HRMS m/z [M]+ calcd for C24H2035Cl2O4 442.0740, found 
442.0756). 
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(R)-3,3’-Dichloro-BINOL (142) 
(R)-3,3'-Dichloro-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene (1.00 g, 
2.26 mmol) was dissolved in 1:1 CH3OH:THF (40 mL). DOWEX 50WX8-100 
(1.50 g) was added, and the reaction mixture was refluxed overnight. After 
refluxing for 18 hours, the DOWEX 50WX8-100 was filtered off, and the organic 
solution was concentrated. The residue was purified by column chromatography 
(1:10 EtOAc:hexanes) to give (R)-3,3’-dichloro-BINOL (0.80 g, quant.) as a pale 
yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.08 (s, 2H), 7.83 (d, J = 8.2 Hz, 2H), 
7.40 (td, J = 1.0, 6.8 Hz, 2H), 7.32 (td, J = 1.2, 6.9 Hz, 2H), 7.13 (d, J = 8.5 Hz, 
2H), 5.59 (s, 2H). HRMS (EI) m/z [M]+ calcd for C20H1235Cl2O2 354.0214, found 
354.0228 (lit (Chong et al., 2011)52 HRMS m/z [M]+ calcd for C20H1235Cl2O2 
354.0214, found 354.0211). 
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Benzyl (2S,3aS,8aS)-8-allyl-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-
hexahydropyrrolo[2,3-b]indole-2-carboxylate (140b) 
To an oven-dried round-bottomed flask under argon, the following reagents were 
added sequentially: 1-allyl-3-methyl-1H-indole (3.66 g, 21.40 mmol), CH2Cl2 
(152 mL), benzyl 2-(2,2,2-trifluoroacetamido)acrylate (6.98 g, 25.60 mmol), (R)-
BINOL (1.20 g, 4.30 mmol), and 2,6-dibromophenol (2.10 g, 8.50 mmol). SnCl4 
(1 M in CH2Cl2, 34 mL, 34.16 mmol ) was then added slowly via syringe. The 
reaction mixture was allowed to stir at room temperature for 2 days, after which it 
was diluted with CH3CN and quenched with 1 M HCl. The reaction mixture was 
further diluted with H2O and CH2Cl2, and the layers were separated. The aqueous 
layer was extracted three times with Et2O. The combined organic layers were 
washed three times with 3 M NaOH, dried over MgSO4, and concentrated. The 
residue was purified by column chromatography (1-8% EtOAc in hexanes) to give 
benzyl (2S,3aS,8aS)-8-allyl-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-
hexahydro-pyrrolo[2,3-b]indole-2-carboxylate (5.15 g, 54%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3, compound exists as a 6.1:1 mixture of rotamers, the 
major rotamer is denoted by *, minor rotamer denoted by §) δ 7.40 (br s, 5H*, 5H§), 
7.1 (t, J = 7.6 Hz, 1H*, 1H§), 7.01 (d, J = 7.1 Hz, 1H*, 1H§), 6.84 (br s, 1H§), 6.77 
(t, J = 7.2 Hz, 1H*), 6.64 (br s, 1H§), 6.55 (d, J = 7.8 Hz, 1H*), 5.83 (m, 1H*, 1H§), 
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5.74 (s, 1H*), 5.53 (br s, 1H§), 5.30-5.15 (m, 4H*, 4H§), 4.75 (d, J = 9.0 Hz, 1H*), 
4.42 (br s, 1H§), 4.27 (d, J = 15.2 Hz, 1H*), 4.05 (dd, J = 5.8, 16.5 Hz, 1H*, 1H§), 
3.84 (br s, 1H§), 2.60 (dd, J = 10.1, 13.2 Hz, 1H*, 1H§), 2.36 (d, J = 13.4 Hz, 1H*), 
2.11 (br s, 1H§), 1.28 (s, 3H*, 3H§). HRMS (ESI-TOF) m/z [M + H]+ calcd for 
C24H24F3N2O3 445.1739, found 445.1713 (lit (Reisman et al., 2010)42 HRMS (ESI) 
m/z [M + H]+ calcd for C24H24F3N2O3 445.1734, found 445.1750). 
 
Methyl (2S,3aS,8aS)-8-allyl-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-
hexahydropyrrolo[2,3-b]indole-2-carboxylate (140a) 
Benzyl (2S,3aS,8aS)-8-allyl-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-
hexahydropyrrolo[2,3-b]indole-2-carboxylate (393 mg, 0.88 mmol) was dissolved 
in dry CH3OH (9 mL) in a round-bottomed flask. K2CO3 (24 mg, 0.18 mmol) was 
added, and the reaction mixture was stirred overnight. The reaction was quenched 
with 1 M HCl and extracted three times with EtOAc. The organic layers were 
washed with saturated aqueous NaHCO3, dried over Na2SO4, and concentrated. 
The residue was purified by column chromatography (0-15% EtOAc in hexanes) 
to give methyl (2S,3aS,8aS)-8-allyl-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a, 
8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (252 mg, 78%) as a white 
crystalline solid. 1H NMR (500 MHz, CDCl3) δ 7.15 (t, J = 7.7 Hz, 1H), 7.06 (d, J = 
7.2 Hz, 1H), 6.81 (t, J = 7.0 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 5.82 (m, 2H), 5.28 
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(d, J = 17.2 Hz, 1H), 5.15 (d, J = 10.1 Hz, 1H), 4.73 (d, J = 8.5 Hz, 1H), 4.26 (d, 
J = 15.7 Hz, 1H), 4.05 (dd, J = 5.5, 16.4 Hz, 1H), 3.81 (s, 3H), 2.60 (dd, J = 10.4, 
12.9 Hz, 1H), 2.41 (d, J = 13.3 Hz, 1H), 1.40 (s, 3H). HRMS (ESI-TOF) m/z [M]+ 
calcd for C18H19F3N2O3 368.1348, found 368.1344 (lit (Reisman et al., 2013)43 
HRMS (APCI) m/z [M + H]+ calcd for C18H20F3N2O3 369.1421, found 369.1416). 
 
Methyl (2S,3aS,8aS)-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-hexa-
hydropyrrolo[2,3-b]indole-2-carboxylate (146) 
Methyl (2S,3aS,8aS)-8-allyl-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-
hexahydropyrrolo[2,3-b]indole-2-carboxylate (60 mg, 0.16 mmol) was suspended 
in n-PrOH (5 mL), sparged with argon for 10 minutes, and heated to dissolution. 
RhCl3∙3H2O (4 mg, 0.008 mmol) was added, and the reaction mixture was refluxed 
overnight under argon. The reaction was cooled to room temperature, diluted with 
a large amount of H2O, and extracted three times with CH2Cl2. The organic layers 
were dried over Na2SO4 and concentrated by rotary evaporation. The residue was 
purified by column chromatography (0-10% EtOAc in hexanes) to give methyl 
(2S,3aS,8aS)-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-hexahydropyrrolo-
[2,3-b]indole-2-carboxylate (27 mg, 51%) as a pale yellow oil. 1H NMR (500 MHz, 
CDCl3, compound exists as a 1:1 mixture of rotamers) δ 7.10 (m, 2H), 6.84 (t, J = 
7.4 Hz, 0.5H), 6.78 (t, J = 7.4 Hz, 0.5H), 6.65 (d, J = 7.8 Hz, 0.5H), 6.61 (d, J = 
7.8 Hz, 0.5H), 5.64 (s, 0.5H), 5.59 (s, 0.5H), 5.33 (br s, 0.5H), 4.77 (s, 0.5H), 4.63 
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(ddd, J = 1.3, 4.1, 9.1 Hz, 0.5H), 4.46 (t, J = 7.4 Hz, 0.5H), 3.83 (s, 1.5H), 3.76 (s, 
1.5H), 2.76 (dd, J = 9.2, 13.5 Hz, 0.5H), 2.61 (dd, J = 8.5, 13.2 Hz, 0.5H), 2.38 (dd, 
J = 4.3, 13.4 Hz, 0.5H), 2.22 (dd, J = 7.0, 13.2 Hz, 0.5H), 1.50 (s, 1.5H), 1.41 (s, 
1.5H). 13C NMR (125 MHz, CDCl3, compound exists as a 1:1 mixture of rotamers) 
δ 172.3, 171.1, 147.1, 146.6, 133.4, 133.4, 129.1, 129.0, 122.5, 122.4, 120.5, 
119.6, 110.2, 109.6, 86.7, 84.7, 61.4, 59.8, 54.8, 53.2, 52.9, 50.5, 43.9, 40.6, 31.8, 
24.5, 24.2. HRMS (ESI-TOF) m/z [M + H]+ calcd for C15H16F3N2O3 329.1113, found 
329.1095. 
 
Methyl (2S,3aS,8aR)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-
2-carboxylate (148) 
Methyl (2S,3aS,8aS)-3a-methyl-1-(2,2,2-trifluoroacetyl)-1,2,3,3a,8,8a-hexahydro-
pyrrolo[2,3-b]indole-2-carboxylate (1.81 g, 5.51 mmol) was dissolved in methanol 
(55 mL) in a round-bottomed flask. Triflic acid (4.8 mL, 55.10 mmol) was added 
slowly, and the reaction mixture was stirred at room temperature for 2 days. The 
reaction was then slowly quenched with saturated aqueous NaHCO3 and extracted 
three times with CH2Cl2. The organic layers were dried over Na2SO4 and 
concentrated. The residue was purified by column chromatography (100% EtOAc) 
to give methyl (2S,3aS,8aR)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo-[2,3-
b]indole-2-carboxylate (0.96 g, 75%) as a pale yellow oil. 1H NMR (500 MHz, 
CDCl3) δ 7.03 (m, 2H), 6.74 (td, J = 0.9, 7.4 Hz, 1H), 6.56 (d, J = 7.6 Hz, 1H), 4.91 
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(s, 1H), 3.74 (dd, J = 6.0, 10.4 Hz, 1H), 3.71 (s, 3H), 2.43 (dd, J = 6.0, 12.2 Hz, 
1H), 1.96 (dd, J = 10.4, 12.1 Hz, 1H), 1.48 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
174.5, 149.6, 134.6, 128.3, 123.2, 119.2, 109.2, 84.9, 59.9, 54.6, 52.3, 46.5, 26.0. 
HRMS (ESI-TOF) m/z [M + H]+ calcd for C13H17N2O2 233.1290, found 233.1274. 
 
2-((tert-Butoxycarbonyl)amino)-2-methylpropanoic acid (127a) 
In a round-bottomed flask, 2-methylalanine (1.00 g, 9.70 mmol) was stirred with 
Boc2O (4.2 g, 19.40 mmol), 1 M NaOH (40 mL), and 1,4-dioxane (40 mL) overnight 
at room temperature. The reaction mixture was then concentrated to remove the 
dioxane, acidified to pH 3 with 1 M HCl, and extracted three times with EtOAc. The 
organic layers were dried over MgSO4 and concentrated to give 2-((tert-
butoxycarbonyl)amino)-2-methylpropanoic acid (1.35 g, 68%) as a white 
crystalline solid. 1H NMR (500 MHz, CDCl3) δ 5.10 (br s, 1H), 1.53 (s, 6H), 1.42 (s, 
9H). HRMS (ESI-TOF) m/z [M - H]- calcd for C9H16NO4 202.1079, found 202.1097 
(lit (Balamurugan and Muraleedharan, 2012)53 HRMS (ESI) m/z [M + H]+ calcd for  
C9H18NO4  204.1236,  found 204.1239). 
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Methyl (2S,3aS,8aS)-1-(2-((tert-butoxycarbonyl)amino)-2-methylpropanoyl)-
3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylate (149) 
In a round-bottomed flask, 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid 
(800 mg, 3.94 mmol) was dissolved in DMF (33 mL). 
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexa-
fluorophosphate (HATU, 1.49 g, 3.94 mmol) and Et3N (1.4 mL, 9.84 mmol) were 
added, and the reaction mixture was allowed to stir for 10 minutes. Methyl 
(2S,3aS,8aR)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carbox-
ylate (380 mg, 1.64 mmol) was then added, and the reaction mixture was allowed 
to stir overnight at room temperature. The reaction mixture was then diluted with 
water and extracted three times with EtOAc. The combined organic layers were 
washed with saturated aqueous NaHCO3 and saturated aqueous NaCl, and were 
dried over Na2SO4 and concentrated. The combined product and 1-hydroxy-7-
azabenzotriazole (HOAt) activated carboxylic acid were purified from the starting 
material via column chromatography (100% EtOAc). The crude product (629 mg), 
an inseparable mixture of several compounds, was carried on without further 
purification. 
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Methyl (2S,3aS,8aR)-1-(2-((tert-butoxycarbonyl)amino)-2-methylpropanoyl)-
3a-methyl-8-(phenylsulfonyl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-
carboxylate (150) 
A crude mixture containing methyl (2S,3aS,8aS)-1-(2-((tert-butoxy-
carbonyl)amino)-2-methylpropanoyl)-3a-methyl-1,2,3,3a,8,8a-hexahydropyrrolo-
[2,3-b]indole-2-carboxylate (730 mg) was suspended in 1 M aqueous NaOH 
(4.4 mL) in a round-bottomed flask. To this suspension was added 
benzenesulfonyl chloride (245 µL, 1.93 mmol), and the reaction mixture was stirred 
for 18 hours. The mixture was then acidified with 1 M aqueous HCl and extracted 
three times with Et2O. The ether extracts were washed with saturated aqueous 
NaCl, dried over Na2SO4, and concentrated in vacuo. The crude residue was 
purified by column chromatography (25-50% EtOAc in hexanes) to give 617.9 mg 
of methyl (2S,3aS,8aR)-1-(2-((tert-butoxycarbonyl)amino)-2-methylpropanoyl)-3a-
methyl-8-(phenylsulfonyl)-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-
carboxylate as an inseparable mixture with several unidentified compounds. The 
crude product was carried on without further purification. 
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(5aR,10bS,11aS)-3,3,10b-Trimethyl-6-(phenylsulfonyl)-2,3,6,10b,11,11a-
hexahydro-4H-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-1,4(5aH)-dione (151) 
The crude methyl (2S,3aS,8aR)-1-(2-((tert-butoxycarbonyl)amino)-2-
methylpropanoyl)-3a-methyl-8-(phenylsulfonyl)-1,2,3,3a,8,8a-hexahydropyrrolo-
[2,3-b]indole-2-carboxylate (96.3 mg) was dissolved in CH2Cl2 (2.5 mL) in a round-
bottomed flask and chilled to 0 °C in an ice bath. TFA (640 µL, 8.63 mmol) was 
added, and the reaction mixture was allowed to slowly warm to room temperature 
and stir for 3 hours. The reaction mixture was concentrated to remove the CH2Cl2, 
and the residue was then dissolved in 10% NH4OH in CH3OH (2.5 mL). DMAP 
(4 mg, 0.034 mmol) was added, and the reaction mixture was allowed to stir 
overnight at room temperature. The reaction mixture was then concentrated and 
purified by column chromatography (100% EtOAc) to give (5aR,10bS,11aS)-
3,3,10b-trimethyl-6-(phenylsulfonyl)-2,3,6,10b,11,11a-hexahydro-4H-pyrazino-
[1',2':1,5]pyrrolo[2,3-b]indole-1,4(5aH)-dione (25 mg, 1.5 % over four steps) as a 
yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 7 Hz, 2H), 7.66 (d, J = 8.1 Hz, 
1H), 7.55 (d, J = 7.4 Hz, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.30 (td, J = 1.4, 7.0 Hz, 1H), 
7.13 (m, 2H), 6.84 (br s, 1H), 6.07 (s, 1H), 4.00 (dd, J = 6.0, 11.2 Hz, 1H), 2.63 
(dd, J = 6.0, 12.7 Hz, 1H), 2.07 (dd, J = 11.4, 12.6 Hz, 1H), 1.51 (s, 3H), 1.41 (s, 
3H), 1.03 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 168.1, 167.8, 141.6, 138.7, 136.1, 
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133.5, 129.2, 127.6, 125.6, 123.3, 117.0, 83.2, 58.6, 57.5, 50.7, 44.2, 29.0, 25.7, 
24.9. HRMS (ESI-TOF) m/z [M + Na]+ calcd  for C22H23N3NaO4S 448.1307, found 
448.1325. 
 
(5aR,10bS,11aS)-2-(4-Methoxybenzyl)-3,3,10b-trimethyl-6-(phenylsulfonyl)-
2,3,6,10b,11,11a-hexahydro-4H-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-1,4 
(5aH)-dione (154) 
(5aR,10bS,11aS)-3,3,10b-Trimethyl-6-(phenylsulfonyl)-2,3,6,10b,11,11a-hexa-
hydro-4H-pyrazino[1’,2’:1,5]pyrrolo[2,3-b]indole-1,4(5aH)-dione (18 mg, 
0.042 mmol) was dissolved in DMF (1 mL) in a round-bottomed flask under argon 
and chilled in an ice bath to 0 °C. NaH (60% in mineral oil, 2 mg, 0.046 mmol) was 
added, and the reaction mixture was allowed to stir for 30 minutes. PMB-Cl (5.7 µL, 
0.042 mmol) was then added, and the reaction mixture was allowed to slowly warm 
to room temperature overnight. After stirring for 18 hours, the reaction was 
quenched with saturated aqueous NH4Cl, diluted with water, and extracted three 
times with EtOAc. The combined EtOAc extracts were washed three times with 
water and once with saturated aqueous NaCl. The EtOAc extracts were then dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (1:1 EtOAc:hexanes) to give (5aR,10bS,11aS)-2-(4-
methoxybenzyl)-3,3,10b-trimethyl-6-(phenylsulfonyl)-2,3,6,10b,11,11a-hexa-
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hydro-4H-pyrazino[1’,2’:1,5]pyrrolo[2,3-b]indole-1,4(5aH)-dione (13 mg, 57%) as a 
pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 7.4 Hz, 2H), 7.66 (d, J = 
8.1 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.32 (td, J = 1.9, 
7.0 Hz, 1H), 7.15 (m, 4H), 6.82 (d, J = 8.7 Hz, 2H), 6.09 (s, 1H), 4.62 (dd, J = 15.7, 
24.8 Hz, 2H), 4.05 (dd, J = 5.9, 11.0 Hz, 1H), 3.78 (s, 3H), 2.76 (dd, J = 5.9, 
12.8 Hz, 1H), 2.14 (dd, J = 11.2, 12.7 Hz, 1H), 1.56 (s, 3H), 1.22 (s, 3H), 1.01 (s, 
3H). 13C NMR (125 MHz, CDCl3) δ 167.7, 167.4, 159.0, 141.6, 138.9, 136.4, 133.4, 
130.4, 129.2, 129.2, 128.9, 127.6, 125.7, 123.3, 117.2, 114.2, 83.5, 62.8, 58.3, 
55.4, 50.7, 45.0, 44.8, 26.8, 24.8, 23.6.  HRMS (ESI-TOF) m/z [M + H]+ calcd for 
C30H32N3O5S 546.2063, found 546.2072. 
 
(5aR,10bS)-11a-Hydroxy-2-(4-methoxybenzyl)-3,3,10b-trimethyl-6-(phenyl-
sulfonyl)-2,3,6,10b,11,11a-hexahydro-4H-pyrazino[1’,2’:1,5]pyrrolo[2,3-
b]indole-1,4(5aH)-dione (155) 
5aR,10bS,11aS)-2-(4-Methoxybenzyl)-3,3,10b-trimethyl-6-(phenylsulfonyl)-2,3, 
6,10b,11,11a-hexahydro-4H-pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-1,4(5aH)-
dione (13 mg, 0.024 mmol) was dissolved in dry CH2Cl2 (1 mL) in a round-
bottomed flask. Py2AgMnO4 (184 mg, 0.48 mmol) was added, and the dark purple 
reaction mixture was stirred at room temperature for 48 h. The reaction was 
quenched with 10% aqueous Na2S2O3 and diluted with CH2Cl2 and water. The 
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biphasic system was extracted three times with CH2Cl2, and the combined organic 
extracts were washed once with 30% aqueous CuSO4, dried over Na2SO4, and 
concentrated in vacuo. The crude product was purified by column chromatography 
(1:1 EtOAc:hexanes) to give (5aR,10bS)-11a-hydroxy-2-(4-methoxybenzyl)-
3,3,10b-trimethyl-6-(phenylsulfonyl)-2,3,6,10b,11,11a-hexa-hydro-4H-
pyrazino[1',2':1,5]pyrrolo[2,3-b]indole-1,4(5aH)-dione (7 mg, 52 %) as a pale 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.81 (dd, J  = 1.0, 8.6 Hz, 2H), 7.56 (d, J = 
8.1 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.40 (t, J = 8.1 Hz, 2H), 7.30 (td, J = 1.1, 
8.7 Hz, 1H), 7.15 (td, J = 0.8, 7.6 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.97 (d, J = 
8.6 Hz, 2H), 6.75 (d, J = 8.7 Hz, 2H), 6.04 (s, 1H), 4.69 (d, J = 15.6 Hz, 1H), 4.38 
(d, J = 15.6 Hz, 1H), 3.76 (s, 3H), 2.90 (d, J = 14.3 Hz, 1H), 2.42 (d, J = 14.3 Hz, 
1H), 1.54 (s, 3H), 1.47 (s 3 H), 1.06 (s 3 H). 13C NMR (125 MHz, CDCl3) δ 172.2, 
167.5, 158.6, 140.0, 138.5, 133.3, 133.1, 128.9, 128.6, 128.3, 128.2, 127.7, 125.9, 
123.0, 118.1, 114.0, 86.8, 85.1, 64.8, 55.2, 50.0, 49.4, 45.1, 26.6, 26.3, 25.2. 
HRMS (ESI-TOF) m/z [M + Na]+ calcd for C30H31N3NaO6S 584.1831, found 
584.1852. 
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Appendix 4A: Description of Human Cell Lines 
Cell line Tissue/cell type Disease 
A-549 Lung Carcinoma 
BEL-7402 Liver Hepatocellular carcinoma 
HL-60 Promyeloblast Acute promyelocytic leukemia 
Jurkat T lymphocyte Acute T cell leukemia 
MOLT-4 T lymphoblast Acute lymphoblastic leukemia 
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Appendix 4B: Spectra Relevant to Chapter 4 
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Supplementary Figure 4.1: 1H NMR (500 MHz, DMSO-d6) Spectrum of 113 
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Supplementary Figure 4.2: 1H NMR (500 MHz, CDCl3) Spectrum of 114 
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Supplementary Figure 4.3: 1H NMR (500 MHz, CDCl3) Spectrum of 115 
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Supplementary Figure 4.4: 1H NMR (500 MHz, CDCl3) Spectrum of 118 
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Supplementary Figure 4.5: 13C NMR (125 MHz, CDCl3) Spectrum of 118 
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Supplementary Figure 4.6: 1H NMR (500 MHz, CDCl3) Spectrum of 119 
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Supplementary Figure 4.7: 1H NMR (500 MHz, CDCl3) Spectrum of 120 
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Supplementary Figure 4.8: 13C NMR (125 MHz, CDCl3) Spectrum of 120 
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Supplementary Figure 4.9: 1H NMR (500 MHz, CDCl3) Spectrum of 121 
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Supplementary Figure 4.10: 13C NMR (125 MHz, CDCl3) Spectrum of 121 
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Supplementary Figure 4.11: 1H NMR (500 MHz, CDCl3) Spectrum of 126b 
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Supplementary Figure 4.12: 1H NMR (500 MHz, CDCl3) Spectrum of 133 
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Supplementary Figure 4.13: 1H NMR (500 MHz, CDCl3) Spectrum of 144 
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Supplementary Figure 4.14: 1H NMR (500 MHz, CDCl3) Spectrum of 145 
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Supplementary Figure 4.15: 1H NMR (500 MHz, CDCl3) Spectrum of 142 
C
H
C
l3
 
 247 
 
 
Supplementary Figure 4.16: 1H NMR (500 MHz, CDCl3) Spectrum of 140b 
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Supplementary Figure 4.17: 1H NMR (500 MHz, CDCl3) Spectrum of 140a 
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Supplementary Figure 4.18: 1H NMR (500 MHz, CDCl3) Spectrum of 146 
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Supplementary Figure 4.19: 13C NMR (125 MHz, CDCl3) Spectrum of 146 
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Supplementary Figure 4.20: 1H NMR (500 MHz, CDCl3) Spectrum of 148 
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Supplementary Figure 4.21: 13C NMR (125 MHz, CDCl3) Spectrum of 148 
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Supplementary Figure 4.22: 1H NMR (500 MHz, CDCl3) Spectrum of 127a 
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Supplementary Figure 4.23: 1H NMR (500 MHz, CDCl3) Spectrum of 151 
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Supplementary Figure 4.24: 13C NMR (125 MHz, CDCl3) Spectrum of 151 
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Supplementary Figure 4.25: 1H NMR (500 MHz, CDCl3) Spectrum of 154 
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Supplementary Figure 4.26: 13C NMR (125 MHz, CDCl3) Spectrum of 154 
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Supplementary Figure 4.27: 1H NMR (500 MHz, CDCl3) Spectrum of 155 
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Supplementary Figure 4.28: 13C NMR (125 MHz, CDCl3) Spectrum of 155 
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Supplementary Figure 4.29: 1H-13C HSQC NMR (500 MHz, CDCl3) Spectrum of 155 
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Appendix 4C: X-Ray Crystal Structures Relevant to Chapter 4 
X-ray Structure Determination of Compound 121 
Compound 121, C18H18N4SO4, crystallizes in the triclinic space P1
_
 with 
a=8.0132(4)Å, b=8.0532(4)Å, c=13.8714(6)Å, a=101.108(2)°, b=97.013(2)°, 
g=95.669(2)°, V=864.90(7)Å
3
, Z=2, and dcalc=1.484 g/cm
3
. X-ray intensity data 
were collected on a Bruker APEXII CCD area detector employing graphite-
monochromated Mo-Ka radiation (λ=0.71073 Å) at a temperature of 100(1)K. 
Preliminary indexing was performed from a series of thirty-six 0.5° rotation frames 
with exposures of 10 seconds. A total of 2301 frames were collected with a crystal 
to detector distance of 37.6 mm, rotation widths of 0.5° and exposures of 3 
seconds:  
scan type 2θ ω φ χ frames 
φ 19.50 59.55 348.71 -26.26 739 
φ -20.50 342.55 321.55 -73.06 739 
ω -10.50 352.00 80.80 -60.33 84 
φ -23.00 315.83 12.48 28.88 739 
 Rotation frames were integrated using SAINT i , producing a listing of 
unaveraged F2 and σ(F2) values which were then passed to the SHELXTL ii 
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program package for further processing and structure solution. A total of 17301 
reflections were measured over the ranges 2.58 ≤ θ ≤ 25.38°, -9 ≤ h ≤ 9, -9 ≤ k ≤ 
9, -16 ≤ l ≤ 16 yielding 3146 unique reflections (Rint = 0.0177). The intensity data 
were corrected for Lorentz and polarization effects and for absorption using 
SADABSiii (minimum and maximum transmission 0.6977, 0.7452). 
The structure was solved by direct methods (SHELXS-97 iv ). During 
development of the structure, some “extra” electron density was apparent in the 
C5-C6-N1 area. A disorder model was devised that included alternate locations for 
these three atoms resulting from the superposition of the two molecules depicted 
in Figures 1. and 2.  The two disorder models had relative occupancies of 
0.55/0.45.  Refinement was by full-matrix least squares based on F2 using 
SHELXL-97.v All reflections were used during refinement. The weighting scheme 
used was w=1/[σ2(Fo2 )+ (0.0338P)2 + 0.31336435P] where P = (Fo 2 + 2Fc2)/3. 
Non-hydrogen atoms were refined anisotropically and hydrogen atoms were 
refined using a riding model.  Refinement converged to R1=0.0318 and 
wR2=0.0825 for 3040 observed reflections for which F > 4σ(F) and R1=0.0326 and 
wR2=0.0831 and GOF =1.106 for all 3146 unique, non-zero reflections and 282 
variables.vi The maximum Δ/σ in the final cycle of least squares was 0.002 and the 
two most prominent peaks in the final difference Fourier were +0.412 and -0.372 
e/Å
3
. 
Supplementary Table 4.1 lists cell information, data collection parameters, 
and refinement data. Final positional and equivalent isotropic thermal parameters 
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are given in Supplementary Tables 4.2 and 4.3.  Anisotropic thermal parameters 
are in Supplementary Table 4.4.  Supplementary Tables 4.5 and 4.6 list bond 
distances and bond angles.  Supplementary Figures 4.26 and 4.27 are ORTEPvii 
representations of the molecule with 50% probability thermal ellipsoids displayed. 
 
Supplementary Figure 4.26: ORTEP drawing of disorder model no. 1 of the 
asymmetric with 50% probability thermal ellipsoids. 
 
 
Supplementary Figure 4.27: ORTEP drawing of disorder model no. 2 of the 
asymmetric with 50% probability thermal ellipsoids. 
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Supplementary Table 4.1:  Summary of Structure Determination of 
Compound 121 
Empirical formula  C18H18N4SO4 
Formula weight  386.42 
Temperature  100(1) K 
Wavelength  0.71073 Å 
Crystal system  triclinic 
Space group  P1
_
  
Cell constants:   
a  8.0132(4) Å 
b  8.0532(4) Å 
c  13.8714(6) Å 
a 101.108(2)° 
b 97.013(2)° 
g 95.669(2)° 
Volume 864.90(7) Å
3
 
Z 2 
Density (calculated) 1.484 Mg/m
3
 
Absorption coefficient 0.222 mm-1 
F(000) 404 
Crystal size 0.25 x 0.22 x 0.15 mm
3
 
 265 
 
Theta range for data collection 2.58 to 25.38° 
Index ranges -9 ≤ h ≤ 9, -9 ≤ k ≤ 9, -16 ≤ l ≤ 16 
Reflections collected 17301 
Independent reflections 3146 [R(int) = 0.0177] 
Completeness to theta = 25.38° 98.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7452 and 0.6977 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3146 / 0 / 282 
Goodness-of-fit on F2 1.106 
Final R indices [I>2sigma(I)] R1 = 0.0318, wR2 = 0.0825 
R indices (all data) R1 = 0.0326, wR2 = 0.0831 
Largest diff. peak and hole 0.412 and -0.372 e.Å-3 
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Supplementary Table 4.2: Refined Positional Parameters for Compound 121 
  Atom x y z Ueq, Å2 
C1 0.6649(2) 0.48482(19) 0.43450(12) 0.0189(3) 
C2 0.7730(2) 0.5283(2) 0.53377(12) 0.0205(3) 
C3 0.9251(2) 0.4121(2) 0.66531(12) 0.0220(3) 
C4 0.9480(2) 0.2272(2) 0.67058(13) 0.0258(4) 
C5 0.8748(6) 0.1266(5) 0.5670(3) 0.0243(9) 
C6 0.7225(4) 0.2180(3) 0.5415(2) 0.0178(6) 
N1 0.7894(6) 0.3973(8) 0.5807(4) 0.0175(10) 
O1 0.8218(14) 0.6747(17) 0.5758(10) 0.018(3) 
C5' 0.8092(7) 0.1154(6) 0.5900(4) 0.0223(10) 
C6' 0.8152(5) 0.2155(4) 0.5083(3) 0.0199(7) 
N1' 0.8406(8) 0.3940(10) 0.5628(5) 0.0176(12) 
O1' 0.829(2) 0.677(2) 0.5756(14) 0.035(5) 
C7 0.6540(2) 0.1775(2) 0.43121(12) 0.0230(4) 
C8 0.6278(2) 0.6083(2) 0.38616(12) 0.0197(3) 
C9 0.53425(19) 0.58446(19) 0.28718(11) 0.0171(3) 
C10 0.5099(2) 0.7061(2) 0.23277(11) 0.0186(3) 
C11 0.38706(19) 0.45197(19) 0.14816(11) 0.0173(3) 
C12 0.20155(19) 0.83555(19) 0.08551(11) 0.0158(3) 
C13 0.25426(19) 0.99682(19) 0.14546(12) 0.0184(3) 
C14 0.1331(2) 1.09395(19) 0.18064(12) 0.0196(3) 
C15 -0.0397(2) 1.0347(2) 0.15444(12) 0.0190(3) 
C16 -0.0885(2) 0.8746(2) 0.09319(12) 0.0213(3) 
C17 0.0308(2) 0.7730(2) 0.05926(12) 0.0198(3) 
C18 -0.1698(2) 1.1419(2) 0.19391(14) 0.0280(4) 
N2 0.61064(17) 0.31197(16) 0.39343(10) 0.0188(3) 
N3 0.41533(16) 0.62128(16) 0.14317(9) 0.0160(3) 
 267 
 
N4 0.45616(17) 0.42501(16) 0.23242(10) 0.0182(3) 
O2 0.60708(17) 0.03014(14) 0.38878(9) 0.0289(3) 
O3 0.49787(13) 0.81381(14) 0.03153(8) 0.0189(2) 
O4 0.27594(14) 0.56404(14) -0.03040(8) 0.0193(2) 
S1 0.35327(4) 0.70729(5) 0.04492(3) 0.01467(11) 
Ueq=1/3[U11(aa*)2+U22(bb*)2+U33(cc*)2+2U12aa*bb*cos γ+2U13aa*cc*cos β+2U23bb*cc*cosα] 
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Supplementary Table 4.3: Positional Parameters for Hydrogens in 
Compound 121 
 Atom x y z Uiso, Å2 
H3a 0.8918 0.4717 0.7263 0.029 
H3b 1.0291 0.4728 0.6539 0.029 
H3a' 0.8548 0.4598 0.7131 0.029 
H3b' 1.0334 0.4834 0.6767 0.029 
H4A 1.0668 0.2147 0.6862 0.034 
H4B 0.8867 0.1898 0.7203 0.034 
H5a 0.8402 0.0080 0.5675 0.032 
H5b 0.9555 0.1329 0.5208 0.032 
H6 0.6322 0.1858 0.5786 0.024 
H5a' 0.8379 0.0009 0.5694 0.030 
H5b' 0.6991 0.1095 0.6124 0.030 
H6' 0.9136 0.1918 0.4747 0.027 
H8 0.6656 0.7200 0.4192 0.026 
H10 0.5487 0.8220 0.2517 0.025 
H11 0.3260 0.3673 0.0974 0.023 
H13 0.3689 1.0382 0.1615 0.024 
H14 0.1669 1.2002 0.2223 0.026 
H16 -0.2032 0.8350 0.0747 0.028 
H17 -0.0028 0.6650 0.0196 0.026 
H18a -0.2812 1.0883 0.1637 0.042 
H18b -0.1510 1.2529 0.1786 0.042 
H18c -0.1602 1.1527 0.2646 0.042 
H2 0.5426 0.2894 0.3383 0.025 
 
 269 
 
Supplementary Table 4.4:   Refined Thermal Parameters (U's) for 
Compound 121 
Atom U11 U22 U33 U23 U13 U12 
C1 0.0232(8) 0.0145(7) 0.0175(8) 0.0012(6) 0.0023(6) 0.0005(6) 
C2 0.0266(8) 0.0160(8) 0.0182(8) 0.0041(7) 0.0010(6) 0.0015(6) 
C3 0.0235(8) 0.0236(8) 0.0184(8) 0.0061(6) -0.0007(6) 0.0022(7) 
C4 0.0262(9) 0.0258(9) 0.0276(9) 0.0120(7) 0.0014(7) 0.0048(7) 
C5 0.028(2) 0.0187(17) 0.030(2) 0.0091(15) 0.0085(17) 0.0075(18) 
C6 0.0219(15) 0.0128(14) 0.0196(15) 0.0041(11) 0.0067(13) 0.0006(11) 
N1 0.021(3) 0.0147(15) 0.015(2) 0.0022(14) 0.0029(16) -0.0003(19) 
O1 0.021(3) 0.014(6) 0.016(5) 0.001(4) -0.008(3) 0.004(3) 
C5' 0.025(3) 0.021(2) 0.023(2) 0.0073(17) 0.0040(19) 0.005(2) 
C6' 0.026(2) 0.0122(17) 0.0218(19) 0.0019(14) 0.0046(17) 0.0046(14) 
N1' 0.023(3) 0.0143(18) 0.015(3) 0.0030(18) 0.001(2) 0.001(2) 
O1' 0.057(8) 0.015(8) 0.029(8) 0.002(6) 0.001(6) -0.007(5) 
C7 0.0332(9) 0.0154(8) 0.0194(8) 0.0033(6) 0.0022(7) 0.0004(7) 
C8 0.0249(8) 0.0140(7) 0.0179(8) 0.0009(6) 0.0000(6) 0.0001(6) 
C9 0.0171(7) 0.0161(7) 0.0176(8) 0.0021(6) 0.0029(6) 0.0020(6) 
C10 0.0210(8) 0.0151(7) 0.0172(8) 0.0007(6) -0.0020(6) 0.0005(6) 
C11 0.0191(7) 0.0143(7) 0.0175(8) 0.0020(6) 0.0027(6) 0.0001(6) 
C12 0.0153(7) 0.0163(7) 0.0166(7) 0.0047(6) 0.0018(6) 0.0036(6) 
C13 0.0158(7) 0.0167(7) 0.0218(8) 0.0048(6) 0.0007(6) -0.0008(6) 
C14 0.0230(8) 0.0142(7) 0.0215(8) 0.0043(6) 0.0031(6) 0.0008(6) 
C15 0.0198(8) 0.0211(8) 0.0194(8) 0.0090(6) 0.0048(6) 0.0061(6) 
C16 0.0133(7) 0.0269(8) 0.0224(8) 0.0040(7) -0.0001(6) 0.0006(6) 
C17 0.0176(8) 0.0195(8) 0.0194(8) 0.0004(6) -0.0010(6) -0.0007(6) 
C18 0.0252(9) 0.0282(9) 0.0332(10) 0.0060(7) 0.0098(7) 0.0093(7) 
N2 0.0244(7) 0.0143(6) 0.0157(6) 0.0013(5) -0.0001(5) 0.0012(5) 
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N3 0.0172(6) 0.0146(6) 0.0154(6) 0.0025(5) 0.0001(5) 0.0023(5) 
N4 0.0206(7) 0.0154(6) 0.0177(7) 0.0018(5) 0.0030(5) 0.0008(5) 
O2 0.0468(8) 0.0141(6) 0.0230(6) 0.0018(5) 0.0008(5) -0.0002(5) 
O3 0.0159(5) 0.0206(6) 0.0210(6) 0.0063(4) 0.0033(4) 0.0017(4) 
O4 0.0199(6) 0.0194(6) 0.0166(5) 0.0004(4) 0.0006(4) 0.0018(4) 
S1 0.01374(19) 0.01536(19) 0.01446(19) 0.00272(14) 0.00096(14) 0.00174(14) 
The form of the anisotropic displacement parameter is: 
exp[-2π2(a*2U11h2+b*2U22k2+c*2U33l2+2b*c*U23kl+2a*c*U13hl+2a*b*U12hk)] 
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  Supplementary Table 4.5: Bond Distances in Compound 121, Å 
C1-C8  1.339(2) C1-N2  1.4020(19) C1-C2  1.494(2) 
C2-O1  1.213(14) C2-O1'  1.236(19) C2-N1  1.351(7) 
C2-N1'  1.362(8) C3-N1'  1.472(8) C3-N1  1.477(7) 
C3-C4  1.533(2) C4-C5  1.521(5) C4-C5'  1.552(5) 
C5-C6  1.525(5) C6-N1  1.463(7) C6-C7  1.522(3) 
C5'-C6'  1.515(6) C6'-N1'  1.471(8) C6'-C7  1.537(4) 
C7-O2  1.219(2) C7-N2  1.347(2) C8-C9  1.450(2) 
C9-C10  1.361(2) C9-N4  1.4024(19) C10-N3  1.3878(19) 
C11-N4  1.298(2) C11-N3  1.3763(19) C12-C17  1.389(2) 
C12-C13  1.395(2) C12-S1  1.7473(15) C13-C14  1.383(2) 
C14-C15  1.399(2) C15-C16  1.391(2) C15-C18  1.506(2) 
C16-C17  1.386(2) N3-S1  1.6885(13) O3-S1  1.4250(11) 
O4-S1  1.4293(11)     
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Supplementary Table 4.6: Bond Angles in Compound 121, ° 
C8-C1-N2 122.11(14) C8-C1-C2 120.15(14) N2-C1-C2 117.69(14) 
O1-C2-O1' 2.6(14) O1-C2-N1 121.5(6) O1'-C2-N1 121.3(9) 
O1-C2-N1' 122.1(6) O1'-C2-N1' 120.8(8) N1-C2-N1' 21.4(2) 
O1-C2-C1 122.0(5) O1'-C2-C1 122.7(8) N1-C2-C1 115.6(3) 
N1'-C2-C1 114.5(3) N1'-C3-N1 19.7(2) N1'-C3-C4 102.2(3) 
N1-C3-C4 104.4(3) C5-C4-C3 103.86(19) C5-C4-C5' 24.58(15) 
C3-C4-C5' 105.5(2) C4-C5-C6 102.0(3) N1-C6-C7 113.9(3) 
N1-C6-C5 102.3(3) C7-C6-C5 113.2(3) C2-N1-C6 126.8(5) 
C2-N1-C3 120.4(4) C6-N1-C3 110.1(4) C6'-C5'-C4 100.1(3) 
N1'-C6'-C5' 103.2(4) N1'-C6'-C7 111.7(4) C5'-C6'-C7 113.7(3) 
C2-N1'-C6' 127.1(6) C2-N1'-C3 120.0(5) C6'-N1'-C3 112.0(5) 
O2-C7-N2 122.92(15) O2-C7-C6 119.75(17) N2-C7-C6 115.23(16) 
O2-C7-C6' 118.49(18) N2-C7-C6' 114.83(18) C6-C7-C6' 35.02(17) 
C1-C8-C9 126.21(14) C10-C9-N4 109.77(13) C10-C9-C8 127.16(14) 
N4-C9-C8 123.07(14) C9-C10-N3 105.76(13) N4-C11-N3 111.65(13) 
C17-C12-C13 121.36(14) C17-C12-S1 119.21(12) C13-C12-S1 119.41(11) 
C14-C13-C12 118.81(14) C13-C14-C15 120.94(14) C16-C15-C14 118.93(14) 
C16-C15-C18 120.87(15) C14-C15-C18 120.19(15) C17-C16-C15 121.12(14) 
C16-C17-C12 118.80(14) C7-N2-C1 126.82(14) C11-N3-C10 106.86(13) 
C11-N3-S1 126.38(11) C10-N3-S1 126.72(11) C11-N4-C9 105.97(13) 
O3-S1-O4 121.49(7) O3-S1-N3 106.06(6) O4-S1-N3 104.12(6) 
O3-S1-C12 108.88(7) O4-S1-C12 110.67(7) N3-S1-C12 104.02(7) 
  
 273 
 
 
iBruker (2009) SAINT. Bruker AXS Inc., Madison, Wisconsin, USA. 
 
iiBruker (2009) SHELXTL. Bruker AXS Inc., Madison, Wisconsin, USA. 
 
iiiSheldrick, G.M. (2007) SADABS. University of Gottingen, Germany. 
 
ivSheldrick, G.M. (2008) Acta Cryst. A64,112-122. 
 
vSheldrick, G.M. (2008) Acta Cryst. A64,112-122. 
 
viR1 = ||Fo| - |Fc|| /  |Fo| 
wR2 = [w(Fo2 - Fc2)2/w(Fo2)2]½ 
GOF = [w(Fo2 - Fc2)2/(n - p)]½ 
where n = the number of reflections and p = the number of parameters refined. 
 
vii“ORTEP-II: A Fortran Thermal Ellipsoid Plot Program for Crystal Structure Illustrations”. C.K. 
Johnson (1976) ORNL-5138. 
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List of Acronyms and Abbreviations 
°C: degrees Celsius 
Å: angstroms 
AA: amino acid 
antiSMASH: antibiotics & Secondary Metabolite Analysis Shell 
B3LYP: Becke, three-parameter, Lee-Yang-Parr 
BDE: bond dissociation energy 
BHT: tert-butylhydroxytoluene 
BINOL: 1,1'-bi-2-naphthol 
Boc: tert-butyloxycarbonyl 
Boc2O: di-tert-butyl dicarbonate 
br s: broad singlet 
CAN: cerium ammonium nitrate 
Cbz: carboxybenzyl 
cDNA: complementary DNA 
CDY: Czapek-Dox yeast extract 
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COSY: homonuclear correlation spectroscopy 
d: doublet 
Da: Dalton 
DBN: 1,5-diazabicyclo[4.3.0]non-5-ene 
DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene 
dd: doublet of doublets 
dd H2O: double distilled water 
DFT: density functional theory 
DHTD: dehydrohistidyltryptophanyldiketopiperazine 
DMAP: 4-dimethylaminopyridine 
DMAPP: dimethylallyl pyrophosphate 
DMDO: dimethyldioxirane 
DMF: dimethylformamide 
DMSO: dimethylsulfoxide 
dr: diastereomeric ratio 
dT: deoxy-thymidine 
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e: elementary charge 
EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA: ethylenediaminetetraacetic acid 
EI: electron ionization 
Equiv: equivalent 
ESI-TOF: electrospray ionization time-of-flight 
Et: ethyl 
Et3N: triethylamine 
FAD: flavin adenine dinucleotide 
FCC: flash column chromatography  
Fmoc: fluorenylmethyloxycarbonyl 
F-TEDA-PF6: 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane dihexa-
fluorophosphate 
g: grams 
g: standard acceleration due to gravity at the Earth's surface 
G2 phase: Gap 2 phase 
GC-MS: gas chromatography-mass spectrometry 
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gCOSY: gradient correlation spectroscopy 
gHMBCAD: gradient heteronuclear multiple bond correlation adiabatic 
gHSQCAD: gradient heteronuclear single quantum coherence adiabatic 
h: hours 
HATU: 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HF: Hartree-Fock 
His: histidine 
HMBC: heteronuclear multiple bond correlation 
HMQC: heteronuclear multiple quantum coherence 
HOAt: 1-hydroxy-7-azabenzotriazole 
HOBt: hydroxybenzotriazole 
HOMO: highest occupied molecular orbital 
hp: hypothetical protein 
HPLC: high-performance liquid chromatography 
HPLC-MS: high-performance liquid chromatography-mass spectrometry 
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HRMS: high resolution mass spectrometry 
HSQC: heteronuclear single quantum coherence 
HTD: histidyltryptophanyldiketopiperazine 
Hz: hertz 
IC50: half maximal inhibitory concentration 
IPTG: Isopropyl β-D-1-thiogalactopyranoside 
IR: infrared 
k: rate constant 
K: equilibrium constant 
kcat: turnover number 
kDa: kilodaltons 
kJ: kilojoules 
KM: Michaelis constant 
k-mer: all possible subsequences obtained from DNA sequencing 
L: liter 
LB: lysogeny broth 
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LC-MS: liquid chromatography-mass spectrometry 
LiHMDS: lithium bis(trimethylsilyl)amide 
LUMO: lowest unoccupied molecular orbital 
M: molar 
m: multiplet 
M phase: mitotic phase 
m/z: mass-to-charge ratio 
mCPBA: meta-chloroperbenzoic acid 
mg: milligrams 
MGS: mannitol, glucose, succinic acid 
MHz: megahertz 
mL: milliliters 
mM: millimolar 
mmol: millimoles 
mol: moles 
MoOPH: oxodiperoxymolybdenum(pyridine)-(hexamethylphosphoric triamide) 
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Ms: mesyl 
MTS: methyl p-tolyl sulfide 
MTSO: methyl p-tolyl sulfoxide 
N: normal 
N50: the shortest sequence length at 50% of the genome 
NADH: nicotinamide adenine dinucleotide 
NADPH: nicotinamide adenine dinucleotide phosphate 
NBS: N-bromosuccinimide 
NCS: N-chlorosuccinimide 
NFSI: N-fluorobenzenesulfonimide 
Ni-NTA: nickel- nitrilotriacetic acid 
NIS: N-iodosuccinimide 
nM: nanomolar 
NMR: nuclear magnetic resonance 
NOESY: nuclear Overhauser effect spectroscopy 
NPSP: N-(phenylseleno)phthalimide 
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NRPS: nonribosomal peptide synthase 
ORF: open reading frame 
PCR: polymerase chain reaction 
PMA: phosphomolybdic acid 
PMB: para-methoxybenzyl 
PPTS: pyridinium p-toluenesulfonate 
Py2AgMnO4: bis(pyridine) silver (I) permanganate 
q: quartet 
Rf: retention factor 
RT-PCR: reverse transcription- polymerase chain reaction 
s: singlet 
SET: single electron transfer 
t: triplet 
TBAOH: tetrabutylammonium hydroxide 
TCEP: tris(2-carboxyethyl)phosphine 
td: triplet of doublets 
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TEV: tobacco etch virus 
TFA: trifluoroacetic acid; trifluoroacetyl 
TFAA: trifluoroacetic anhydride 
TfOH: triflic acid 
THF: tetrahydrofuran 
TLC: thin-layer chromatography 
TMS: tetramethylsilane 
TMSI: trimethylsilyl iodide 
Ts: tosyl 
TTN: total turnover number 
UV: ultraviolet 
UV-Vis: ultraviolet-visible 
μg: microgram 
μL: microliter 
μM: micromolar
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